##SAMPLE=<ID=DX000000_01,Gender=female,ExternalSampleName=DNA-000000 A1,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=n/a>
##SAMPLE=<ID=DX000001_01,Gender=female,ExternalSampleName=DNA-000001 A1,IsTumor=yes,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##ANALYSISTYPE=SOMATIC_PAIR
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DX000000_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DX000000_01).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample DX000001_01).
##DESCRIPTION=normal_dp=Normal depth (Sample DX000001_01).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=ihdb_hom=Homozygous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_het=Heterozyous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_wt=Wildtype variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=General gene information from the NGSD.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##FILTER=all-unknown=Allele unknown (filter_vcf).
##FILTER=depth-nor=Sequencing depth normal is too low < 20 (filter_vcf).
##FILTER=depth-tum=Sequencing depth tumor is too low < 20 (filter_vcf).
##FILTER=freq-nor=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=freq-tum=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=lt-3-reads=Less than 3 supporting tumor reads (filter_vcf).
##FILTER=not-cod-spli=Not a coding or splicing variant (filter_vcf).
##FILTER=off-target=Variant outside the panel/exome target region.
##FILTER=special_chromosome=Special chromosome.
##FILTER=syn-var=Synonymous variant (filter_vcf).
##CGI_CANCER_TYPE=CANCER
##DESCRIPTION=CGI_id=Identifier for CGI statements
##DESCRIPTION=CGI_driver_statement=CancerGenomeInterpreter.org oncogenic classification
##DESCRIPTION=CGI_gene_role=CancerGenomeInterpreter.org gene role. LoF: Loss of Function, Act: Activating
##DESCRIPTION=CGI_transcript=CancerGenomeInterpreter.org CGI Ensembl transcript ID
##DESCRIPTION=CGI_gene=Gene symbol returned by CancerGenomeInterpreter.org
##DESCRIPTION=CGI_consequence=Consequence of the mutation assessed by CancerGenomeInterpreter.org
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	snp_q	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	gnomAD	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	ihdb_hom	ihdb_het	ihdb_wt	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info	som_ihdb_c	som_ihdb_p	CGI_id	CGI_driver_statement	CGI_gene_role	CGI_transcript	CGI_gene	CGI_consequence
chr1	23208744	23208744	C	T	0.8333	12	0.0000	22	"not-cod-spli;depth-tum;off-target"	61	EPHB2	sequence_feature,intron_variant	EPHB2:ENST00000400191:sequence_feature:LOW::c.1304-108C>T:,EPHB2:ENST00000374630:sequence_feature:LOW::c.1304-108C>T:,EPHB2:ENST00000374632:sequence_feature:LOW::c.1304-108C>T:,EPHB2:ENST00000400191:intron_variant:MODIFIER:exon5/16:c.1304-108C>T:,EPHB2:ENST00000544305:intron_variant:MODIFIER:exon5/6:c.1304-108C>T:,EPHB2:ENST00000374630:intron_variant:MODIFIER:exon5/15:c.1304-108C>T:,EPHB2:ENST00000374632:intron_variant:MODIFIER:exon5/15:c.1304-108C>T:,EPHB2:ENST00000374627:intron_variant:MODIFIER:exon5/14:c.1286-108C>T:,EPHB2:ENST00000465676:intron_variant:MODIFIER:exon3/6:n.545-108C>T:,EPHB2:ENST00000490436:intron_variant:MODIFIER:exon1/1:n.55-108C>T:		Axon guidance	Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. Beside axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor				0.0000	0.0000	0.0000		"600997 [EPHB2 (confirmed) Prostate cancer/brain cancer susceptibility,somatic,603688];"												0	0					EPHB2 (inh=n/a pLI=1.00)	0							
chr1	47395691	47395691	G	A	0.4054	74	0.0000	38	"not-cod-spli;off-target"	99	CYP4A11	3_prime_UTR_variant,intron_variant	CYP4A11:ENST00000310638:3_prime_UTR_variant:MODIFIER:exon12/12:c.*96C>T:,CYP4A11:ENST00000475477:3_prime_UTR_variant:MODIFIER:exon9/9:c.*450C>T:,CYP4A11:ENST00000462347:3_prime_UTR_variant:MODIFIER:exon10/10:c.*96C>T:,CYP4A11:ENST00000371904:intron_variant:MODIFIER:exon12/12:c.*74+22C>T:		"Fatty acid metabolism;Arachidonic acid metabolism;Retinol metabolism;PPAR signaling pathway"	Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE)				0.0000	0.0000	0.0000														0	0					CYP4A11 (inh=n/a pLI=0.00)	0							
chr1	118165825	118165825	T	G	0.3692	781	0.0000	620		895	FAM46C	missense_variant	FAM46C:ENST00000369448:missense_variant:MODERATE:exon2/2:c.335T>G:p.Val112Gly	Domain_of_unknown_function_DUF1693__1_		Seems to enhance replication of some viruses, including yellow fever virus, in response to type I interferon				0.0000	0.0000	0.0000					8.040.000	T	D	B	T	24.60				0	0					FAM46C (inh=n/a pLI=0.52)	0		chr1_118165825_118165825_T_G	predicted passenger	LoF	ENST00000369448	FAM46C	Missense
chr1	145281632	145281632	C	T	0.1509	1167	0.0000	656	off-target	413	NOTCH2NL,RP11-458D21.5	missense_variant	NOTCH2NL:ENST00000362074:missense_variant:MODERATE:exon4/5:c.562C>T:p.Pro188Ser,RP11-458D21.5:ENST00000468030:missense_variant:MODERATE:exon4/23:c.562C>T:p.Pro188Ser,NOTCH2NL:ENST00000344859:missense_variant:MODERATE:exon4/6:c.562C>T:p.Pro188Ser,NOTCH2NL:ENST00000369340:missense_variant:MODERATE:exon5/6:c.562C>T:p.Pro188Ser	Epidermal_growth_factor-like__1_,Epidermal_growth_factor-like__type_3__1_		May function in the Notch signaling pathway and regulate neutrophil differentiation				0.0000	0.0000	0.0000					7.590.000	T	D,D,D	B,P	T,T,T	25.90				0	0					NOTCH2NL (inh=n/a pLI=0.00), RP11-458D21.5 (inh=n/a pLI=n/a)	0		chr1_145281632_145281632_C_T	predicted passenger	.	ENST00000369340	NOTCH2NL	Missense
chr1	145281945	145281945	C	T	0.0870	3326	0.0000	1524	"not-cod-spli;off-target"	487	NOTCH2NL,RP11-458D21.5	intron_variant	NOTCH2NL:ENST00000362074:intron_variant:MODIFIER:exon4/4:c.635-10C>T:,RP11-458D21.5:ENST00000468030:intron_variant:MODIFIER:exon4/22:c.634+241C>T:,NOTCH2NL:ENST00000344859:intron_variant:MODIFIER:exon4/5:c.634+241C>T:,NOTCH2NL:ENST00000369340:intron_variant:MODIFIER:exon5/5:c.635-10C>T:			May function in the Notch signaling pathway and regulate neutrophil differentiation			rs781811052	0.0000	0.00003	0.00000														0	0					NOTCH2NL (inh=n/a pLI=0.00), RP11-458D21.5 (inh=n/a pLI=n/a)	0							
chr1	156834189	156834189	G	A	0.4956	565	0.0000	317		733	NTRK1	missense_variant,intron_variant,non_coding_transcript_exon_variant	NTRK1:ENST00000524377:missense_variant:MODERATE:exon2/17:c.256G>A:p.Asp86Asn,NTRK1:ENST00000392302:missense_variant:MODERATE:exon3/17:c.166G>A:p.Asp56Asn,NTRK1:ENST00000497019:missense_variant:MODERATE:exon3/16:c.166G>A:p.Asp56Asn,NTRK1:ENST00000368196:missense_variant:MODERATE:exon2/16:c.256G>A:p.Asp86Asn,NTRK1:ENST00000358660:missense_variant:MODERATE:exon2/16:c.256G>A:p.Asp86Asn,NTRK1:ENST00000489021:intron_variant:MODIFIER:exon2/2:n.313-9236G>A:,NTRK1:ENST00000530298:non_coding_transcript_exon_variant:MODIFIER:exon4/17:n.314G>A:,NTRK1:ENST00000533630:non_coding_transcript_exon_variant:MODIFIER:exon2/3:n.278G>A:		"MAPK signaling pathway;Apoptosis;Thyroid cancer"	Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand, it can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras- PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors	"Role of Erk5 in Neuronal Survival;Trka Receptor Signaling Pathway;Y branching of actin filaments"			0.0000	0.0000	0.0000		"191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800|Medullary thyroid carcinoma,familial,155240];"			2.958.000	T	D,D,D,D	B,B,B,B	D,D,D,D	23.70				0	0					NTRK1 (inh=AR+AD pLI=0.00)	0		chr1_156834189_156834189_G_A	predicted passenger	Act	ENST00000524377	NTRK1	Missense
chr1	158493450	158493450	C	T	0.2093	43	0.0000	19	"not-cod-spli;depth-nor;off-target"	65	OR10R1P-RP11-144L1.8	intergenic_region	OR10R1P-RP11-144L1.8:ENSG00000227445-ENSG00000231434:intergenic_region:MODIFIER::n.158493450C>T:							0.0000	0.0000	0.0000														0	0					OR10R1P-RP11-144L1.8 (inh=n/a pLI=n/a)	0							
chr1	161310197	161310197	T	C	0.0893	60	0.0000	24	"not-cod-spli;off-target"	55	SDHC	intron_variant	SDHC:ENST00000367975:intron_variant:MODIFIER:exon3/5:c.180-187T>C:,SDHC:ENST00000342751:intron_variant:MODIFIER:exon3/4:c.180-187T>C:,SDHC:ENST00000432287:intron_variant:MODIFIER:exon2/4:c.78-187T>C:,SDHC:ENST00000392169:intron_variant:MODIFIER:exon1/3:c.21-187T>C:,SDHC:ENST00000513009:intron_variant:MODIFIER:exon2/3:c.78-187T>C:,SDHC:ENST00000504963:intron_variant:MODIFIER:exon4/6:c.*3-187T>C:,SDHC:ENST00000470743:intron_variant:MODIFIER:exon3/5:n.278-187T>C:,SDHC:ENST00000513700:intron_variant:MODIFIER:exon1/2:n.97-187T>C:		"Citrate cycle (TCA cycle);Oxidative phosphorylation"	Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q)	Electron Transport Reaction in Mitochondria			0.0000	0.0000	0.0000		"602413 [SDHC (confirmed) Paragangliomas 3,605373|Paraganglioma and gastric stromal sarcoma,606864|Gastrointestinal stromal tumor,606764];"												0	0					SDHC (inh=AD pLI=0.10)	0							
chr1	198672341	198672341	G	A	0.2684	354	0.0000	215	"not-cod-spli;off-target"	272	PTPRC	intron_variant	PTPRC:ENST00000442510:intron_variant:MODIFIER:exon6/32:c.584-86G>A:,PTPRC:ENST00000367379:intron_variant:MODIFIER:exon3/6:c.101-86G>A:,PTPRC:ENST00000352140:intron_variant:MODIFIER:exon5/31:c.434-86G>A:,PTPRC:ENST00000367376:intron_variant:MODIFIER:exon6/32:c.578-86G>A:,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon3/29:c.95-86G>A:,PTPRC:ENST00000530727:intron_variant:MODIFIER:exon4/17:c.242-86G>A:,PTPRC:ENST00000462363:intron_variant:MODIFIER:exon4/4:n.350-86G>A:,PTPRC:ENST00000367367:intron_variant:MODIFIER:exon5/21:c.386-86G>A:,PTPRC:ENST00000348564:intron_variant:MODIFIER:exon3/29:c.101-86G>A:,PTPRC:ENST00000529828:intron_variant:MODIFIER:exon5/21:c.440-86G>A:,PTPRC:ENST00000391970:intron_variant:MODIFIER:exon4/4:n.360-86G>A:,PTPRC:ENST00000427110:intron_variant:MODIFIER:exon3/3:n.216-86G>A:		"Cell adhesion molecules (CAMs);T cell receptor signaling pathway;Primary immunodeficiency"	Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity)	"Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;B Lymphocyte Cell Surface Molecules;Lck and Fyn tyrosine kinases in initiation of TCR Activation;T Cytotoxic Cell Surface Molecules;T Helper Cell Surface Molecules"			0.0000	0.0000	0.0000		"151460 [PTPRC (confirmed) Hepatitic C virus,susceptibility to,609532|Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];"												0	0					PTPRC (inh=AR pLI=1.00)	0							
chr1	204399266	204399266	C	T	0.3162	136	0.0000	97	"not-cod-spli;off-target"	167	RP11-739N20.2,PIK3C2B	intron_variant	RP11-739N20.2:ENST00000443515:intron_variant:MODIFIER:exon1/2:n.147-5199C>T:,PIK3C2B:ENST00000367187:intron_variant:MODIFIER:exon29/33:c.4281-100G>A:,PIK3C2B:ENST00000424712:intron_variant:MODIFIER:exon30/34:c.4197-100G>A:		Phosphatidylinositol signaling system	Phosphorylates PtdIns and PtdIns4P with a preference for PtdIns. Does not phosphorylate PtdIns(4,5)P2. May be involved in EGF and PDGF signaling cascades				0.0000	0.0000	0.0000														0	0					RP11-739N20.2 (inh=n/a pLI=n/a), PIK3C2B (inh=n/a pLI=0.98)	0							
chr2	27447499	27447499	C	G	0.3816	152	0.0000	132	"not-cod-spli;off-target"	237	CAD	intron_variant	CAD:ENST00000264705:intron_variant:MODIFIER:exon9/43:c.1255-114C>G:,CAD:ENST00000403525:intron_variant:MODIFIER:exon9/42:c.1255-114C>G:		"Pyrimidine metabolism;Glutamate metabolism;Alanine and aspartate metabolism"	"This protein is a ""fusion"" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase)"				0.0000	0.0000	0.0000		"114010 [CAD (provisional) Epileptic encephalopathy,early infantile,50,616457];"												0	0					CAD (inh=AR pLI=1.00)	0							
chr2	43453553	43453553	A	T	0.1064	110	0.0244	44	"not-cod-spli;freq-nor;off-target"	65	ZFP36L2,THADA	5_prime_UTR_variant,intron_variant	ZFP36L2:ENST00000282388:5_prime_UTR_variant:MODIFIER:exon1/2:c.-99T>A:,THADA:ENST00000330266:intron_variant:MODIFIER:exon19/19:c.3189-59648T>A:			mRNA-binding protein that plays a key role in self- renewal of erythroid cells in response to glucocorticoids. Specifically binds to the AU-rich element (ARE) in the 3'-UTR of target mRNAs, promoting their deadenylation and degradation (PubMed:14981510). Specifically expressed in burst-forming unit- erythroid (BFU-E) progenitors in response to glucocorticoids and acts as a negative regulator of erythroid cell differentiation: promotes self-renewal of erythroid cells by binding mRNAs that are induced or highly expressed during terminal erythroid differentiation and promotes their degradation, preventing erythroid cell differentiation. Down-regulated during erythroid differentiation from the BFU-E stage, stabilizing mRNAs required for terminal differentiation (By similarity)				0.0000	0.0000	0.0000														0	0					ZFP36L2 (inh=n/a pLI=0.46), THADA (inh=n/a pLI=0.00)	0							
chr2	47629891	47629891	T	-	0.0220	689	0.0029	398	"not-cod-spli;freq-tum"	72	EPCAM-MSH2	intergenic_region	EPCAM-MSH2:ENSG00000119888-ENSG00000095002:intergenic_region:MODIFIER::n.47629891delT:						rs544188883	0.000798722	0.0000	0.0000														0	0					EPCAM-MSH2 (inh=n/a pLI=n/a)	0							
chr2	48018314	48018314	T	A	0.0186	384	0.0033	302	"not-cod-spli;freq-tum;freq-nor;off-target"	56	MSH6,FBXO11	intron_variant	MSH6:ENST00000234420:intron_variant:MODIFIER:exon2/9:c.457+52T>A:,MSH6:ENST00000445503:intron_variant:MODIFIER:exon2/8:c.457+52T>A:,MSH6:ENST00000456246:intron_variant:MODIFIER:exon1/2:c.261-4719T>A:,MSH6:ENST00000540021:intron_variant:MODIFIER:exon1/7:c.238-7436T>A:,MSH6:ENST00000455383:intron_variant:MODIFIER:exon2/3:c.160+52T>A:,MSH6:ENST00000420813:intron_variant:MODIFIER:exon2/2:c.160+52T>A:,MSH6:ENST00000538136:intron_variant:MODIFIER:exon2/9:c.-446+52T>A:,MSH6:ENST00000411819:intron_variant:MODIFIER:exon2/3:c.160+52T>A:,FBXO11:ENST00000434234:intron_variant:MODIFIER:exon3/3:c.*125-1735A>T:,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.170-1735A>T:		"Mismatch repair;Colorectal cancer"	Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. Recruited on chromatin in G1 and early S phase via its PWWP domain that specifically binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early recruitment to chromatin to be replicated allowing a quick identification of mismatch repair to initiate the DNA mismatch repair reaction.,Substrate recognition component of the a (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. SCF(FBXO11) does not seem to direct ubiquitination of TP53			rs3136282	0.185503	0.27148	0.0000		"600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350|Endometrial cancer,familial,608089|Mismatch repair cancer syndrome,276300];"	"RCV000074995.2 [benign]; RCV000412274.1 [benign]; "											452	1792	2	[2] auto-classification 21.10.2017  			MSH6 (inh=AD pLI=n/a), FBXO11 (inh=n/a pLI=1.00)	1	SomaticAndTreatment,						
chr2	83088309	83088309	C	T	0.3947	38	0.0000	24	"not-cod-spli;off-target"	57	AC098817.5-AC138623.1	intergenic_region	AC098817.5-AC138623.1:ENSG00000168129-ENSG00000223977:intergenic_region:MODIFIER::n.83088309C>T:							0.0000	0.0000	0.0000														0	0					AC098817.5-AC138623.1 (inh=n/a pLI=n/a)	0							
chr2	91899651	91899651	G	A	0.2166	175	0.0000	124	"not-cod-spli;off-target"	141	AC027612.3	intron_variant	AC027612.3:ENST00000445955:intron_variant:MODIFIER:exon2/7:n.234+121C>T:,AC027612.3:ENST00000436174:intron_variant:MODIFIER:exon2/9:n.168+121C>T:							0.0000	0.0000	0.0000														0	0					AC027612.3 (inh=n/a pLI=n/a)	0							
chr2	107040700	107040700	T	G	0.3579	542	0.0000	414	off-target	611	RGPD3	missense_variant	RGPD3:ENST00000304514:missense_variant:MODERATE:exon20/23:c.3723A>C:p.Glu1241Asp,RGPD3:ENST00000409886:missense_variant:MODERATE:exon20/23:c.3723A>C:p.Glu1241Asp							0.0000	0.0000	0.0000					0.202000	T	T,T	B	T,T	0.03				0	0					RGPD3 (inh=n/a pLI=n/a)	0		chr2_107040700_107040700_T_G	predicted passenger	ambiguous	ENST00000409886	RGPD3	Missense
chr2	141202380	141202380	C	T	0.4286	49	0.0000	59	"not-cod-spli;off-target"	138	LRP1B	intron_variant	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon63/90:c.10058-132G>A:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs541719419	0.000199681	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0							
chr2	141213993	141213993	T	G	0.3404	282	0.0000	278	"not-cod-spli;off-target"	382	LRP1B	intron_variant	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon62/90:c.9963+31A>C:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0							
chr2	141609261	141609261	G	A	0.3344	652	0.0000	566	syn-var	736	LRP1B	synonymous_variant	LRP1B:ENST00000389484:synonymous_variant:LOW:exon28/91:c.4671C>T:p.Pro1557Pro,LRP1B:ENST00000434794:synonymous_variant:LOW:exon13/14:c.2106C>T:p.Pro702Pro			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0		chr2_141609261_141609261_G_A	not protein-affecting	LoF	ENST00000389484	LRP1B	Synonymous
chr2	141739925	141739925	C	T	0.3527	241	0.0000	209	"not-cod-spli;off-target"	320	LRP1B	intron_variant	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon17/90:c.2771-80G>A:,LRP1B:ENST00000434794:intron_variant:MODIFIER:exon2/13:c.206-80G>A:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0							
chr2	158739607	158739607	C	T	0.3420	388	0.0000	310	not-cod-spli	439	UPP2	intron_variant	UPP2:ENST00000605860:intron_variant:MODIFIER:exon1/9:c.-20+6367C>T:		"Pyrimidine metabolism;Drug metabolism - other enzymes"	Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1- phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. Shows substrate specificity and accept uridine, deoxyuridine, and thymidine as well as the two pyrimidine nucleoside analogs 5-fluorouridine and 5-fluoro-2(')-deoxyuridine as substrates				0.0000	0.0000	0.0000														0	0					UPP2 (inh=n/a pLI=0.00)	0							
chr2	178882930	178882930	T	C	0.2941	136	0.0000	138	"not-cod-spli;off-target"	189	PDE11A,AC011998.2	intron_variant,non_coding_transcript_exon_variant	PDE11A:ENST00000286063:intron_variant:MODIFIER:exon1/19:c.913-3743A>G:,PDE11A:ENST00000358450:intron_variant:MODIFIER:exon2/20:c.163-3743A>G:,AC011998.2:ENST00000430884:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.211T>C:		Purine metabolism	Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'- GMP, respectively				0.0000	0.0000	0.0000		"604961 [PDE11A (provisional) Pigmented nodular adrenocortical disease,primary,2,610475];"												0	0					PDE11A (inh=AD pLI=0.00), AC011998.2 (inh=n/a pLI=n/a)	0							
chr2	189864366	189864366	A	C	0.3745	268	0.0000	238	"not-cod-spli;off-target"	376	COL3A1	intron_variant	COL3A1:ENST00000304636:intron_variant:MODIFIER:exon31/50:c.2229+63A>C:,COL3A1:ENST00000317840:intron_variant:MODIFIER:exon31/41:c.2229+63A>C:		"Cell Communication;Focal adhesion;ECM-receptor interaction"	Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12				0.0000	0.0000	0.0000		"120180 [COL3A1 (confirmed) Ehlers-Danlos syndrome,type IV,130050];"												0	0					COL3A1 (inh=AD pLI=1.00)	0							
chr2	209938245	209938245	C	T	0.2963	218	0.0000	141	"not-cod-spli;off-target"	214	HSPA8P6	non_coding_transcript_exon_variant	HSPA8P6:ENST00000451965:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.628G>A:							0.0000	0.0000	0.0000														0	0					HSPA8P6 (inh=n/a pLI=n/a)	0							
chr2	223083526	223083526	T	-	0.0226	1355	0.0054	674	"not-cod-spli;freq-tum;freq-nor"	69	PAX3	intron_variant	PAX3:ENST00000392069:intron_variant:MODIFIER:exon7/9:c.1173+1333delA:,PAX3:ENST00000344493:intron_variant:MODIFIER:exon7/7:c.1173+1333delA:,PAX3:ENST00000350526:intron_variant:MODIFIER:exon7/7:c.1173+1333delA:,PAX3:ENST00000336840:intron_variant:MODIFIER:exon7/8:c.1173+1333delA:,PAX3:ENST00000392070:intron_variant:MODIFIER:exon7/8:c.1173+1333delA:,PAX3:ENST00000409551:intron_variant:MODIFIER:exon7/8:c.1170+1333delA:,PAX3:ENST00000464706:intron_variant:MODIFIER:exon3/3:n.597+1333delA:,PAX3:ENST00000555548:intron_variant:MODIFIER:exon2/2:n.404+1333delA:			Transcription factor that may regulate cell proliferation, migration and apoptosis. Involved in neural development and myogenesis	Regulation of transcriptional activity by PML		rs75129267	0.0000	0.0000	0.0000		"606597 [PAX3 (confirmed) Waardenburg syndrome,type 1,193500|Waardenburg syndrome,type 3,148820|Craniofacial-deafness-hand syndrome,122880|Rhabdomyosarcoma 2,alveolar,268220];"												0	0					PAX3 (inh=AR+AD pLI=0.90)	0							
chr3	14219887	14219887	C	T	0.4157	256	0.0000	128	"not-cod-spli;off-target"	282	LSM3,XPC	5_prime_UTR_premature_start_codon_gain_variant,5_prime_UTR_variant,intron_variant	LSM3:ENST00000306024:5_prime_UTR_premature_start_codon_gain_variant:LOW:exon1/4:c.-474C>T:,LSM3:ENST00000306024:5_prime_UTR_variant:MODIFIER:exon1/4:c.-474C>T:,XPC:ENST00000285021:intron_variant:MODIFIER:exon1/15:c.103+79G>A:,XPC:ENST00000476581:intron_variant:MODIFIER:exon1/14:c.103+79G>A:,XPC:ENST00000449060:intron_variant:MODIFIER:exon1/15:c.103+79G>A:,XPC:ENST00000511155:intron_variant:MODIFIER:exon1/3:c.85+97G>A:		Nucleotide excision repair	Binds specifically to the 3'-terminal U-tract of U6 snRNA.,Involved in global genome nucleotide excision repair (GG-NER) by acting as damage sensing and DNA-binding factor component of the XPC complex. Has only a low DNA repair activity by itself which is stimulated by RAD23B and RAD23A. Has a preference to bind DNA containing a short single-stranded segment but not to damaged oligonucleotides. This feature is proposed to be related to a dynamic sensor function: XPC can rapidly screen duplex DNA for non-hydrogen-bonded bases by forming a transient nucleoprotein intermediate complex which matures into a stable recognition complex through an intrinsic single-stranded DNA- binding activity				0.0000	0.0000	0.0000		"613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];"												0	0					LSM3 (inh=n/a pLI=0.00), XPC (inh=AR pLI=0.00)	0							
chr3	16646713	16646713	G	A	0.2245	49	0.0000	17	"not-cod-spli;depth-nor;off-target"	62	DAZL	5_prime_UTR_variant,intron_variant	DAZL:ENST00000399444:5_prime_UTR_variant:MODIFIER:exon1/11:c.-1C>T:,DAZL:ENST00000454457:intron_variant:MODIFIER:exon2/6:c.118-6608C>T:			RNA-binding protein, which is essential for gametogenesis in both males and females. Plays a central role during spermatogenesis. Acts by binding to the 3'-UTR of mRNA, specifically recognizing GUU triplets, and thereby regulating the translation of key transcripts (By similarity)			rs779798025	0.0000	0.00001	0.00000		"601486 [DAZL (provisional) Spermatogenic failure,susceptibility to];"												0	0					DAZL (inh=n/a pLI=0.96)	0							
chr3	29250576	29250576	G	A	0.3649	349	0.0000	193	"not-cod-spli;off-target"	340	MESTP4-RBMS3-AS3	intergenic_region	MESTP4-RBMS3-AS3:ENSG00000215004-ENSG00000235904:intergenic_region:MODIFIER::n.29250576G>A:							0.0000	0.0000	0.0000														0	0					MESTP4-RBMS3-AS3 (inh=n/a pLI=n/a)	0							
chr3	38770068	38770068	G	A	0.3864	44	0.0000	29	off-target	72	SCN10A	missense_variant	SCN10A:ENST00000449082:missense_variant:MODERATE:exon15/27:c.2605C>T:p.Leu869Phe	Ion_transport__1_		This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant sodium channel isoform. Its electrophysiological properties vary depending on the type of the associated beta subunits (in vitro). Plays a role in neuropathic pain mechanisms (By similarity)				0.0000	0.0000	0.00000		"604427 [SCN10A (confirmed) Episodic pain syndrome,familial,2,615551];"			3.668.000	D	D	P	D	23.20				0	0					SCN10A (inh=AD pLI=0.00)	0		chr3_38770068_38770068_G_A	predicted passenger	.	ENST00000449082	SCN10A	Missense
chr3	97251204	97251204	G	A	0.3590	456	0.0034	292		431	EPHA6	missense_variant&splice_region_variant	EPHA6:ENST00000389672:missense_variant&splice_region_variant:MODERATE:exon11/18:c.2203G>A:p.Glu735Lys,EPHA6:ENST00000503760:missense_variant&splice_region_variant:MODERATE:exon8/16:c.379G>A:p.Glu127Lys,EPHA6:ENST00000477384:missense_variant&splice_region_variant:MODERATE:exon7/13:c.301G>A:p.Glu101Lys,EPHA6:ENST00000514100:missense_variant&splice_region_variant:MODERATE:exon8/13:c.379G>A:p.Glu127Lys,EPHA6:ENST00000508345:missense_variant&splice_region_variant:MODERATE:exon6/10:c.301G>A:p.Glu101Lys,EPHA6:ENST00000502694:missense_variant&splice_region_variant:MODERATE:exon8/12:c.379G>A:p.Glu127Lys,EPHA6:ENST00000442602:missense_variant&splice_region_variant:MODERATE:exon5/9:c.301G>A:p.Glu101Lys	Serine-threonine/tyrosine-protein_kinase__1_,Protein_kinase-like_domain__1_,Tyrosine-protein_kinase__catalytic_domain__1_,Protein_kinase__catalytic_domain__1_	Axon guidance	Receptor tyrosine kinase which binds promiscuously GPI- anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling (By similarity)				0.0000	0.0000	0.00002	COSM229466, COSM1317126, COSM145371				9.869.000	D	D,D,D,D	P,B,B,D	T,T,T,D	34.00				0	0					EPHA6 (inh=n/a pLI=0.95)	0		chr3_97251204_97251204_G_A	predicted passenger	.	ENST00000389672	EPHA6	Missense
chr3	119642196	119642196	G	A	0.3245	303	0.0000	195	not-cod-spli	302	GSK3B	intron_variant	GSK3B:ENST00000316626:intron_variant:MODIFIER:exon4/11:c.477+24C>T:,GSK3B:ENST00000264235:intron_variant:MODIFIER:exon4/10:c.477+24C>T:		"ErbB signaling pathway;Cell cycle;Wnt signaling pathway;Hedgehog signaling pathway;Axon guidance;Focal adhesion;B cell receptor signaling pathway;Insulin signaling pathway;Melanogenesis;Alzheimer's disease;Colorectal cancer;Endometrial cancer;Prostate cancer;Basal cell carcinoma"	Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation	"ALK in cardiac myocytes;Cell Cycle: G1/S Check Point ;Deregulation of CDK5 in Alzheimers Disease;Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages;Multi-step Regulation of Transcription by Pitx2;NFAT and Hypertrophy of the heart (Transcription in the broken heart);Phosphoinositides and their downstream targets.;Presenilin action in Notch and Wnt signaling;Regulation of eIF2;Segmentation Clock;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway;Sonic Hedgehog (Shh) Pathway;WNT Signaling Pathway"			0.0000	0.0000	0.0000														0	0					GSK3B (inh=n/a pLI=1.00)	0							
chr3	123891086	123891086	C	T	0.2432	37	0.0000	33	"not-cod-spli;off-target"	80	KALRN	intron_variant	KALRN:ENST00000360013:intron_variant:MODIFIER:exon1/59:c.68-55751C>T:,KALRN:ENST00000448253:intron_variant:MODIFIER:exon2/5:c.149-55751C>T:,KALRN:ENST00000460856:intron_variant:MODIFIER:exon1/33:c.68-55751C>T:,KALRN:ENST00000240874:intron_variant:MODIFIER:exon1/33:c.68-55751C>T:			Promotes the exchange of GDP by GTP. Activates specific Rho GTPase family members, thereby inducing various signaling mechanisms that regulate neuronal shape, growth, and plasticity, through their effects on the actin cytoskeleton. Induces lamellipodia independent of its GEF activity				0.0000	0.0000	0.0000		"604605 [KALRN (confirmed) Coronary heart disease,susceptibility to,5,608901];"												0	0					KALRN (inh=n/a pLI=1.00)	0							
chr3	138382605	138382605	G	A	0.3409	44	0.0000	33	"not-cod-spli;off-target"	88	PIK3CB	intron_variant	PIK3CB:ENST00000289153:intron_variant:MODIFIER:exon19/21:c.2796+143C>T:,PIK3CB:ENST00000477593:intron_variant:MODIFIER:exon20/22:c.2796+143C>T:,PIK3CB:ENST00000469284:intron_variant:MODIFIER:exon11/13:c.*1273+143C>T:,PIK3CB:ENST00000544716:intron_variant:MODIFIER:exon12/14:c.1149+143C>T:,PIK3CB:ENST00000462898:intron_variant:MODIFIER:exon20/22:c.*2365+143C>T:,PIK3CB:ENST00000481749:intron_variant:MODIFIER:exon10/12:n.1678+143C>T:,PIK3CB:ENST00000493568:intron_variant:MODIFIER:exon12/14:c.1689+143C>T:,PIK3CB:ENST00000487552:intron_variant:MODIFIER:exon1/1:n.28+143C>T:		"Inositol phosphate metabolism;ErbB signaling pathway;Phosphatidylinositol signaling system;mTOR signaling pathway;Apoptosis;VEGF signaling pathway;Focal adhesion;Toll-like receptor signaling pathway;Jak-STAT signaling pathway;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Leukocyte transendothelial migration;Regulation of actin cytoskeleton;Insulin signaling pathway;Type II diabetes mellitus;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer"	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4- phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors				0.0000	0.0000	0.0000														0	0					PIK3CB (inh=n/a pLI=1.00)	0							
chr3	149213581	149213581	C	T	0.4727	110	0.0000	83	"not-cod-spli;off-target"	209	TM4SF4,RP11-278L15.6	intron_variant,non_coding_transcript_exon_variant	TM4SF4:ENST00000305354:intron_variant:MODIFIER:exon3/4:c.402-2928C>T:,TM4SF4:ENST00000463068:intron_variant:MODIFIER:exon2/2:n.267-2928C>T:,RP11-278L15.6:ENST00000492880:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1135C>T:			Regulates the adhesive and proliferative status of intestinal epithelial cells. Can mediate density-dependent cell proliferation				0.0000	0.0000	0.0000														0	0					TM4SF4 (inh=n/a pLI=0.00), RP11-278L15.6 (inh=n/a pLI=n/a)	0							
chr3	169201807	169201807	C	T	0.3821	212	0.0000	181	"not-cod-spli;off-target"	307	MECOM,RP11-641D5.1	intron_variant,non_coding_transcript_exon_variant	MECOM:ENST00000494292:intron_variant:MODIFIER:exon1/15:c.38-102495G>A:,MECOM:ENST00000485957:intron_variant:MODIFIER:exon1/2:n.284-102495G>A:,MECOM:ENST00000486748:intron_variant:MODIFIER:exon2/2:c.109+81950G>A:,RP11-641D5.1:ENST00000418623:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.62G>A:		"MAPK signaling pathway;Chronic myeloid leukemia"	Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signaling. Involved in hematopoiesis				0.0000	0.0000	0.0000		"165215 [MECOM (confirmed) Radioulnar synostosis with amegakaryocytic thrombocytopenia 2,616738];"												0	0					MECOM (inh=n/a pLI=1.00), RP11-641D5.1 (inh=n/a pLI=n/a)	0							
chr3	189612350	189612350	C	T	0.3165	139	0.0000	130	"not-cod-spli;off-target"	194	TP63	3_prime_UTR_variant	TP63:ENST00000264731:3_prime_UTR_variant:MODIFIER:exon14/14:c.*59C>T:,TP63:ENST00000382063:3_prime_UTR_variant:MODIFIER:exon13/13:c.*59C>T:,TP63:ENST00000320472:3_prime_UTR_variant:MODIFIER:exon12/12:c.*330C>T:,TP63:ENST00000354600:3_prime_UTR_variant:MODIFIER:exon12/12:c.*59C>T:			Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter				0.0000	0.0000	0.0000		"603273 [TP63 (confirmed) Ectrodactyly,ectodermal dysplasia,and cleft lip/palate syndrome 3,604292|Split-hand/foot malformation 4,605289|Hay-Wells syndrome,106260|ADULT syndrome,103285|Limb-mammary syndrome,603543|Rapp-Hodgkin syndrome,129400|Orofacial cleft 8,129400];"												0	0					TP63 (inh=AD pLI=0.98)	0							
chr3	189612351	189612351	C	T	0.3188	138	0.0000	130	"not-cod-spli;off-target"	195	TP63	3_prime_UTR_variant	TP63:ENST00000264731:3_prime_UTR_variant:MODIFIER:exon14/14:c.*60C>T:,TP63:ENST00000382063:3_prime_UTR_variant:MODIFIER:exon13/13:c.*60C>T:,TP63:ENST00000320472:3_prime_UTR_variant:MODIFIER:exon12/12:c.*331C>T:,TP63:ENST00000354600:3_prime_UTR_variant:MODIFIER:exon12/12:c.*60C>T:			Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter				0.0000	0.0000	0.0000		"603273 [TP63 (confirmed) Ectrodactyly,ectodermal dysplasia,and cleft lip/palate syndrome 3,604292|Split-hand/foot malformation 4,605289|Hay-Wells syndrome,106260|ADULT syndrome,103285|Limb-mammary syndrome,603543|Rapp-Hodgkin syndrome,129400|Orofacial cleft 8,129400];"												0	0					TP63 (inh=AD pLI=0.98)	0							
chr3	196547300	196547300	C	T	0.3757	173	0.0000	142	"syn-var;off-target"	251	PAK2	synonymous_variant	PAK2:ENST00000327134:synonymous_variant:LOW:exon13/15:c.1212C>T:p.Val404Val,PAK2:ENST00000426668:synonymous_variant:LOW:exon5/6:c.438C>T:p.Val146Val		"MAPK signaling pathway;ErbB signaling pathway;Axon guidance;Focal adhesion;T cell receptor signaling pathway;Regulation of actin cytoskeleton;Renal cell carcinoma"	Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell motility, cell cycle progression, apoptosis or proliferation. Acts as downstream effector of the small GTPases CDC42 and RAC1. Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Full-length PAK2 stimulates cell survival and cell growth. Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration. Phosphorylates JUN and plays an important role in EGF- induced cell proliferation. Phosphorylates many other substrates including histone H4 to promote assembly of H3.3 and H4 into nucleosomes, BAD, ribosomal protein S6, or MBP. Additionally, associates with ARHGEF7 and GIT1 to perform kinase-independent functions such as spindle orientation control during mitosis. On the other hand, apoptotic stimuli such as DNA damage lead to caspase-mediated cleavage of PAK2, generating PAK-2p34, an active p34 fragment that translocates to the nucleus and promotes cellular apoptosis involving the JNK signaling pathway. Caspase- activated PAK2 phosphorylates MKNK1 and reduces cellular translation	"Agrin in Postsynaptic Differentiation;FAS signaling pathway ( CD95 );Fc Epsilon Receptor I Signaling in Mast Cells;HIV-I Nef: negative effector of Fas and TNF;MAPKinase Signaling Pathway;TNFR1 Signaling Pathway"		rs375799971	0.0000	0.00009	0.00009					-0.492000	T				13.29				0	0					PAK2 (inh=n/a pLI=0.94)	0		chr3_196547300_196547300_C_T	not protein-affecting	.	ENST00000327134	PAK2	Synonymous
chr4	1807879	1807879	C	T	0.6341	360	0.0029	350	syn-var	894	FGFR3	synonymous_variant,sequence_feature	FGFR3:ENST00000340107:synonymous_variant:LOW:exon14/18:c.1944C>T:p.Asp648Asp,FGFR3:ENST00000481110:synonymous_variant:LOW:exon14/17:c.1941C>T:p.Asp647Asp,FGFR3:ENST00000412135:synonymous_variant:LOW:exon12/16:c.1602C>T:p.Asp534Asp,FGFR3:ENST00000440486:synonymous_variant:LOW:exon14/18:c.1938C>T:p.Asp646Asp,FGFR3:ENST00000260795:synonymous_variant:LOW:exon13/17:c.1938C>T:p.Asp646Asp,FGFR3:ENST00000352904:synonymous_variant:LOW:exon11/15:c.1602C>T:p.Asp534Asp,FGFR3:ENST00000340107:sequence_feature:LOW:exon14/18:c.1944C>T:,FGFR3:ENST00000412135:sequence_feature:LOW:exon12/16:c.1602C>T:,FGFR3:ENST00000440486:sequence_feature:LOW:exon14/18:c.1938C>T:		"MAPK signaling pathway;Regulation of actin cytoskeleton;Bladder cancer"	Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B			rs767489382	0.0000	0.00001	0.00001		"134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];"												0	0					FGFR3 (inh=AR+AD pLI=0.00)	0		chr4_1807879_1807879_C_T	not protein-affecting	Act	ENST00000440486	FGFR3	Synonymous
chr4	133885705	133885705	G	A	0.6364	22	0.0000	19	"not-cod-spli;depth-nor;off-target"	43	RP11-404I7.2	intron_variant	RP11-404I7.2:ENST00000509628:intron_variant:MODIFIER:exon1/2:n.32+17096C>T:							0.0000	0.0000	0.0000														0	0					RP11-404I7.2 (inh=n/a pLI=n/a)	0							
chr5	1254104	1254104	G	A	0.3571	56	0.0000	19	"not-cod-spli;depth-nor;off-target"	47	TERT	intron_variant	TERT:ENST00000310581:intron_variant:MODIFIER:exon15/15:c.3296-158C>T:,TERT:ENST00000484238:intron_variant:MODIFIER:exon10/10:n.1738-158C>T:,TERT:ENST00000296820:intron_variant:MODIFIER:exon13/13:c.*690-158C>T:,TERT:ENST00000334602:intron_variant:MODIFIER:exon14/14:c.3107-158C>T:,TERT:ENST00000460137:intron_variant:MODIFIER:exon12/12:c.*501-158C>T:			Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA- dependent extension of 3'-chromosomal termini with the 6- nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis	"Role of nicotinic acetylcholine receptors in the regulation of apoptosis;Telomeres, Telomerase, Cellular Aging, and  Immortality"		rs571636002	0.000798722	0.0000	0.0000		"187270 [TERT (confirmed) Pulmonary fibrosis and/or bone marrow failure,telomere-related,1,614742|Dyskeratosis congenita,autosomal recessive 4,613989|Dyskeratosis congenita,autosomal dominant 2,613989|Leukemia,acute myeloid,601626|Melanoma,cutaneous malignant,9,615134];"												0	0					TERT (inh=AD pLI=0.87)	0							
chr5	67522715	67522715	G	A	0.6076	553	0.0000	459		1240	PIK3R1	missense_variant,sequence_feature,non_coding_transcript_exon_variant	PIK3R1:ENST00000396611:missense_variant:MODERATE:exon1/15:c.212G>A:p.Gly71Glu,PIK3R1:ENST00000521381:missense_variant:MODERATE:exon2/16:c.212G>A:p.Gly71Glu,PIK3R1:ENST00000521657:missense_variant:MODERATE:exon2/16:c.212G>A:p.Gly71Glu,PIK3R1:ENST00000274335:missense_variant:MODERATE:exon1/15:c.212G>A:p.Gly71Glu,PIK3R1:ENST00000521657:sequence_feature:LOW:exon2/16:c.212G>A:,PIK3R1:ENST00000517412:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.451G>A:	Src_homology-3_domain__3_,Variant_SH3__1_	"ErbB signaling pathway;Phosphatidylinositol signaling system;mTOR signaling pathway;Apoptosis;VEGF signaling pathway;Focal adhesion;Toll-like receptor signaling pathway;Jak-STAT signaling pathway;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Leukocyte transendothelial migration;Regulation of actin cytoskeleton;Insulin signaling pathway;Type II diabetes mellitus;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer"	Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling	"AKT Signaling Pathway;Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK);Corticosteroids and cardioprotection;CTCF: First Multivalent Nuclear Factor;CXCR4 Signaling Pathway;EGF Signaling Pathway;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Fc Epsilon Receptor I Signaling in Mast Cells;Growth Hormone Signaling Pathway;Human Cytomegalovirus and Map Kinase Pathways;IGF-1 Signaling Pathway;IL-2 Receptor Beta Chain in T cell Activation;IL-7 Signal Transduction;Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages;Influence of Ras and Rho proteins on G1 to S Transition;Inhibition of Cellular Proliferation by Gleevec;Insulin Signaling Pathway;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);mTOR Signaling Pathway;Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation;Nerve growth factor pathway (NGF);NFAT and Hypertrophy of the heart (Transcription in the broken heart);PDGF Signaling Pathway;Phospholipase C Signaling Pathway;Phospholipids as signalling intermediaries;PTEN dependent cell cycle arrest and apoptosis;Rac 1 cell motility signaling pathway;Ras Signaling Pathway;Ras-Independent pathway in NK cell-mediated cytotoxicity;Regulation of BAD phosphorylation;Regulation of eIF4e and p70 S6 Kinase;Role of ERBB2 in Signal Transduction and Oncology;Role of Erk5 in Neuronal Survival;Role of nicotinic acetylcholine receptors in the regulation of apoptosis;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration;Signaling of Hepatocyte Growth Factor Receptor;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway;T Cell Receptor Signaling Pathway;The Co-Stimulatory Signal During T-cell Activation;The IGF-1 Receptor and Longevity;Thrombin signaling and protease-activated receptors;TPO Signaling Pathway;Transcription factor CREB and its extracellular signals;Trefoil Factors Initiate  Mucosal Healing;Trka Receptor Signaling Pathway;Tumor Suppressor Arf Inhibits Ribosomal Biogenesis;VEGF, Hypoxia, and Angiogenesis"			0.0000	0.0000	0.0000		"171833 [PIK3R1 (provisional) Agammaglobulinemia 7,autosomal recessive,615214|SHORT syndrome,269880|Immunodeficiency 36,616005];"			9.813.000	T	D,D,D,D	D	T,T,T,T	28.30				0	0					PIK3R1 (inh=AR+AD pLI=1.00)	0		chr5_67522715_67522715_G_A	predicted driver: tier 1	LoF	ENST00000521381	PIK3R1	Missense
chr5	112090708	112090708	G	A	0.5685	496	0.0000	583		1268	APC	missense_variant,intron_variant,non_coding_transcript_exon_variant	APC:ENST00000257430:missense_variant:MODERATE:exon2/16:c.121G>A:p.Ala41Thr,APC:ENST00000509732:missense_variant:MODERATE:exon2/4:c.121G>A:p.Ala41Thr,APC:ENST00000457016:missense_variant:MODERATE:exon2/16:c.121G>A:p.Ala41Thr,APC:ENST00000508624:missense_variant:MODERATE:exon2/17:c.121G>A:p.Ala41Thr,APC:ENST00000508376:missense_variant:MODERATE:exon3/17:c.121G>A:p.Ala41Thr,APC:ENST00000512211:missense_variant:MODERATE:exon2/16:c.121G>A:p.Ala41Thr,APC:ENST00000507379:intron_variant:MODIFIER:exon1/13:c.166-11315G>A:,APC:ENST00000505350:non_coding_transcript_exon_variant:MODIFIER:exon2/3:n.501G>A:		"Wnt signaling pathway;Regulation of actin cytoskeleton;Colorectal cancer;Endometrial cancer;Basal cell carcinoma"	Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. It is required for the localization of MACF1 to the cell membrane and this localization of MACF1 is critical for its function in microtubule stabilization	"ALK in cardiac myocytes;Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages;Multi-step Regulation of Transcription by Pitx2;Presenilin action in Notch and Wnt signaling;TGF beta signaling pathway;WNT Signaling Pathway"			0.0000	0.0000	0.0000		"611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];"			9.326.000	T	T,T,T,T,T	B	T,T,T,T,T	17. Jul				0	0					APC (inh=AD pLI=1.00)	0		chr5_112090708_112090708_G_A	predicted passenger	LoF	ENST00000257430	APC	Missense
chr5	131925254	131925254	C	T	0.6852	54	0.0000	105	"not-cod-spli;off-target"	281	RAD50	intron_variant	RAD50:ENST00000265335:intron_variant:MODIFIER:exon8/24:c.1246-69C>T:,RAD50:ENST00000378823:intron_variant:MODIFIER:exon8/24:c.829-69C>T:,RAD50:ENST00000533482:intron_variant:MODIFIER:exon8/24:c.*872-69C>T:,RAD50:ENST00000453394:intron_variant:MODIFIER:exon8/11:c.1246-69C>T:,RAD50:ENST00000423956:intron_variant:MODIFIER:exon8/17:c.1246-69C>T:		"Homologous recombination;Non-homologous end-joining"	Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis. The complex possesses single-strand endonuclease activity and double-strand- specific 3'-5' exonuclease activity, which are provided by MRE11A. RAD50 may be required to bind DNA ends and hold them in close proximity. This could facilitate searches for short or long regions of sequence homology in the recombining DNA templates, and may also stimulate the activity of DNA ligases and/or restrict the nuclease activity of MRE11A to prevent nucleolytic degradation past a given point. The complex may also be required for DNA damage signaling via activation of the ATM kinase. In telomeres the MRN complex may modulate t-loop formation	"ATM Signaling Pathway;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility"			0.0000	0.0000	0.0000		"604040 [RAD50 (provisional) Nijmegen breakage syndrome-like disorder,613078];"												0	0					RAD50 (inh=AR pLI=0.00)	0							
chr5	131927550	131927550	-	T	0.5816	112	0.0000	124		262	RAD50	splice_region_variant&intron_variant,intron_variant	RAD50:ENST00000265335:splice_region_variant&intron_variant:LOW:exon10/24:c.1636-9dupT:,RAD50:ENST00000378823:splice_region_variant&intron_variant:LOW:exon10/24:c.1219-9dupT:,RAD50:ENST00000533482:splice_region_variant&intron_variant:LOW:exon10/24:c.*1262-9dupT:,RAD50:ENST00000453394:splice_region_variant&intron_variant:LOW:exon9/11:c.1453-9dupT:,RAD50:ENST00000434288:splice_region_variant&intron_variant:LOW:exon1/2:c.130-9dupT:,RAD50:ENST00000423956:intron_variant:MODIFIER:exon10/17:c.1635+462dupT:		"Homologous recombination;Non-homologous end-joining"	Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis. The complex possesses single-strand endonuclease activity and double-strand- specific 3'-5' exonuclease activity, which are provided by MRE11A. RAD50 may be required to bind DNA ends and hold them in close proximity. This could facilitate searches for short or long regions of sequence homology in the recombining DNA templates, and may also stimulate the activity of DNA ligases and/or restrict the nuclease activity of MRE11A to prevent nucleolytic degradation past a given point. The complex may also be required for DNA damage signaling via activation of the ATM kinase. In telomeres the MRN complex may modulate t-loop formation	"ATM Signaling Pathway;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility"		rs764051891	0.0000	0.00491	0.00429		"604040 [RAD50 (provisional) Nijmegen breakage syndrome-like disorder,613078];"												0	11					RAD50 (inh=AR pLI=0.00)	0							
chr6	7988298	7988298	G	A	0.3375	320	0.0000	235	"not-cod-spli;off-target"	352	BLOC1S5-TXNDC5,TXNDC5,PIP5K1P1	intron_variant,non_coding_transcript_exon_variant	BLOC1S5-TXNDC5:ENST00000439343:intron_variant:MODIFIER:exon4/12:c.372+38302C>T:,TXNDC5:ENST00000539054:intron_variant:MODIFIER:exon1/9:c.47+38302C>T:,PIP5K1P1:ENST00000460661:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1529G>A:,PIP5K1P1:ENST00000438779:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1569G>A:			Possesses thioredoxin activity. Has been shown to reduce insulin disulfide bonds. Also complements protein disulfide- isomerase deficiency in yeast (By similarity)				0.0000	0.0000	0.00000														0	0					BLOC1S5-TXNDC5 (inh=n/a pLI=n/a), TXNDC5 (inh=n/a pLI=0.00), PIP5K1P1 (inh=n/a pLI=n/a)	0							
chr6	93982167	93982167	C	A	0.3532	436	0.0000	356	"not-cod-spli;off-target"	514	EPHA7	sequence_feature,intron_variant	EPHA7:ENST00000369303:sequence_feature:LOW::c.1325-27G>T:,EPHA7:ENST00000369303:intron_variant:MODIFIER:exon5/16:c.1325-27G>T:		Axon guidance	Receptor tyrosine kinase which binds promiscuously GPI- anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signaling may result in activation of components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 AND MAPK3 which are phosphorylated upon activation of EPHA7				0.0000	0.0000	0.0000														0	0					EPHA7 (inh=n/a pLI=0.99)	0							
chr6	117609547	117609547	A	C	0.4041	146	0.0000	122	"not-cod-spli;off-target"	238	ROS1	3_prime_UTR_variant	ROS1:ENST00000368508:3_prime_UTR_variant:MODIFIER:exon43/43:c.*108T>G:,ROS1:ENST00000368507:3_prime_UTR_variant:MODIFIER:exon44/44:c.*108T>G:			Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2				0.0000	0.0000	0.0000														0	0					ROS1 (inh=n/a pLI=0.00)	0							
chr6	117643569	117643569	C	T	0.3355	1087	0.0000	796	not-cod-spli	1020	ROS1,GOPC	intron_variant	ROS1:ENST00000368508:intron_variant:MODIFIER:exon34/42:c.5642-1012G>A:,ROS1:ENST00000368507:intron_variant:MODIFIER:exon35/43:c.5624-1012G>A:,GOPC:ENST00000467125:intron_variant:MODIFIER:exon4/6:n.548-1012G>A:			Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.,Plays a role in intracellular protein trafficking and degradation. May regulate CFTR chloride currents and acid-induced ASIC3 currents by modulating cell surface expression of both channels. May also regulate the intracellular trafficking of the ADR1B receptor. May play a role in autophagy. Overexpression results in CFTR intracellular retention and degradation in the lysosomes				0.0000	0.0000	0.0000														0	0					ROS1 (inh=n/a pLI=0.00), GOPC (inh=n/a pLI=0.02)	0							
chr6	117645576	117645576	C	T	0.3348	448	0.0000	453		575	ROS1,GOPC	missense_variant&splice_region_variant,intron_variant	ROS1:ENST00000368508:missense_variant&splice_region_variant:MODERATE:exon34/43:c.5560G>A:p.Asp1854Asn,ROS1:ENST00000368507:missense_variant&splice_region_variant:MODERATE:exon35/44:c.5542G>A:p.Asp1848Asn,GOPC:ENST00000467125:intron_variant:MODIFIER:exon4/6:n.548-3019G>A:			Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.,Plays a role in intracellular protein trafficking and degradation. May regulate CFTR chloride currents and acid-induced ASIC3 currents by modulating cell surface expression of both channels. May also regulate the intracellular trafficking of the ADR1B receptor. May play a role in autophagy. Overexpression results in CFTR intracellular retention and degradation in the lysosomes				0.0000	0.0000	0.0000					2.001.000	T	T,T	B	T,T	21.60				0	0					ROS1 (inh=n/a pLI=0.00), GOPC (inh=n/a pLI=0.02)	0		chr6_117645576_117645576_C_T	predicted passenger	Act	ENST00000368508	ROS1	Missense
chr6	117646923	117646923	C	T	0.3953	506	0.0000	380	not-cod-spli	634	ROS1,GOPC	intron_variant	ROS1:ENST00000368508:intron_variant:MODIFIER:exon33/42:c.5557+464G>A:,ROS1:ENST00000368507:intron_variant:MODIFIER:exon34/43:c.5539+464G>A:,GOPC:ENST00000467125:intron_variant:MODIFIER:exon4/6:n.548-4366G>A:			Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.,Plays a role in intracellular protein trafficking and degradation. May regulate CFTR chloride currents and acid-induced ASIC3 currents by modulating cell surface expression of both channels. May also regulate the intracellular trafficking of the ADR1B receptor. May play a role in autophagy. Overexpression results in CFTR intracellular retention and degradation in the lysosomes				0.0000	0.0000	0.0000														0	0					ROS1 (inh=n/a pLI=0.00), GOPC (inh=n/a pLI=0.02)	0							
chr6	134583387	134583387	G	A	0.2889	45	0.0000	57	"not-cod-spli;off-target"	104	SGK1	intron_variant	SGK1:ENST00000367858:intron_variant:MODIFIER:exon1/13:c.70-101C>T:,SGK1:ENST00000461976:intron_variant:MODIFIER:exon1/5:c.-24-101C>T:,SGK1:ENST00000524929:intron_variant:MODIFIER:exon1/1:c.70-101C>T:,SGK1:ENST00000533224:intron_variant:MODIFIER:exon2/2:c.70-101C>T:			Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1				0.0000	0.0000	0.0000														0	0					SGK1 (inh=n/a pLI=0.99)	0							
chr6	152647771	152647771	G	A	0.3421	606	0.0000	459		642	SYNE1	splice_region_variant&intron_variant	SYNE1:ENST00000265368:splice_region_variant&intron_variant:LOW:exon78/145:c.14956-3C>T:,SYNE1:ENST00000367255:splice_region_variant&intron_variant:LOW:exon78/145:c.14956-3C>T:,SYNE1:ENST00000423061:splice_region_variant&intron_variant:LOW:exon77/145:c.14743-3C>T:,SYNE1:ENST00000341594:splice_region_variant&intron_variant:LOW:exon81/146:c.14197-3C>T:,SYNE1:ENST00000448038:splice_region_variant&intron_variant:LOW:exon78/146:c.14743-3C>T:,SYNE1:ENST00000490135:splice_region_variant&intron_variant:LOW:exon2/10:n.2302-3C>T:			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis				0.0000	0.0000	0.0000		"608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];"												0	0					SYNE1 (inh=AR+AD pLI=0.00)	0							
chr6	152651733	152651733	C	T	0.3470	611	0.0000	465		656	SYNE1	missense_variant,non_coding_transcript_exon_variant	SYNE1:ENST00000265368:missense_variant:MODERATE:exon78/146:c.14087G>A:p.Arg4696Lys,SYNE1:ENST00000367255:missense_variant:MODERATE:exon78/146:c.14087G>A:p.Arg4696Lys,SYNE1:ENST00000423061:missense_variant:MODERATE:exon77/146:c.13874G>A:p.Arg4625Lys,SYNE1:ENST00000341594:missense_variant:MODERATE:exon81/147:c.13328G>A:p.Arg4443Lys,SYNE1:ENST00000448038:missense_variant:MODERATE:exon78/147:c.13874G>A:p.Arg4625Lys,SYNE1:ENST00000490135:non_coding_transcript_exon_variant:MODIFIER:exon2/11:n.1433G>A:			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs776787640	0.0000	0.00001	0.00000		"608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];"			0.576000	T	T,T,T,T,T	B,B,B,B	T,T,T,T,T	0.00				0	0					SYNE1 (inh=AR+AD pLI=0.00)	0		chr6_152651733_152651733_C_T	predicted passenger	.	ENST00000367255	SYNE1	Missense
chr6	152668084	152668084	C	T	0.4409	94	0.0000	72	"not-cod-spli;off-target"	175	SYNE1	intron_variant	SYNE1:ENST00000265368:intron_variant:MODIFIER:exon73/145:c.12078+110G>A:,SYNE1:ENST00000367255:intron_variant:MODIFIER:exon73/145:c.12078+110G>A:,SYNE1:ENST00000423061:intron_variant:MODIFIER:exon72/145:c.11865+110G>A:,SYNE1:ENST00000341594:intron_variant:MODIFIER:exon75/146:c.11674-2722G>A:,SYNE1:ENST00000448038:intron_variant:MODIFIER:exon73/146:c.11865+110G>A:,SYNE1:ENST00000471834:intron_variant:MODIFIER:exon16/18:n.5216+110G>A:			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis				0.0000	0.0000	0.0000		"608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];"												0	0					SYNE1 (inh=AR+AD pLI=0.00)	0							
chr6	152751754	152751754	C	T	0.3711	1115	0.0000	795		1178	SYNE1	missense_variant,non_coding_transcript_exon_variant	SYNE1:ENST00000265368:missense_variant:MODERATE:exon35/146:c.4552G>A:p.Glu1518Lys,SYNE1:ENST00000367255:missense_variant:MODERATE:exon35/146:c.4552G>A:p.Glu1518Lys,SYNE1:ENST00000423061:missense_variant:MODERATE:exon35/146:c.4573G>A:p.Glu1525Lys,SYNE1:ENST00000341594:missense_variant:MODERATE:exon38/147:c.4762G>A:p.Glu1588Lys,SYNE1:ENST00000448038:missense_variant:MODERATE:exon36/147:c.4573G>A:p.Glu1525Lys,SYNE1:ENST00000367253:missense_variant:MODERATE:exon33/36:c.4552G>A:p.Glu1518Lys,SYNE1:ENST00000461872:non_coding_transcript_exon_variant:MODIFIER:exon33/55:n.4770G>A:			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis				0.0000	0.0000	0.0000		"608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];"			6.736.000	T	D,D,D,D,D,D	D,P,D,P,P	T,T,T,T,T,T	28.60				0	0					SYNE1 (inh=AR+AD pLI=0.00)	0		chr6_152751754_152751754_C_T	predicted passenger	.	ENST00000367255	SYNE1	Missense
chr6	163836176	163836178	CGG	-	0.0215	346	0.0000	138	"not-cod-spli;freq-tum;off-target"	44	QKI	5_prime_UTR_variant	QKI:ENST00000361752:5_prime_UTR_variant:MODIFIER:exon1/8:c.-29_-27delCGG:,QKI:ENST00000361758:5_prime_UTR_variant:MODIFIER:exon1/8:c.-29_-27delCGG:,QKI:ENST00000275262:5_prime_UTR_variant:MODIFIER:exon1/7:c.-29_-27delCGG:,QKI:ENST00000392127:5_prime_UTR_variant:MODIFIER:exon1/6:c.-29_-27delCGG:,QKI:ENST00000453779:5_prime_UTR_variant:MODIFIER:exon1/7:c.-29_-27delCGG:			RNA-binding protein that plays a central role in myelinization. Binds to the 5'-NACUAAY-N(1,20)-UAAY-3' RNA core sequence. Acts by regulating pre-mRNA splicing, mRNA export, mRNA stability and protein translation. Required to protect and promote stability of mRNAs such as MBP and CDKN1B. Regulator of oligodendrocyte differentiation and maturation in the brain that may play a role in myelin and oligodendrocyte dysfunction in schizophrenia. Participates in mRNA transport by regulating the nuclear export of MBP mRNA. Also involved in regulation of mRNA splicing of MAG pre-mRNA. Acts as a translational repressor (By similarity)			rs752519245	0.0000	0.01689	0.02606														0	13					QKI (inh=n/a pLI=0.96)	0							
chr7	2955146	2955146	C	T	0.3210	81	0.0000	79	"not-cod-spli;off-target"	142	CARD11	intron_variant	CARD11:ENST00000396946:intron_variant:MODIFIER:exon20/24:c.2704-140G>A:		"T cell receptor signaling pathway;B cell receptor signaling pathway"	Involved in the costimulatory signal essential for T- cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Activates NF-kappa-B via BCL10 and IKK. Stimulates the phosphorylation of BCL10				0.0000	0.0000	0.0000		"607210 [CARD11 (provisional) B-cell expansion with NFKB and T-cell anergy,616452|Immunodeficiency 11,615206];"												0	0					CARD11 (inh=AR pLI=1.00)	0							
chr7	57269043	57269043	C	T	0.3400	50	0.0000	56	off-target	116	GUSBP12	splice_region_variant&non_coding_transcript_exon_variant	GUSBP12:ENST00000513727:splice_region_variant&non_coding_transcript_exon_variant:LOW:exon3/4:n.390G>A:,GUSBP12:ENST00000412912:splice_region_variant&non_coding_transcript_exon_variant:LOW:exon2/4:n.185G>A:							0.0000	0.0000	0.0000														0	0					GUSBP12 (inh=n/a pLI=n/a)	0							
chr7	57269097	57269097	G	A	0.3438	32	0.0000	40	"not-cod-spli;off-target"	97	GUSBP12	intron_variant	GUSBP12:ENST00000513727:intron_variant:MODIFIER:exon2/3:n.389-53C>T:,GUSBP12:ENST00000412912:intron_variant:MODIFIER:exon1/3:n.184-53C>T:							0.0000	0.0000	0.0000														0	0					GUSBP12 (inh=n/a pLI=n/a)	0							
chr7	84658220	84658220	G	A	0.3918	293	0.0000	196	"not-cod-spli;off-target"	362	SEMA3D,HSPA8P16	intron_variant,non_coding_transcript_exon_variant	SEMA3D:ENST00000284136:intron_variant:MODIFIER:exon10/16:c.1192-6291C>T:,SEMA3D:ENST00000484038:intron_variant:MODIFIER:exon3/9:n.318-6291C>T:,HSPA8P16:ENST00000454171:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1077G>A:		Axon guidance	Induces the collapse and paralysis of neuronal growth cones. Could potentially act as repulsive cues toward specific neuronal populations. Binds to neuropilin (By similarity)				0.0000	0.0000	0.0000														0	0					SEMA3D (inh=n/a pLI=0.00), HSPA8P16 (inh=n/a pLI=n/a)	0							
chr7	97793095	97793095	T	A	0.3857	71	0.0000	68	"not-cod-spli;off-target"	145	LMTK2	intron_variant	LMTK2:ENST00000297293:intron_variant:MODIFIER:exon6/13:c.657+4358T>A:			Phosphorylates PPP1C, phosphorylase b and CFTR				0.0000	0.0000	0.0000														0	0					LMTK2 (inh=n/a pLI=0.99)	0							
chr7	98551029	98551029	C	T	0.3562	467	0.0026	382	syn-var	505	TRRAP	synonymous_variant	TRRAP:ENST00000359863:synonymous_variant:LOW:exon39/72:c.5682C>T:p.Phe1894Phe,TRRAP:ENST00000355540:synonymous_variant:LOW:exon38/71:c.5628C>T:p.Phe1876Phe,TRRAP:ENST00000446306:synonymous_variant:LOW:exon37/70:c.5625C>T:p.Phe1875Phe,TRRAP:ENST00000456197:synonymous_variant:LOW:exon30/63:c.4845C>T:p.Phe1615Phe			Adapter protein, which is found in various multiprotein chromatin complexes with histone acetyltransferase activity (HAT), which gives a specific tag for epigenetic transcription activation. Component of the NuA4 histone acetyltransferase complex which is responsible for acetylation of nucleosomal histones H4 and H2A. Plays a central role in MYC transcription activation, and also participates in cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4-mediated transcription activation. Also involved in transcription activation mediated by the adenovirus E1A, a viral oncoprotein that deregulates transcription of key genes. Probably acts by linking transcription factors such as E1A, MYC or E2F1 to HAT complexes such as STAGA thereby allowing transcription activation. Probably not required in the steps following histone acetylation in processes of transcription activation. May be required for the mitotic checkpoint and normal cell cycle progression	Multi-step Regulation of Transcription by Pitx2		rs781821183	0.0000	0.00002	0.00001					-0.126000	T				15.22				0	1					TRRAP (inh=n/a pLI=1.00)	0		chr7_98551029_98551029_C_T	not protein-affecting	ambiguous	ENST00000355540	TRRAP	Synonymous
chr7	99459310	99459310	C	T	0.3720	674	0.0000	441	"syn-var;off-target"	703	CYP3A43	synonymous_variant,3_prime_UTR_variant,intron_variant,non_coding_transcript_exon_variant	CYP3A43:ENST00000222382:synonymous_variant:LOW:exon11/13:c.1101C>T:p.Phe367Phe,CYP3A43:ENST00000354829:synonymous_variant:LOW:exon11/13:c.1101C>T:p.Phe367Phe,CYP3A43:ENST00000342499:synonymous_variant:LOW:exon9/10:c.681C>T:p.Phe227Phe,CYP3A43:ENST00000417625:synonymous_variant:LOW:exon8/10:c.771C>T:p.Phe257Phe,CYP3A43:ENST00000415413:synonymous_variant:LOW:exon5/7:c.468C>T:p.Phe156Phe,CYP3A43:ENST00000444905:synonymous_variant:LOW:exon4/5:c.342C>T:p.Phe114Phe,CYP3A43:ENST00000312017:synonymous_variant:LOW:exon11/12:c.1101C>T:p.Phe367Phe,CYP3A43:ENST00000436834:3_prime_UTR_variant:MODIFIER:exon9/10:c.*787C>T:,CYP3A43:ENST00000433277:3_prime_UTR_variant:MODIFIER:exon9/10:c.*663C>T:,CYP3A43:ENST00000434806:3_prime_UTR_variant:MODIFIER:exon12/14:c.*469C>T:,CYP3A43:ENST00000463915:intron_variant:MODIFIER:exon2/2:n.299+1697C>T:,CYP3A43:ENST00000477658:non_coding_transcript_exon_variant:MODIFIER:exon7/8:n.772C>T:,CYP3A43:ENST00000491648:non_coding_transcript_exon_variant:MODIFIER:exon5/7:n.569C>T:,CYP3A43:ENST00000495115:non_coding_transcript_exon_variant:MODIFIER:exon3/4:n.374C>T:,CYP3A43:ENST00000481362:non_coding_transcript_exon_variant:MODIFIER:exon8/10:n.1437C>T:,CYP3A43:ENST00000472352:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.534C>T:		"gamma-Hexachlorocyclohexane degradation;Linoleic acid metabolism;Retinol metabolism;Metabolism of xenobiotics by cytochrome P450;Drug metabolism - cytochrome P450;Drug metabolism - other enzymes"	Exhibits low testosterone 6-beta-hydroxylase activity				0.0000	0.0000	0.0000														0	0					CYP3A43 (inh=n/a pLI=0.00)	0		chr7_99459310_99459310_C_T	not protein-affecting	.	ENST00000222382	CYP3A43	Synonymous
chr7	107415387	107415387	C	T	0.3714	351	0.0000	251	"not-cod-spli;off-target"	410	SLC26A3	intron_variant	SLC26A3:ENST00000340010:intron_variant:MODIFIER:exon15/20:c.1678-70G>A:,SLC26A3:ENST00000379083:intron_variant:MODIFIER:exon15/19:c.*1469-70G>A:,SLC26A3:ENST00000422236:intron_variant:MODIFIER:exon15/19:c.1573-70G>A:			Chloride/bicarbonate exchanger. Mediates the efficient absorbtion of chloride ions in the colon, participating in fluid homeostasis. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation				0.0000	0.0000	0.0000		"126650 [SLC26A3 (confirmed) Diarrhea 1,secretory chloride,congenital,214700];"												0	0					SLC26A3 (inh=AR pLI=0.00)	0							
chr7	140453136	140453136	A	T	0.5611	1788	0.0000	745		2094	BRAF	missense_variant,3_prime_UTR_variant	BRAF:ENST00000288602:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu,BRAF:ENST00000496384:missense_variant:MODERATE:exon6/10:c.620T>A:p.Val207Glu,BRAF:ENST00000479537:missense_variant:MODERATE:exon2/6:c.83T>A:p.Val28Glu,BRAF:ENST00000497784:3_prime_UTR_variant:MODIFIER:exon16/19:c.*1249T>A:	Serine-threonine/tyrosine-protein_kinase__1_,Protein_kinase-like_domain__1_,Protein_kinase__catalytic_domain__1_,	"MAPK signaling pathway;ErbB signaling pathway;mTOR signaling pathway;Focal adhesion;Natural killer cell mediated cytotoxicity;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer"	Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron	MAPKinase Signaling Pathway		rs113488022	0.0000	0.00002	0.00000	COSM476	"164757 [BRAF (confirmed) Melanoma,malignant,somatic|Colorectal cancer,somatic|Adenocarcinoma of lung,somatic,211980|Nonsmall cell lung cancer,somatic|Cardiofaciocutaneous syndrome,115150|Noonan syndrome 7,613706|LEOPARD syndrome 3,613707];"	"RCV000014992.14 [pathogenic]; RCV000014993.14 [pathogenic]; RCV000014994.14 [pathogenic]; RCV000022677.14 [pathogenic]; RCV000037936.2 [pathogenic]; RCV000067669.13 [pathogenic]; RCV000080903.4 [pathogenic]; RCV000208763.1 [pathogenic]; "		9.197000,9.197000	T,	D,	D,	D,	32.00				5	2		"[import GPD] Christopher Schroeder 2013-05-07 09:14:08 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/21663470?dopt=Abstract&holding=npg -doi: 10.1056/NEJMoa1014209 BRAF mutations in hairy-cell leukemia.  [import GPD] Christopher Schroeder 2013-05-07 09:14:45 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22210875?dopt=Abstract&holding=npg -doi: 10.1182/blood-2011-09-379339 Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.  [import GPD] Christopher Schroeder 2013-05-02 17:26:11 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMc1215697?query=TOC -drugs: vemurafenib BRAF V600E Inhibition in Anaplastic Thyroid Cancer  [import GPD] Christopher Schroeder 2013-05-07 18:21:28 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22395615?dopt=Abstract&holding=npg -doi: 10.1038/ncomms1727 Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.  [import GPD] Christopher Schroeder 2013-05-15 11:43:10 -type: lit / preclinical study -link: http://www.nature.com/nature/journal/v483/n7387/full/nature10868.html -doi: 10.1038/nature10868 -drugs: vemurafenib, cetuximab, gefitinib, panitumumab Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.  => Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8–10% of all colon cancers2, 3, 5), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.  [import GPD] Christopher Schroeder 2013-05-03 17:12:18 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMoa1103782 -drugs: vemurafenib Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation  [import GPD] Christopher Schroeder 2013-05-28 15:50:19 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/20818844 -doi: 10.1056/NEJMoa1002011 -drugs: vemurafenib Inhibition of mutated, activated BRAF in metastatic melanoma. => Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.  [import GPD] Christopher Schroeder 2013-06-05 15:32:18 -type: lit / druggable -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.45.7739?papetoc -doi: 10.1200/JCO.2012.45.7739 -drugs: vemurafenib Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation  [import GPD] Christopher Schroeder 2013-09-04 10:29:28 -type: lit / preclinical study -link: http://www.ncbi.nlm.nih.gov/pubmed/18676837 -doi: 10.1158/0008-5472.CAN-08-1430 -drugs: selumetinib, Trametinib Tumors harboring BRAF V600E mutations lack this negative feedback loop and are sensitive to MEK inhibitors.  [import GPD] Christopher Schroeder 2013-12-22 15:16:45 -type: lit / clinical trial -link: http://jco.ascopubs.org/content/31/35/e448?cmpid=jco_etoc_10December2013 -doi: 10.1200/JCO.2013.50.4118 -drugs: dabrafenib, Trametinib BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition => First, caution must be exercised when using BRAFis in patients or populations that might harbor RAS-mutated cells, be they in skin, bowel, or other sites.  [import GPD] Christopher Schroeder 2013-06-05 15:27:37 -type: case report -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.47.6143?papetoc -doi: 10.1200/JCO.2012.47.6143 -drugs: vemurafenib, radiation Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma. Radiosensitizing effect of vemurafenib (""should probably not be combined with radiation"")."			BRAF (inh=AR+AD pLI=1.00)	16	SomaticAndTreatment,TEST_cfDNA_ThruPLEX_Tag-seq,	chr7_140453136_140453136_A_T	known in: G;head_and_neck_squamous_cell_carcinoma;colorectal_cancer;brain_glioma;colon_cancer;ovarian_cancer;brain_stem_glioma;gastrointestinal_stromal_tumor;CM;brain_cancer;thyroid_carcinoma;lung_adenocarcinoma;non-small_cell_lung_carcinoma;HCL;papillary_renal_cell_carcinoma;THCA;LUAD;papillary_thyroid_carcinoma;COREAD;myeloma;skin_melanoma;OV;NEU;MYMA;lung_cancer;HISEC;MA;TH;melanoma;NSCLC;glioblastoma_multiforme;GIST;hairy_cell_leukemia;PG;multiple_myeloma;thyroid_cancer;cancer;HISLC	Act	ENST00000288602	BRAF	Missense
chr7	142568218	142568218	G	A	0.2961	485	0.0000	281	"not-cod-spli;off-target"	377	EPHB6	intron_variant	EPHB6:ENST00000392957:intron_variant:MODIFIER:exon18/19:c.2801+58G>A:,EPHB6:ENST00000442129:intron_variant:MODIFIER:exon18/19:c.2801+58G>A:,EPHB6:ENST00000466783:intron_variant:MODIFIER:exon16/17:n.3951+58G>A:,EPHB6:ENST00000425995:intron_variant:MODIFIER:exon17/18:c.*2583+58G>A:,EPHB6:ENST00000422643:intron_variant:MODIFIER:exon16/17:c.*1946+58G>A:,EPHB6:ENST00000411471:intron_variant:MODIFIER:exon13/14:c.1970+58G>A:,EPHB6:ENST00000486511:intron_variant:MODIFIER:exon5/6:n.1845+58G>A:,EPHB6:ENST00000471581:intron_variant:MODIFIER:exon2/2:n.389+58G>A:,EPHB6:ENST00000476059:intron_variant:MODIFIER:exon2/3:n.263+58G>A:		Axon guidance	Kinase-defective receptor for members of the ephrin-B family. Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2				0.0000	0.0000	0.0000														0	0					EPHB6 (inh=n/a pLI=0.25)	0							
chr7	142655413	142655413	G	A	0.2485	685	0.0000	407		433	KEL	missense_variant,non_coding_transcript_exon_variant	KEL:ENST00000355265:missense_variant:MODERATE:exon5/19:c.503C>T:p.Pro168Leu,KEL:ENST00000476829:missense_variant:MODERATE:exon5/6:c.503C>T:p.Pro168Leu,KEL:ENST00000467543:missense_variant:MODERATE:exon5/6:c.446C>T:p.Pro149Leu,KEL:ENST00000460479:missense_variant:MODERATE:exon5/5:c.533C>T:p.Pro178Leu,KEL:ENST00000479768:non_coding_transcript_exon_variant:MODIFIER:exon5/11:n.621C>T:,KEL:ENST00000494148:non_coding_transcript_exon_variant:MODIFIER:exon1/4:n.102C>T:	Peptidase_M13__1_		Zinc endopeptidase with endothelin-3-converting enzyme activity. Cleaves EDN1, EDN2 and EDN3, with a marked preference for EDN3				0.0000	0.0000	0.0000	COSM484970	"613883 [KEL (confirmed) Blood group,Kell,110900];"			5.111.000	D	D,D,T	P	T,T,T	25.40				0	0					KEL (inh=n/a pLI=0.00)	0		chr7_142655413_142655413_G_A	predicted passenger	.	ENST00000355265	KEL	Missense
chr7	142659031	142659031	C	T	0.5128	430	0.0000	273	"not-cod-spli;off-target"	656	KEL	intron_variant	KEL:ENST00000355265:intron_variant:MODIFIER:exon1/18:c.4-72G>A:,KEL:ENST00000479768:intron_variant:MODIFIER:exon1/10:n.122-72G>A:,KEL:ENST00000476829:intron_variant:MODIFIER:exon1/5:c.4-72G>A:,KEL:ENST00000467543:intron_variant:MODIFIER:exon1/5:c.-50-76G>A:,KEL:ENST00000460479:intron_variant:MODIFIER:exon1/4:c.34-72G>A:			Zinc endopeptidase with endothelin-3-converting enzyme activity. Cleaves EDN1, EDN2 and EDN3, with a marked preference for EDN3				0.0000	0.0000	0.0000		"613883 [KEL (confirmed) Blood group,Kell,110900];"												0	0					KEL (inh=n/a pLI=0.00)	0							
chr8	48809905	48809905	C	T	0.3351	369	0.0000	285	"not-cod-spli;off-target"	406	PRKDC	intron_variant	PRKDC:ENST00000314191:intron_variant:MODIFIER:exon29/86:c.3465-51G>A:,PRKDC:ENST00000338368:intron_variant:MODIFIER:exon29/85:c.3465-51G>A:,PRKDC:ENST00000523565:intron_variant:MODIFIER:exon29/85:n.3522-51G>A:,PRKDC:ENST00000518216:intron_variant:MODIFIER:exon29/84:n.3517-51G>A:		"Non-homologous end-joining;Cell cycle"	Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA nonhomologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D	"Cell Cycle: G2/M Checkpoint;FAS signaling pathway ( CD95 );HIV-I Nef: negative effector of Fas and TNF;TNFR1 Signaling Pathway"			0.0000	0.0000	0.0000		"600899 [PRKDC (confirmed) Immunodeficiency 26,with or without neurologic abnormalities,615966];"												0	0					PRKDC (inh=AR pLI=1.00)	0							
chr8	59338957	59338957	C	T	0.0467	150	0.0000	89	"not-cod-spli;freq-tum;off-target"	70	UBXN2B,RP11-114M5.1	intron_variant	UBXN2B:ENST00000399598:intron_variant:MODIFIER:exon2/7:c.189-4121C>T:,RP11-114M5.1:ENST00000510501:intron_variant:MODIFIER:exon1/1:n.177+111G>A:,UBXN2B:ENST00000522978:intron_variant:MODIFIER:exon3/6:n.289-4121C>T:,UBXN2B:ENST00000520732:intron_variant:MODIFIER:exon2/5:c.189-6762C>T:,UBXN2B:ENST00000523409:intron_variant:MODIFIER:exon2/8:c.189-4121C>T:,UBXN2B:ENST00000521796:intron_variant:MODIFIER:exon1/4:c.24-4121C>T:			"Adapter protein required for Golgi and endoplasmic reticulum biogenesis. Involved in Golgi and endoplasmic reticulum maintenance during interphase and in their reassembly at the end of mitosis. The complex formed with VCP has membrane fusion activity; membrane fusion activity requires USO1-GOLGA2 tethering and BET1L. VCPIP1 is also required, but not its deubiquitinating activity"			rs557805702	0.000199681	0.0000	0.0000														0	0					UBXN2B (inh=n/a pLI=0.49), RP11-114M5.1 (inh=n/a pLI=n/a)	2	SomaticAndTreatment,						
chr8	110664631	110664631	C	T	0.2667	30	0.0000	26	"not-cod-spli;off-target"	69	SYBU	intron_variant	SYBU:ENST00000532779:intron_variant:MODIFIER:exon1/5:c.26-33363G>A:,SYBU:ENST00000408889:intron_variant:MODIFIER:exon1/5:c.-129+28309G>A:,SYBU:ENST00000419099:intron_variant:MODIFIER:exon1/7:c.-57-7686G>A:,SYBU:ENST00000422135:intron_variant:MODIFIER:exon1/7:c.-57-7686G>A:,SYBU:ENST00000533171:intron_variant:MODIFIER:exon1/7:c.-57-7686G>A:,SYBU:ENST00000527664:intron_variant:MODIFIER:exon1/2:n.164+28309G>A:,SYBU:ENST00000529190:intron_variant:MODIFIER:exon1/5:c.-57-7686G>A:,SYBU:ENST00000532189:intron_variant:MODIFIER:exon1/3:c.-129+28309G>A:,SYBU:ENST00000533821:intron_variant:MODIFIER:exon1/4:c.-57-7686G>A:,SYBU:ENST00000531230:intron_variant:MODIFIER:exon1/3:c.-209-7686G>A:,SYBU:ENST00000534184:intron_variant:MODIFIER:exon1/3:c.-57-7686G>A:,SYBU:ENST00000528716:intron_variant:MODIFIER:exon1/4:c.-178-6398G>A:,SYBU:ENST00000534578:intron_variant:MODIFIER:exon1/2:c.-57-7686G>A:,SYBU:ENST00000527600:intron_variant:MODIFIER:exon1/3:c.-220-6398G>A:			Part of a kinesin motor-adapter complex that is critical for the anterograde axonal transport of active zone components and contributes to activity-dependent presynaptic assembly during neuronal development (By similarity)				0.0000	0.0000	0.0000														0	0					SYBU (inh=n/a pLI=0.01)	0							
chr9	8460022	8460022	G	A	0.8889	9	0.0000	14	"not-cod-spli;depth-tum;depth-nor;off-target"	38	PTPRD	intron_variant	PTPRD:ENST00000356435:intron_variant:MODIFIER:exon22/34:c.3875+389C>T:,PTPRD:ENST00000381196:intron_variant:MODIFIER:exon30/42:c.3875+389C>T:,PTPRD:ENST00000355233:intron_variant:MODIFIER:exon17/30:c.2642+389C>T:,PTPRD:ENST00000358503:intron_variant:MODIFIER:exon18/30:c.3809+389C>T:,PTPRD:ENST00000360074:intron_variant:MODIFIER:exon19/31:c.3836+389C>T:,PTPRD:ENST00000397611:intron_variant:MODIFIER:exon16/29:c.2633+389C>T:,PTPRD:ENST00000397617:intron_variant:MODIFIER:exon15/28:c.2612+389C>T:,PTPRD:ENST00000537002:intron_variant:MODIFIER:exon16/28:c.2637+255C>T:,PTPRD:ENST00000540109:intron_variant:MODIFIER:exon22/35:c.3875+389C>T:,PTPRD:ENST00000486161:intron_variant:MODIFIER:exon17/30:c.2642+389C>T:,PTPRD:ENST00000397606:intron_variant:MODIFIER:exon15/28:c.2612+389C>T:							0.0000	0.0000	0.0000														0	0					PTPRD (inh=n/a pLI=1.00)	0							
chr9	8518411	8518411	C	T	0.5963	374	0.0000	440		1004	PTPRD	missense_variant	PTPRD:ENST00000356435:missense_variant:MODERATE:exon10/35:c.980G>A:p.Gly327Glu,PTPRD:ENST00000381196:missense_variant:MODERATE:exon18/43:c.980G>A:p.Gly327Glu,PTPRD:ENST00000355233:missense_variant:MODERATE:exon10/31:c.980G>A:p.Gly327Glu,PTPRD:ENST00000358503:missense_variant:MODERATE:exon7/31:c.941G>A:p.Gly314Glu,PTPRD:ENST00000360074:missense_variant:MODERATE:exon7/32:c.941G>A:p.Gly314Glu,PTPRD:ENST00000397611:missense_variant:MODERATE:exon9/30:c.971G>A:p.Gly324Glu,PTPRD:ENST00000397617:missense_variant:MODERATE:exon8/29:c.950G>A:p.Gly317Glu,PTPRD:ENST00000537002:missense_variant:MODERATE:exon8/29:c.971G>A:p.Gly324Glu,PTPRD:ENST00000540109:missense_variant:MODERATE:exon10/36:c.980G>A:p.Gly327Glu,PTPRD:ENST00000486161:missense_variant:MODERATE:exon10/31:c.980G>A:p.Gly327Glu,PTPRD:ENST00000397606:missense_variant:MODERATE:exon8/29:c.950G>A:p.Gly317Glu	Fibronectin__type_III__4_,Immunoglobulin-like_fold__1_						0.0000	0.0000	0.0000					7.770.000	T	T,T,T,T,T,T,T,T,T,T,T,T	P,P,P,D,P,P,B,D,B	T,T,T,T,T,T,T,T,T,T,T	25. Okt				0	0					PTPRD (inh=n/a pLI=1.00)	0		chr9_8518411_8518411_C_T	predicted driver: tier 1	LoF	ENST00000381196	PTPRD	Missense
chr9	21971219	21971219	A	T	0.0258	426	0.0000	519	"not-cod-spli;freq-tum"	133	CDKN2A,RP11-145E5.5	5_prime_UTR_variant,intron_variant,non_coding_transcript_exon_variant	CDKN2A:ENST00000578845:5_prime_UTR_variant:MODIFIER:exon1/2:c.-15T>A:,RP11-145E5.5:ENST00000404796:intron_variant:MODIFIER:exon4/5:c.348-58213A>T:,CDKN2A:ENST00000361570:intron_variant:MODIFIER:exon1/2:c.317-12T>A:,CDKN2A:ENST00000304494:intron_variant:MODIFIER:exon1/2:c.151-12T>A:,CDKN2A:ENST00000579755:intron_variant:MODIFIER:exon1/2:c.194-12T>A:,CDKN2A:ENST00000579122:intron_variant:MODIFIER:exon1/2:c.151-12T>A:,CDKN2A:ENST00000530628:intron_variant:MODIFIER:exon1/2:c.194-12T>A:,CDKN2A:ENST00000498124:intron_variant:MODIFIER:exon1/3:c.151-12T>A:,CDKN2A:ENST00000498628:intron_variant:MODIFIER:exon1/2:c.-3-12T>A:,CDKN2A:ENST00000380151:intron_variant:MODIFIER:exon1/2:c.*74-12T>A:,CDKN2A:ENST00000494262:intron_variant:MODIFIER:exon2/3:c.-3-12T>A:,CDKN2A:ENST00000446177:intron_variant:MODIFIER:exon1/2:c.151-12T>A:,CDKN2A:ENST00000479692:intron_variant:MODIFIER:exon1/2:c.-3-12T>A:,CDKN2A:ENST00000497750:intron_variant:MODIFIER:exon1/1:c.-3-12T>A:,CDKN2A:ENST00000380150:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.113T>A:		"Cell cycle;p53 signaling pathway;Pancreatic cancer;Glioma;Melanoma;Bladder cancer;Chronic myeloid leukemia;Non-small cell lung cancer"	Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein	"Cell Cycle: G1/S Check Point ;CTCF: First Multivalent Nuclear Factor;Cyclins and Cell Cycle Regulation;Tumor Suppressor Arf Inhibits Ribosomal Biogenesis"			0.0000	0.0000	0.0000		"156540 [MTAP (confirmed) Diaphyseal medullary stenosis with malignant fibrous histiocytoma,112250]:600160 [CDKN2A (confirmed) Melanoma,cutaneous malignant,2,155601|Melanoma and neural system tumor syndrome,155755|Pancreatic cancer/melanoma syndrome,606719|Orolaryngeal cancer,multiple,];"												0	0					CDKN2A (inh=AD pLI=0.36), RP11-145E5.5 (inh=n/a pLI=n/a)	0							
chr9	87310168	87310168	C	T	0.3362	934	0.0000	696	not-cod-spli	928	NTRK2	intron_variant	NTRK2:ENST00000277120:intron_variant:MODIFIER:exon2/18:c.213-6906C>T:,NTRK2:ENST00000376213:intron_variant:MODIFIER:exon4/19:c.213-6906C>T:,NTRK2:ENST00000376214:intron_variant:MODIFIER:exon4/20:c.213-6906C>T:,NTRK2:ENST00000395882:intron_variant:MODIFIER:exon2/12:c.213-6906C>T:,NTRK2:ENST00000304053:intron_variant:MODIFIER:exon2/14:c.213-6906C>T:,NTRK2:ENST00000376208:intron_variant:MODIFIER:exon2/13:c.213-6906C>T:,NTRK2:ENST00000323115:intron_variant:MODIFIER:exon1/16:c.213-6906C>T:,NTRK2:ENST00000359847:intron_variant:MODIFIER:exon1/11:c.213-6906C>T:,NTRK2:ENST00000395866:intron_variant:MODIFIER:exon1/11:c.-256-6906C>T:		MAPK signaling pathway	Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin- 4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin- dependent calcium signaling in glial cells and mediate communication between neurons and glia				0.0000	0.0000	0.0000		"600456 [NTRK2 (confirmed) Obesity,hyperphagia,and developmental delay,613886];"												0	0					NTRK2 (inh=AD pLI=1.00)	0							
chr9	98241201	98241201	G	A	0.4144	444	0.0000	227	"not-cod-spli;off-target"	456	PTCH1	intron_variant	PTCH1:ENST00000331920:intron_variant:MODIFIER:exon8/23:c.1215+81C>T:,PTCH1:ENST00000418258:intron_variant:MODIFIER:exon8/23:c.762+81C>T:,PTCH1:ENST00000421141:intron_variant:MODIFIER:exon8/23:c.762+81C>T:,PTCH1:ENST00000437951:intron_variant:MODIFIER:exon8/23:c.1017+81C>T:,PTCH1:ENST00000375290:intron_variant:MODIFIER:exon5/20:c.852+81C>T:,PTCH1:ENST00000430669:intron_variant:MODIFIER:exon8/22:c.1017+81C>T:,PTCH1:ENST00000429896:intron_variant:MODIFIER:exon8/23:c.762+81C>T:,PTCH1:ENST00000375274:intron_variant:MODIFIER:exon8/23:c.1212+81C>T:,PTCH1:ENST00000375271:intron_variant:MODIFIER:exon3/7:c.366+81C>T:		"Hedgehog signaling pathway;Basal cell carcinoma"	Acts as a receptor for sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). Associates with the smoothened protein (SMO) to transduce the hedgehog's proteins signal. Seems to have a tumor suppressor function, as inactivation of this protein is probably a necessary, if not sufficient step for tumorigenesis	"Sonic Hedgehog (Shh) Pathway;Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle"			0.0000	0.0000	0.0000		"601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];"												0	0					PTCH1 (inh=AD pLI=1.00)	0							
chr10	39011287	39011287	A	T	0.5000	112	0.0000	140	"not-cod-spli;off-target"	295	CHEK2P5	intron_variant	CHEK2P5:ENST00000423877:intron_variant:MODIFIER:exon2/2:n.168+27A>T:							0.0000	0.0000	0.0000														0	0					CHEK2P5 (inh=n/a pLI=n/a)	0							
chr10	43613723	43613723	A	G	0.5603	116	0.0000	146	"not-cod-spli;off-target"	344	RET	intron_variant	RET:ENST00000355710:intron_variant:MODIFIER:exon12/19:c.2285-98A>G:,RET:ENST00000340058:intron_variant:MODIFIER:exon12/18:c.2285-98A>G:		Thyroid cancer	"Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut- associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration"				0.0000	0.0000	0.0000		"164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];"												0	0					RET (inh=AR+AD pLI=1.00)	0							
chr10	49842688	49842688	C	T	0.4267	75	0.0000	117	"not-cod-spli;off-target"	206	ARHGAP22	intron_variant	ARHGAP22:ENST00000435790:intron_variant:MODIFIER:exon1/9:c.52+17591G>A:,ARHGAP22:ENST00000460425:intron_variant:MODIFIER:exon2/10:c.52+17591G>A:,ARHGAP22:ENST00000464445:intron_variant:MODIFIER:exon1/1:n.88+17591G>A:			Rho GTPase-activating protein involved in the signal transduction pathway that regulates endothelial cell capillary tube formation during angiogenesis. Acts as a GTPase activator for the RAC1 by converting it to an inactive GDP-bound state. Inhibits RAC1-dependent lamellipodia formation. May also play a role in transcription regulation via its interaction with VEZF1, by regulating activity of the endothelin-1 (EDN1) promoter (By similarity)				0.0000	0.0000	0.0000														0	0					ARHGAP22 (inh=n/a pLI=0.00)	0							
chr10	63661328	63661328	G	A	0.5622	217	0.0000	140	"not-cod-spli;off-target"	399	ARID5B	5_prime_UTR_variant	ARID5B:ENST00000279873:5_prime_UTR_variant:MODIFIER:exon1/10:c.-141G>A:			Transcription coactivator that binds to the 5'-AATA[CT]- 3' core sequence and plays a key role in adipogenesis and liver development. Acts by forming a complex with phosphorylated PHF2, which mediates demethylation at Lys-336, leading to target the PHF2-ARID5B complex to target promoters, where PHF2 mediates demethylation of dimethylated 'Lys-9' of histone H3 (H3K9me2), followed by transcription activation of target genes. The PHF2- ARID5B complex acts as a coactivator of HNF4A in liver. Required for adipogenesis: regulates triglyceride metabolism in adipocytes by regulating expression of adipogenic genes. Overexpression leads to induction of smooth muscle marker genes, suggesting that it may also act as a regulator of smooth muscle cell differentiation and proliferation. Represses the cytomegalovirus enhancer				0.0000	0.0000	0.0000														0	0					ARID5B (inh=n/a pLI=1.00)	0							
chr10	70547624	70547624	C	T	0.5877	211	0.0000	281	"not-cod-spli;off-target"	635	CCAR1	intron_variant,non_coding_transcript_exon_variant	CCAR1:ENST00000265872:intron_variant:MODIFIER:exon21/24:c.2881-60C>T:,CCAR1:ENST00000535016:intron_variant:MODIFIER:exon20/23:c.2836-60C>T:,CCAR1:ENST00000543719:intron_variant:MODIFIER:exon20/23:c.2836-60C>T:,CCAR1:ENST00000539539:intron_variant:MODIFIER:exon20/21:c.2836-60C>T:,CCAR1:ENST00000540210:intron_variant:MODIFIER:exon20/23:c.*963-60C>T:,CCAR1:ENST00000543706:intron_variant:MODIFIER:exon6/6:c.748-60C>T:,CCAR1:ENST00000480627:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.32C>T:			Associates with components of the Mediator and p160 coactivator complexes that play a role as intermediaries transducing regulatory signals from upstream transcriptional activator proteins to basal transcription machinery at the core promoter. Recruited to endogenous nuclear receptor target genes in response to the appropriate hormone. Also functions as a p53 coactivator. May thus play an important role in transcriptional regulation (By similarity). May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation				0.0000	0.0000	0.0000														0	0					CCAR1 (inh=n/a pLI=1.00)	0							
chr10	89692901	89692901	G	A	0.6071	965	0.0000	816		2143	PTEN	missense_variant,sequence_feature,non_coding_transcript_exon_variant	PTEN:ENST00000371953:missense_variant:MODERATE:exon5/9:c.385G>A:p.Gly129Arg,PTEN:ENST00000371953:sequence_feature:LOW:exon5/9:c.385G>A:,PTEN:ENST00000498703:non_coding_transcript_exon_variant:MODIFIER:exon3/3:n.211G>A:	Phosphatase_tensin_type__1_,Dual_specificity_phosphatase__catalytic_domain__1_	"Inositol phosphate metabolism;Phosphatidylinositol signaling system;p53 signaling pathway;Focal adhesion;Tight junction;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Small cell lung cancer"	Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability	"CTCF: First Multivalent Nuclear Factor;mTOR Signaling Pathway;PTEN dependent cell cycle arrest and apoptosis;Regulation of eIF4e and p70 S6 Kinase;Signaling of Hepatocyte Growth Factor Receptor;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway"		rs786204929	0.0000	0.0000	0.0000	COSM5092	"601728 [PTEN (confirmed) Cowden syndrome 1,158350|Lhermitte-Duclos syndrome,158350|Bannayan-Riley-Ruvalcaba syndrome,153480|Meningioma,607174|Glioma susceptibility 2,613028|Macrocephaly/autism syndrome,605309|PTEN hamartoma tumor syndrome|VATER association with macrocephaly and ventriculomegaly,276950|Prostate cancer,somatic,176807|Malignant melanoma,somatic,155600|Endometrial carcinoma,somatic,608089|Squamous cell carcinoma,head and neck,somatic,275355];"	"RCV000169874.3 [pathogenic]; "	"CM122894 [CLASS=DM MUT=ALT PHEN=""Cowden disease"" GENE=PTEN]; "	9.429.000	D	D	D	D	29.40				0	0					PTEN (inh=AD pLI=0.98)	0		chr10_89692901_89692901_G_A	predicted driver: tier 1	LoF	ENST00000371953	PTEN	Missense
chr10	123240012	123240012	A	G	0.6111	487	0.0000	631	not-cod-spli	1435	FGFR2	intron_variant	FGFR2:ENST00000457416:intron_variant:MODIFIER:exon17/17:c.2305-477T>C:,FGFR2:ENST00000369061:intron_variant:MODIFIER:exon14/14:c.1966-477T>C:,FGFR2:ENST00000357555:intron_variant:MODIFIER:exon16/16:c.2035-828T>C:,FGFR2:ENST00000358487:intron_variant:MODIFIER:exon17/17:c.2302-477T>C:,FGFR2:ENST00000478859:intron_variant:MODIFIER:exon16/16:c.1618-477T>C:,FGFR2:ENST00000356226:intron_variant:MODIFIER:exon15/15:c.1951-477T>C:,FGFR2:ENST00000369060:intron_variant:MODIFIER:exon15/15:c.1954-477T>C:,FGFR2:ENST00000604236:intron_variant:MODIFIER:exon16/16:c.*1349-477T>C:,FGFR2:ENST00000369059:intron_variant:MODIFIER:exon15/15:c.1960-477T>C:,FGFR2:ENST00000429361:intron_variant:MODIFIER:exon8/8:c.972-477T>C:,FGFR2:ENST00000346997:intron_variant:MODIFIER:exon16/16:c.2296-477T>C:,FGFR2:ENST00000351936:intron_variant:MODIFIER:exon17/17:c.2296-385T>C:		"MAPK signaling pathway;Regulation of actin cytoskeleton;Prostate cancer"	Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1				0.0000	0.0000	0.0000		"176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];"												0	0					FGFR2 (inh=AR+AD pLI=1.00)	0							
chr11	3723543	3723543	A	T	0.1522	46	0.0000	24	"not-cod-spli;off-target"	65	NUP98	intron_variant	NUP98:ENST00000324932:intron_variant:MODIFIER:exon23/32:c.3512+150T>A:,NUP98:ENST00000359171:intron_variant:MODIFIER:exon23/33:c.3512+150T>A:,NUP98:ENST00000355260:intron_variant:MODIFIER:exon23/31:c.3512+150T>A:,NUP98:ENST00000429801:intron_variant:MODIFIER:exon3/12:c.368+459T>A:,NUP98:ENST00000529063:intron_variant:MODIFIER:exon1/2:c.188+150T>A:			Plays a role in the nuclear pore complex (NPC) assembly and/or maintenance. Nup98 and Nup96 are involved in the bidirectional transport across the NPC. May anchor NUP153 and TPR to the NPC			rs868640062	0.0000	0.0000	0.0000														0	0					NUP98 (inh=n/a pLI=1.00)	0							
chr11	59211067	59211067	C	T	0.5900	403	0.0000	563	syn-var	1213	OR5A1	synonymous_variant	OR5A1:ENST00000302030:synonymous_variant:LOW:exon1/1:c.426C>T:p.Gly142Gly		Olfactory transduction	Odorant receptor (Potential)				0.0000	0.0000	0.0000	COSM1322338													0	0					OR5A1 (inh=n/a pLI=0.00)	0		chr11_59211067_59211067_C_T	not protein-affecting	.	ENST00000302030	OR5A1	Synonymous
chr11	64575552	64575552	G	A	0.5921	381	0.0000	398	syn-var	961	MEN1	synonymous_variant	MEN1:ENST00000337652:synonymous_variant:LOW:exon3/10:c.480C>T:p.Ser160Ser,MEN1:ENST00000377316:synonymous_variant:LOW:exon2/8:c.465C>T:p.Ser155Ser,MEN1:ENST00000377321:synonymous_variant:LOW:exon3/10:c.465C>T:p.Ser155Ser,MEN1:ENST00000377326:synonymous_variant:LOW:exon2/9:c.465C>T:p.Ser155Ser,MEN1:ENST00000312049:synonymous_variant:LOW:exon3/10:c.465C>T:p.Ser155Ser,MEN1:ENST00000315422:synonymous_variant:LOW:exon3/10:c.465C>T:p.Ser155Ser,MEN1:ENST00000443283:synonymous_variant:LOW:exon3/10:c.480C>T:p.Ser160Ser,MEN1:ENST00000394374:synonymous_variant:LOW:exon3/10:c.480C>T:p.Ser160Ser,MEN1:ENST00000394376:synonymous_variant:LOW:exon4/11:c.480C>T:p.Ser160Ser,MEN1:ENST00000377313:synonymous_variant:LOW:exon2/9:c.480C>T:p.Ser160Ser,MEN1:ENST00000440873:synonymous_variant:LOW:exon3/7:c.465C>T:p.Ser155Ser,MEN1:ENST00000450708:synonymous_variant:LOW:exon3/6:c.465C>T:p.Ser155Ser,MEN1:ENST00000413626:synonymous_variant:LOW:exon3/4:c.465C>T:p.Ser155Ser			Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair				0.0000	0.0000	0.00000	COSM3398028	"613733 [MEN1 (confirmed) Multiple endocrine neoplasia 1,131100|Carcinoid tumor of lung|Parathyroid adenoma,somatic|Lipoma,somatic|Angiofibroma,somatic|Adrenal adenoma,somatic];"												0	0					MEN1 (inh=AD pLI=1.00)	0		chr11_64575552_64575552_G_A	not protein-affecting	LoF	ENST00000443283	MEN1	Synonymous
chr11	71939332	71939332	C	T	0.5770	383	0.0000	315	"not-cod-spli;off-target"	798	INPPL1	intron_variant	INPPL1:ENST00000298229:intron_variant:MODIFIER:exon2/27:c.246+35C>T:,INPPL1:ENST00000541756:intron_variant:MODIFIER:exon2/27:c.-481+35C>T:,INPPL1:ENST00000541544:intron_variant:MODIFIER:exon2/2:n.162+35C>T:,INPPL1:ENST00000538751:intron_variant:MODIFIER:exon1/26:c.-481+35C>T:		"Inositol phosphate metabolism;Phosphatidylinositol signaling system"	Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol- 3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Plays a central role in regulation of PI3K-dependent insulin signaling, although the precise molecular mechanisms and signaling pathways remain unclear. While overexpression reduces both insulin-stimulated MAP kinase and Akt activation, its absence does not affect insulin signaling or GLUT4 trafficking. Confers resistance to dietary obesity. May act by regulating AKT2, but not AKT1, phosphorylation at the plasma membrane. Part of a signaling pathway that regulates actin cytoskeleton remodeling. Required for the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation. Participates in regulation of cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling. Regulates cell adhesion and cell spreading. Required for HGF-mediated lamellipodium formation, cell scattering and spreading. Acts as a negative regulator of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1 activation. Acts as a regulator of neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required to form an initial protrusive pattern, and later, maintain proper neurite outgrowth. Acts as a negative regulator of the FC-gamma-RIIA receptor (FCGR2A). Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Involved in EGF signaling pathway. Upon stimulation by EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3. Plays a negative role in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity. Down-regulates Fc-gamma-R-mediated phagocytosis in macrophages independently of INPP5D/SHIP1. In macrophages, down-regulates NF-kappa-B-dependent gene transcription by regulating macrophage colony-stimulating factor (M-CSF)-induced signaling. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6. Involved in endochondral ossification	Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway			0.0000	0.0000	0.00000		"600829 [INPPL1 (provisional) Opsismodysplasia,258480];"												0	0					INPPL1 (inh=AR pLI=0.01)	0							
chr12	994676	994676	C	T	0.3294	1427	0.0000	828		1131	WNK1	missense_variant	WNK1:ENST00000530271:missense_variant:MODERATE:exon21/30:c.6200C>T:p.Pro2067Leu,WNK1:ENST00000535572:missense_variant:MODERATE:exon17/26:c.3965C>T:p.Pro1322Leu,WNK1:ENST00000315939:missense_variant:MODERATE:exon19/28:c.4706C>T:p.Pro1569Leu,WNK1:ENST00000537687:missense_variant:MODERATE:exon19/28:c.5486C>T:p.Pro1829Leu,WNK1:ENST00000340908:missense_variant:MODERATE:exon16/25:c.3485C>T:p.Pro1162Leu			Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival, and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Activates SCNN1A, SCNN1B, SCNN1D and SGK1. Controls sodium and chloride ion transport by inhibiting the activity of WNK4, by either phosphorylating the kinase or via an interaction between WNK4 and the autoinhibitory domain of WNK1. WNK4 regulates the activity of the thiazide- sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation. WNK1 may also play a role in actin cytoskeletal reorganization. Phosphorylates NEDD4L (By similarity)				0.0000	0.0000	0.0000		"605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];"			4.171.000	T	D,D,D,D,D,D	B,B,B	T,T,T,T,T	23.80				0	0					WNK1 (inh=AR+AD pLI=1.00)	0		chr12_994676_994676_C_T	predicted passenger	ambiguous	ENST00000315939	WNK1	Missense
chr12	18719906	18719906	C	T	0.3241	469	0.0000	438		533	PIK3C2G	missense_variant,3_prime_UTR_variant	PIK3C2G:ENST00000538779:missense_variant:MODERATE:exon28/32:c.3926C>T:p.Pro1309Leu,PIK3C2G:ENST00000433979:missense_variant:MODERATE:exon28/32:c.3803C>T:p.Pro1268Leu,PIK3C2G:ENST00000266497:missense_variant:MODERATE:exon27/31:c.3803C>T:p.Pro1268Leu,PIK3C2G:ENST00000546003:3_prime_UTR_variant:MODIFIER:exon28/32:c.*3223C>T:	Phox_homologous_domain__5_	Phosphatidylinositol signaling system	Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. May play a role in SDF1A-stimulated chemotaxis (By similarity)	"CCR3 signaling in Eosinophils;CXCR4 Signaling Pathway;fMLP induced chemokine gene expression in HMC-1 cells"			0.0000	0.0000	0.0000					2.896.000	T	D,D,D	B,B,B	T,T,T	24.70				0	0					PIK3C2G (inh=n/a pLI=0.00)	0		chr12_18719906_18719906_C_T	predicted passenger	.	ENST00000433979	PIK3C2G	Missense
chr12	21032512	21032512	C	T	0.3638	679	0.0000	523	syn-var	768	LST3,SLCO1B3,SLCO1B7	synonymous_variant,sequence_feature,intron_variant	LST3:ENST00000540229:synonymous_variant:LOW:exon9/16:c.1278C>T:p.Phe426Phe,SLCO1B3:ENST00000553473:synonymous_variant:LOW:exon9/16:c.1278C>T:p.Phe426Phe,SLCO1B3:ENST00000261196:synonymous_variant:LOW:exon10/15:c.1278C>T:p.Phe426Phe,SLCO1B3:ENST00000381545:synonymous_variant:LOW:exon11/16:c.1278C>T:p.Phe426Phe,SLCO1B3:ENST00000544370:synonymous_variant:LOW:exon5/10:c.750C>T:p.Phe250Phe,SLCO1B3:ENST00000381545:sequence_feature:LOW:exon11/16:c.1278C>T:,SLCO1B7:ENST00000554957:intron_variant:MODIFIER:exon3/13:c.359+21007C>T:,LST3:ENST00000381541:intron_variant:MODIFIER:exon3/13:c.359+21007C>T:			Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver				0.0000	0.0000	0.0000	COSM3459125	"605495 [SLCO1B3 (provisional) Hyperbilirubinemia,Rotor type,digenic,237450];"												0	0					SLCO1B7 (inh=n/a pLI=0.00), SLCO1B3 (inh=AR pLI=0.00), SLCO1B7 (inh=n/a pLI=0.00)	0							
chr12	21172015	21172015	C	T	0.4000	15	0.0000	25	"not-cod-spli;depth-tum;off-target"	59	LST3,SLCO1B3,SLCO1B7	intron_variant	LST3:ENST00000540229:intron_variant:MODIFIER:exon13/15:c.1866-48238C>T:,SLCO1B3:ENST00000553473:intron_variant:MODIFIER:exon13/15:c.1866-48238C>T:,SLCO1B7:ENST00000554957:intron_variant:MODIFIER:exon3/13:c.360-2380C>T:,LST3:ENST00000381541:intron_variant:MODIFIER:exon3/13:c.360-2380C>T:,SLCO1B7:ENST00000421593:intron_variant:MODIFIER:exon1/12:c.86-167C>T:			Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver				0.0000	0.0000	0.0000		"605495 [SLCO1B3 (provisional) Hyperbilirubinemia,Rotor type,digenic,237450];"												0	0					SLCO1B7 (inh=n/a pLI=0.00), SLCO1B3 (inh=AR pLI=0.00), SLCO1B7 (inh=n/a pLI=0.00)	0							
chr12	33021697	33021697	C	T	0.3704	27	0.0000	32	"not-cod-spli;off-target"	81	PKP2	intron_variant	PKP2:ENST00000070846:intron_variant:MODIFIER:exon4/13:c.1170+164G>A:,PKP2:ENST00000340811:intron_variant:MODIFIER:exon4/12:c.1170+164G>A:			May play a role in junctional plaques				0.0000	0.0000	0.0000		"602861 [PKP2 (confirmed) Arrhythmogenic right ventricular dysplasia 9,609040];"												0	0					PKP2 (inh=AD pLI=0.00)	0							
chr12	46516229	46516229	G	A	0.3622	312	0.0000	209	"not-cod-spli;off-target"	335	RP11-101K23.1-SLC38A1	intergenic_region	RP11-101K23.1-SLC38A1:ENSG00000239397-ENSG00000111371:intergenic_region:MODIFIER::n.46516229G>A:							0.0000	0.0000	0.0000														0	0					RP11-101K23.1-SLC38A1 (inh=n/a pLI=n/a)	0							
chr12	49427108	49427108	G	A	0.3673	198	0.0000	165		275	KMT2D	missense_variant	KMT2D:ENST00000301067:missense_variant:MODERATE:exon39/54:c.11380C>T:p.Pro3794Ser			Histone methyltransferase. Methylates 'Lys-4' of histone H3 (H3K4me). H3K4me represents a specific tag for epigenetic transcriptional activation. Acts as a coactivator for estrogen receptor by being recruited by ESR1, thereby activating transcription			rs113997424	0.000399361	0.00143	0.00063		"602113 [KMT2D (provisional) Kabuki syndrome 1,147920];"	"RCV000269931.1 [likely benign]; "		1.157.000	T	D	B	T	13.65				0	11	3	[3] ahschak1 18.11.2016			KMT2D (inh=AD pLI=1.00)	0		chr12_49427108_49427108_G_A	predicted passenger	LoF	ENST00000301067	MLL2	Missense
chr12	112915819	112915819	G	A	0.3209	430	0.0000	349		429	PTPN11	splice_region_variant&synonymous_variant,sequence_feature	PTPN11:ENST00000351677:splice_region_variant&synonymous_variant:LOW:exon9/16:c.1092G>A:p.Lys364Lys,PTPN11:ENST00000392597:splice_region_variant&synonymous_variant:LOW:exon9/11:c.1092G>A:p.Lys364Lys,PTPN11:ENST00000351677:sequence_feature:LOW:exon9/16:c.1092G>A:,PTPN11:ENST00000392597:sequence_feature:LOW:exon9/11:c.1092G>A:		"Jak-STAT signaling pathway;Natural killer cell mediated cytotoxicity;Leukocyte transendothelial migration;Adipocytokine signaling pathway;Epithelial cell signaling in Helicobacter pylori infection;Renal cell carcinoma;Chronic myeloid leukemia"	Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 resulting in stimulatation of its RhoA binding activity	"IGF-1 Signaling Pathway;IL 6 signaling pathway;Insulin Signaling Pathway;Signaling of Hepatocyte Growth Factor Receptor;The Co-Stimulatory Signal During T-cell Activation"			0.0000	0.0000	0.0000		"176876 [PTPN11 (confirmed) Noonan syndrome 1,163950|LEOPARD syndrome 1,151100|Leukemia,juvenile myelomonocytic,somatic,607785|Metachondromatosis,156250];"												0	0					PTPN11 (inh=AD pLI=1.00)	0		chr12_112915819_112915819_G_A	not protein-affecting	Act	ENST00000351677	PTPN11	Synonymous
chr12	133253112	133253112	C	T	0.3858	650	0.0022	464	not-cod-spli	719	POLE	intron_variant	POLE:ENST00000320574:intron_variant:MODIFIER:exon9/48:c.909+20G>A:,POLE:ENST00000537064:intron_variant:MODIFIER:exon9/48:c.909+20G>A:,POLE:ENST00000535270:intron_variant:MODIFIER:exon8/47:c.828+20G>A:,POLE:ENST00000539006:intron_variant:MODIFIER:exon3/25:c.249+20G>A:		"Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair"	Participates in DNA repair and in chromosomal DNA replication			rs750593090	0.0000	0.0000	0.00002		"174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];"												0	0					POLE (inh=AR pLI=0.00)	0							
chr13	19924367	19924367	A	G	0.3644	267	0.0000	278	off-target	379	PARP4P2	splice_region_variant&intron_variant	PARP4P2:ENST00000446672:splice_region_variant&intron_variant:LOW:exon2/20:n.141+4A>G:							0.0000	0.0000	0.0000														0	0					PARP4P2 (inh=n/a pLI=n/a)	0							
chr13	19962036	19962036	C	T	0.4145	459	0.0056	356	"not-cod-spli;off-target"	553	PARP4P2	intron_variant	PARP4P2:ENST00000446672:intron_variant:MODIFIER:exon16/20:n.1825+31C>T:							0.0000	0.0000	0.0000														0	0					PARP4P2 (inh=n/a pLI=n/a)	0							
chr13	19969242	19969242	C	T	0.3545	189	0.0000	195	"not-cod-spli;off-target"	278	PARP4P2	non_coding_transcript_exon_variant	PARP4P2:ENST00000446672:non_coding_transcript_exon_variant:MODIFIER:exon18/21:n.2539C>T:							0.0000	0.0000	0.0000														0	0					PARP4P2 (inh=n/a pLI=n/a)	0							
chr13	23913736	23913736	G	A	0.3610	1299	0.0000	705		1025	SACS	missense_variant,intron_variant	SACS:ENST00000382292:missense_variant:MODERATE:exon9/9:c.4279C>T:p.Pro1427Ser,SACS:ENST00000402364:missense_variant:MODERATE:exon8/8:c.2029C>T:p.Pro677Ser,SACS:ENST00000382298:missense_variant:MODERATE:exon10/10:c.4279C>T:p.Pro1427Ser,SACS:ENST00000455470:intron_variant:MODIFIER:exon6/6:c.2128+1848C>T:,SACS:ENST00000423156:intron_variant:MODIFIER:exon2/2:c.1058-10113C>T:			Co-chaperone which acts as a regulator of the Hsp70 chaperone machinery and may be involved in the processing of other ataxia-linked proteins				0.0000	0.0000	0.0000		"604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];"			9.476.000	D	T,T,T	D	D,D,D	23.30				0	0					SACS (inh=AR pLI=0.00)	0		chr13_23913736_23913736_G_A	predicted passenger	.	ENST00000382298	SACS	Missense
chr13	23928024	23928024	G	A	0.2969	229	0.0000	206	not-cod-spli	258	SACS	intron_variant	SACS:ENST00000382292:intron_variant:MODIFIER:exon7/8:c.2094-9C>T:,SACS:ENST00000402364:intron_variant:MODIFIER:exon6/7:c.-157-9C>T:,SACS:ENST00000382298:intron_variant:MODIFIER:exon8/9:c.2094-9C>T:,SACS:ENST00000455470:intron_variant:MODIFIER:exon4/6:c.1791-9C>T:,SACS:ENST00000423156:intron_variant:MODIFIER:exon1/2:c.966-9C>T:,SACS:ENST00000476776:intron_variant:MODIFIER:exon1/1:n.373-9C>T:			Co-chaperone which acts as a regulator of the Hsp70 chaperone machinery and may be involved in the processing of other ataxia-linked proteins				0.0000	0.0000	0.0000		"604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];"												0	0					SACS (inh=AR pLI=0.00)	0							
chr13	25015897	25015897	G	A	0.4006	327	0.0000	193	"not-cod-spli;off-target"	369	PARP4,TPTE2P6	intron_variant	PARP4:ENST00000381989:intron_variant:MODIFIER:exon30/33:c.3666+87C>T:,TPTE2P6:ENST00000445572:intron_variant:MODIFIER:exon3/9:n.233+32455G>A:		Base excision repair					0.0000	0.0000	0.0000														0	0					PARP4 (inh=n/a pLI=0.00), TPTE2P6 (inh=n/a pLI=n/a)	0							
chr13	27251013	27251013	G	C	0.4800	50	0.0000	52	"not-cod-spli;off-target"	135	WASF3	intron_variant	WASF3:ENST00000335327:intron_variant:MODIFIER:exon7/9:c.716+152G>C:,WASF3:ENST00000361042:intron_variant:MODIFIER:exon6/9:c.541-3159G>C:		Adherens junction	Downstream effector molecules involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape	Y branching of actin filaments			0.0000	0.0000	0.0000														0	0					WASF3 (inh=n/a pLI=0.96)	0							
chr13	46708234	46708234	G	A	0.3587	669	0.0044	453	"not-cod-spli;off-target"	608	LCP1	intron_variant	LCP1:ENST00000323076:intron_variant:MODIFIER:exon14/15:c.1626+28C>T:,LCP1:ENST00000398576:intron_variant:MODIFIER:exon17/18:c.1626+28C>T:,LCP1:ENST00000435666:intron_variant:MODIFIER:exon3/4:c.333+28C>T:			Actin-binding protein. Plays a role in the activation of T-cells in response to costimulation through TCR/CD3 and CD2 or CD28. Modulates the cell surface expression of IL2RA/CD25 and CD69				0.0000	0.0000	0.0000														0	0					LCP1 (inh=n/a pLI=0.97)	0							
chr13	59105059	59105059	C	T	0.3878	99	0.0000	91	"not-cod-spli;off-target"	177	CTAGE16P	non_coding_transcript_exon_variant	CTAGE16P:ENST00000435601:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.2311C>T:							0.0000	0.0000	0.0000														0	0					CTAGE16P (inh=n/a pLI=n/a)	0							
chr13	79335490	79335490	G	A	0.3556	45	0.0000	48	"not-cod-spli;off-target"	111	RPL21P111	non_coding_transcript_exon_variant	RPL21P111:ENST00000418453:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.181G>A:							0.0000	0.0000	0.0000														0	0					RPL21P111 (inh=n/a pLI=n/a)	0							
chr13	88542418	88542418	G	A	0.3364	217	0.0000	195	"not-cod-spli;off-target"	287	RP11-471M2.3-TET1P1	intergenic_region	RP11-471M2.3-TET1P1:ENSG00000272046-ENSG00000232204:intergenic_region:MODIFIER::n.88542418G>A:							0.0000	0.0000	0.0000														0	0					RP11-471M2.3-TET1P1 (inh=n/a pLI=n/a)	0							
chr14	20347487	20347487	G	A	0.1920	969	0.0000	725	"not-cod-spli;off-target"	534	OR4K2-OR4K4P	intergenic_region	OR4K2-OR4K4P:ENSG00000165762-ENSG00000258541:intergenic_region:MODIFIER::n.20347487G>A:						rs149881235	0.00459265	0.0000	0.0000														0	0					OR4K2-OR4K4P (inh=n/a pLI=n/a)	0							
chr14	21859017	21859017	T	C	0.3623	334	0.0000	224	"not-cod-spli;off-target"	356	CHD8	intron_variant	CHD8:ENST00000399982:intron_variant:MODIFIER:exon36/36:c.7182+89A>G:,CHD8:ENST00000430710:intron_variant:MODIFIER:exon37/37:c.6345+89A>G:,CHD8:ENST00000557364:intron_variant:MODIFIER:exon37/37:c.7182+89A>G:,CHD8:ENST00000553870:intron_variant:MODIFIER:exon3/3:c.513+89A>G:		Wnt signaling pathway	DNA helicase that acts as a chromatin remodeling factor and regulates transcription. Acts as a transcription repressor by remodeling chromatin structure and recruiting histone H1 to target genes. Suppresses p53/TP53-mediated apoptosis by recruiting histone H1 and preventing p53/TP53 transactivation activity. Acts as a negative regulator of Wnt signaling pathway by regulating beta-catenin (CTNNB1) activity. Negatively regulates CTNNB1- targeted gene expression by being recruited specifically to the promoter regions of several CTNNB1 responsive genes. Involved in both enhancer blocking and epigenetic remodeling at chromatin boundary via its interaction with CTCF. Acts as a suppressor of STAT3 activity by suppressing the LIF-induced STAT3 transcriptional activity. Also acts as a transcription activator via its interaction with ZNF143 by participating in efficient U6 RNA polymerase III transcription				0.0000	0.0000	0.0000		"610528 [CHD8 (provisional) Autism,susceptibility to,18,615032];"												0	0					CHD8 (inh=AD pLI=1.00)	0							
chr14	23857301	23857301	C	T	0.3600	100	0.0000	94	"not-cod-spli;off-target"	172	MYH6	intron_variant	MYH6:ENST00000356287:intron_variant:MODIFIER:exon29/37:c.4359+63G>A:,MYH6:ENST00000405093:intron_variant:MODIFIER:exon30/38:c.4359+63G>A:		Tight junction	Muscle contraction				0.0000	0.0000	0.0000		"160710 [MYH6 (confirmed) Cardiomyopathy,hypertrophic,14,613251|Atrial septal defect 3,614089|Cardiomyopathy,dilated,1EE,613252|Sick sinus syndrome 3,614090];"												0	0					MYH6 (inh=AD pLI=0.00)	0							
chr14	65734216	65734216	C	T	0.2143	28	0.0000	32	"not-cod-spli;off-target"	75	CTD-2509G16.5,RPL21P7	intron_variant	CTD-2509G16.5:ENST00000553754:intron_variant:MODIFIER:exon2/2:n.368+1947G>A:,RPL21P7:ENST00000557463:intron_variant:MODIFIER:exon1/1:n.112+81G>A:,CTD-2509G16.5:ENST00000555736:intron_variant:MODIFIER:exon1/3:n.153-19775G>A:							0.0000	0.0000	0.0000														0	0					CTD-2509G16.5 (inh=n/a pLI=n/a), RPL21P7 (inh=n/a pLI=n/a)	0							
chr14	82129157	82129157	G	A	0.4046	173	0.0000	166	"not-cod-spli;off-target"	294	RP11-226P1.3	non_coding_transcript_exon_variant	RP11-226P1.3:ENST00000553854:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1386G>A:							0.0000	0.0000	0.0000														0	0					RP11-226P1.3 (inh=n/a pLI=n/a)	0							
chr15	20488704	20488704	T	A	0.1439	396	0.0000	348	"not-cod-spli;off-target"	227	CHEK2P2	intron_variant	CHEK2P2:ENST00000555186:intron_variant:MODIFIER:exon1/5:n.232-45T>A:							0.0000	0.0000	0.0000														0	0					CHEK2P2 (inh=n/a pLI=n/a)	0							
chr15	42032280	42032280	C	T	0.3893	769	0.0000	595	syn-var	942	MGA	synonymous_variant	MGA:ENST00000219905:synonymous_variant:LOW:exon14/24:c.4464C>T:p.Ser1488Ser,MGA:ENST00000389936:synonymous_variant:LOW:exon14/25:c.4464C>T:p.Ser1488Ser,MGA:ENST00000545763:synonymous_variant:LOW:exon14/23:c.4464C>T:p.Ser1488Ser,MGA:ENST00000566586:synonymous_variant:LOW:exon13/22:c.4464C>T:p.Ser1488Ser,MGA:ENST00000570161:synonymous_variant:LOW:exon13/23:c.4464C>T:p.Ser1488Ser,MGA:ENST00000564190:synonymous_variant:LOW:exon3/11:c.405C>T:p.Ser135Ser			Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Function activated by heterodimerization with MAX. This heterodimerization serves the dual function of both generating an E-box-binding heterodimer and simultaneously blocking interaction of a corepressor (By similarity)				0.0000	0.0000	0.0000														0	0					MGA (inh=n/a pLI=1.00)	0		chr15_42032280_42032280_C_T	not protein-affecting	LoF	ENST00000219905	MGA	Synonymous
chr15	43785349	43785349	G	A	0.3694	223	0.0000	134	"not-cod-spli;off-target"	254	TP53BP1	5_prime_UTR_premature_start_codon_gain_variant,5_prime_UTR_variant,intron_variant,non_coding_transcript_exon_variant	TP53BP1:ENST00000382044:5_prime_UTR_premature_start_codon_gain_variant:LOW:exon1/28:c.-108C>T:,TP53BP1:ENST00000382044:5_prime_UTR_variant:MODIFIER:exon1/28:c.-108C>T:,TP53BP1:ENST00000263801:intron_variant:MODIFIER:exon1/27:c.-8-683C>T:,TP53BP1:ENST00000572085:non_coding_transcript_exon_variant:MODIFIER:exon1/23:n.6C>T:			Plays a key role in the response to DNA damage. May have a role in checkpoint signaling during mitosis. Enhances TP53- mediated transcriptional activation				0.0000	0.0000	0.0000														0	0					TP53BP1 (inh=n/a pLI=1.00)	0							
chr15	48807438	48807438	C	T	0.3814	98	0.0000	39	"not-cod-spli;off-target"	104	FBN1	sequence_feature,intron_variant	FBN1:ENST00000316623:sequence_feature:LOW::c.1468+146G>A:,FBN1:ENST00000316623:intron_variant:MODIFIER:exon12/65:c.1468+146G>A:,FBN1:ENST00000537463:intron_variant:MODIFIER:exon7/30:c.636+22470G>A:			Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-1- containing microfibrils provide long-term force bearing structural support. Regulates osteoblast maturation by controlling TGF-beta bioavailability and calibrating TGF-beta and BMP levels, respectively				0.0000	0.0000	0.0000		"134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];"												0	0					FBN1 (inh=AD pLI=1.00)	0							
chr15	63995240	63995240	A	C	0.0673	106	0.0000	40	"not-cod-spli;off-target"	66	HERC1,RP11-317G6.1	intron_variant	HERC1:ENST00000443617:intron_variant:MODIFIER:exon25/77:c.4636+3739T>G:,RP11-317G6.1:ENST00000559303:intron_variant:MODIFIER:exon3/3:n.288-10425A>C:,HERC1:ENST00000561400:intron_variant:MODIFIER:exon6/7:c.1588+3739T>G:		Ubiquitin mediated proteolysis	Involved in membrane trafficking via some guanine nucleotide exchange factor (GEF) activity and its ability to bind clathrin. Acts as a GEF for Arf and Rab, by exchanging bound GDP for free GTP. Binds phosphatidylinositol 4,5-bisphosphate, which is required for GEF activity. May also act as a E3 ubiquitin- protein ligase which accepts ubiquitin from an E2 ubiquitin- conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates				0.0000	0.0000	0.0000		"605109 [HERC1 (provisional) Macrocephaly,dysmorphic facies,and psychomotor retardation,617011];"												0	0					HERC1 (inh=AR pLI=1.00), RP11-317G6.1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,						
chr15	92829264	92829264	G	A	0.3451	368	0.0000	268	"not-cod-spli;off-target"	402	RP11-152L20.3,NPM1P5	intron_variant,non_coding_transcript_exon_variant	RP11-152L20.3:ENST00000561674:intron_variant:MODIFIER:exon2/3:n.185+27007C>T:,NPM1P5:ENST00000557228:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.194G>A:							0.0000	0.0000	0.0000														0	0					RP11-152L20.3 (inh=n/a pLI=n/a), NPM1P5 (inh=n/a pLI=n/a)	0							
chr15	99460268	99460268	C	T	0.3182	44	0.0000	36	"not-cod-spli;off-target"	92	IGF1R	intron_variant	IGF1R:ENST00000268035:intron_variant:MODIFIER:exon10/20:c.2201+163C>T:,IGF1R:ENST00000558762:intron_variant:MODIFIER:exon10/20:c.2201+163C>T:,IGF1R:ENST00000560144:intron_variant:MODIFIER:exon3/3:c.*159+163C>T:,IGF1R:ENST00000561049:intron_variant:MODIFIER:exon1/2:n.392+163C>T:		"Focal adhesion;Adherens junction;Long-term depression;Colorectal cancer;Glioma;Prostate cancer;Melanoma"	Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K- driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R	"Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK);Erk1/Erk2 Mapk Signaling pathway;IGF-1 Signaling Pathway;Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation;Regulation of BAD phosphorylation;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway;Telomeres, Telomerase, Cellular Aging, and  Immortality;The IGF-1 Receptor and Longevity"			0.0000	0.0000	0.0000		"147370 [IGF1R (confirmed) Insulin-like growth factor I,resistance to,270450];"												0	0					IGF1R (inh=AR+AD pLI=0.55)	0							
chr16	9858383	9858383	C	T	0.3631	689	0.0000	597	syn-var	812	GRIN2A	synonymous_variant	GRIN2A:ENST00000330684:synonymous_variant:LOW:exon13/13:c.3018G>A:p.Ala1006Ala,GRIN2A:ENST00000396573:synonymous_variant:LOW:exon14/14:c.3018G>A:p.Ala1006Ala,GRIN2A:ENST00000562109:synonymous_variant:LOW:exon12/13:c.3018G>A:p.Ala1006Ala,GRIN2A:ENST00000535259:synonymous_variant:LOW:exon12/13:c.2547G>A:p.Ala849Ala,GRIN2A:ENST00000404927:synonymous_variant:LOW:exon13/14:c.3018G>A:p.Ala1006Ala,GRIN2A:ENST00000396575:synonymous_variant:LOW:exon12/12:c.3018G>A:p.Ala1006Ala		"Calcium signaling pathway;Neuroactive ligand-receptor interaction;Long-term potentiation"	NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits			rs761132463	0.0000	0.00003	0.00002	COSM460428	"138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];"												0	0					GRIN2A (inh=AD pLI=1.00)	0		chr16_9858383_9858383_C_T	not protein-affecting	ambiguous	ENST00000396573	GRIN2A	Synonymous
chr16	28617885	28617885	G	A	0.2222	18	0.0000	22	"not-cod-spli;depth-tum;off-target"	59	SULT1A1	intron_variant	SULT1A1:ENST00000314752:intron_variant:MODIFIER:exon6/7:c.594+197C>T:,SULT1A1:ENST00000350842:intron_variant:MODIFIER:exon4/5:c.360+197C>T:,SULT1A1:ENST00000564818:intron_variant:MODIFIER:exon9/10:c.*899+197C>T:,SULT1A1:ENST00000567998:intron_variant:MODIFIER:exon2/3:n.7424+197C>T:,SULT1A1:ENST00000562058:intron_variant:MODIFIER:exon8/9:c.*826+197C>T:,SULT1A1:ENST00000395607:intron_variant:MODIFIER:exon6/7:c.594+197C>T:,SULT1A1:ENST00000395609:intron_variant:MODIFIER:exon8/9:c.594+197C>T:,SULT1A1:ENST00000569554:intron_variant:MODIFIER:exon5/6:c.594+197C>T:,SULT1A1:ENST00000563493:intron_variant:MODIFIER:exon7/8:c.*478+197C>T:,SULT1A1:ENST00000566189:intron_variant:MODIFIER:exon6/7:c.594+197C>T:,SULT1A1:ENST00000567512:intron_variant:MODIFIER:exon5/5:c.468+197C>T:		Sulfur metabolism	Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estrogen sulfotransferase activity. responsible for the sulfonation and activation of minoxidil. Is Mediates the metabolic activation of carcinogenic N- hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk			rs75301646	0.282748	0.0000	0.0000														0	1	2	[2] auto-classification 18.11.2017  			SULT1A1 (inh=n/a pLI=0.00)	0							
chr16	28617888	28617888	C	T	0.2105	19	0.0000	23	"not-cod-spli;depth-tum;off-target"	60	SULT1A1	intron_variant	SULT1A1:ENST00000314752:intron_variant:MODIFIER:exon6/7:c.594+194G>A:,SULT1A1:ENST00000350842:intron_variant:MODIFIER:exon4/5:c.360+194G>A:,SULT1A1:ENST00000564818:intron_variant:MODIFIER:exon9/10:c.*899+194G>A:,SULT1A1:ENST00000567998:intron_variant:MODIFIER:exon2/3:n.7424+194G>A:,SULT1A1:ENST00000562058:intron_variant:MODIFIER:exon8/9:c.*826+194G>A:,SULT1A1:ENST00000395607:intron_variant:MODIFIER:exon6/7:c.594+194G>A:,SULT1A1:ENST00000395609:intron_variant:MODIFIER:exon8/9:c.594+194G>A:,SULT1A1:ENST00000569554:intron_variant:MODIFIER:exon5/6:c.594+194G>A:,SULT1A1:ENST00000563493:intron_variant:MODIFIER:exon7/8:c.*478+194G>A:,SULT1A1:ENST00000566189:intron_variant:MODIFIER:exon6/7:c.594+194G>A:,SULT1A1:ENST00000567512:intron_variant:MODIFIER:exon5/5:c.468+194G>A:		Sulfur metabolism	Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estrogen sulfotransferase activity. responsible for the sulfonation and activation of minoxidil. Is Mediates the metabolic activation of carcinogenic N- hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk			rs74459546	0.284145	0.0000	0.0000														0	1	2	[2] auto-classification 18.11.2017  			SULT1A1 (inh=n/a pLI=0.00)	0							
chr16	28617890	28617890	A	G	0.1905	21	0.0000	25	"not-cod-spli;off-target"	62	SULT1A1	intron_variant	SULT1A1:ENST00000314752:intron_variant:MODIFIER:exon6/7:c.594+192T>C:,SULT1A1:ENST00000350842:intron_variant:MODIFIER:exon4/5:c.360+192T>C:,SULT1A1:ENST00000564818:intron_variant:MODIFIER:exon9/10:c.*899+192T>C:,SULT1A1:ENST00000567998:intron_variant:MODIFIER:exon2/3:n.7424+192T>C:,SULT1A1:ENST00000562058:intron_variant:MODIFIER:exon8/9:c.*826+192T>C:,SULT1A1:ENST00000395607:intron_variant:MODIFIER:exon6/7:c.594+192T>C:,SULT1A1:ENST00000395609:intron_variant:MODIFIER:exon8/9:c.594+192T>C:,SULT1A1:ENST00000569554:intron_variant:MODIFIER:exon5/6:c.594+192T>C:,SULT1A1:ENST00000563493:intron_variant:MODIFIER:exon7/8:c.*478+192T>C:,SULT1A1:ENST00000566189:intron_variant:MODIFIER:exon6/7:c.594+192T>C:,SULT1A1:ENST00000567512:intron_variant:MODIFIER:exon5/5:c.468+192T>C:		Sulfur metabolism	Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estrogen sulfotransferase activity. responsible for the sulfonation and activation of minoxidil. Is Mediates the metabolic activation of carcinogenic N- hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk			rs116840534	0.283347	0.0000	0.0000														0	1	2	[2] auto-classification 18.11.2017  			SULT1A1 (inh=n/a pLI=0.00)	1	TEST_SomaticAndTreatment,						
chr16	28621612	28621613	CC	-	0.1404	167	0.0000	113	"not-cod-spli;off-target"	46	SULT1A1	intron_variant,non_coding_transcript_exon_variant	SULT1A1:ENST00000350842:intron_variant:MODIFIER:exon2/5:c.139-3215_139-3214delGG:,SULT1A1:ENST00000564818:intron_variant:MODIFIER:exon2/10:c.139-101_139-100delGG:,SULT1A1:ENST00000562058:intron_variant:MODIFIER:exon2/9:c.139-101_139-100delGG:,SULT1A1:ENST00000395609:intron_variant:MODIFIER:exon2/9:c.-265-101_-265-100delGG:,SULT1A1:ENST00000563493:intron_variant:MODIFIER:exon2/8:c.139-1433_139-1432delGG:,SULT1A1:ENST00000567998:non_coding_transcript_exon_variant:MODIFIER:exon1/4:n.3988_3989delGG:		Sulfur metabolism	Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estrogen sulfotransferase activity. responsible for the sulfonation and activation of minoxidil. Is Mediates the metabolic activation of carcinogenic N- hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk				0.0000	0.0000	0.0000														0	0					SULT1A1 (inh=n/a pLI=0.00)	0							
chr16	32369712	32369712	G	A	0.1636	386	0.0000	357	"not-cod-spli;off-target"	244	RP11-17M15.4	intron_variant	RP11-17M15.4:ENST00000562853:intron_variant:MODIFIER:exon1/2:n.90-108C>T:							0.0000	0.0000	0.0000														0	0					RP11-17M15.4 (inh=n/a pLI=n/a)	0							
chr17	1761841	1761841	T	C	0.2462	65	0.0000	37	"not-cod-spli;off-target"	86	RPA1	intron_variant	RPA1:ENST00000254719:intron_variant:MODIFIER:exon5/16:c.361+5358T>C:,RPA1:ENST00000571058:intron_variant:MODIFIER:exon5/5:c.322+5358T>C:,RPA1:ENST00000570451:intron_variant:MODIFIER:exon5/6:c.322+5358T>C:		"DNA replication;Nucleotide excision repair;Mismatch repair;Homologous recombination"	Plays an essential role in several cellular processes in DNA metabolism including replication, recombination and DNA repair. Binds and subsequently stabilizes single-stranded DNA intermediates and thus prevents complementary DNA from reannealing	Hypoxia and p53 in the Cardiovascular system			0.0000	0.0000	0.0000														0	0					RPA1 (inh=n/a pLI=0.31)	0							
chr17	10360946	10360946	G	A	0.3871	31	0.0000	29	off-target	72	MYH4,RP11-799N11.1,CTC-297N7.11	missense_variant,intron_variant	MYH4:ENST00000255381:missense_variant:MODERATE:exon16/40:c.1688C>T:p.Ser563Phe,RP11-799N11.1:ENST00000399342:intron_variant:MODIFIER:exon2/3:n.206+51352G>A:,CTC-297N7.11:ENST00000587182:intron_variant:MODIFIER:exon2/10:n.155+51391G>A:,RP11-799N11.1:ENST00000581304:intron_variant:MODIFIER:exon2/3:n.143+51391G>A:	Myosin_head__motor_domain__2_	Tight junction	Muscle contraction				0.0000	0.0000	0.0000					1.771.000	D	D	P	T	24.20				0	0					MYH4 (inh=n/a pLI=0.00), RP11-799N11.1 (inh=n/a pLI=n/a), CTC-297N7.11 (inh=n/a pLI=n/a)	0		chr17_10360946_10360946_G_A	predicted passenger	.	ENST00000255381	MYH4	Missense
chr17	11924130	11924130	C	T	0.2558	43	0.0000	27	"not-cod-spli;off-target"	77	RPL21P122	intron_variant	RPL21P122:ENST00000578024:intron_variant:MODIFIER:exon1/1:n.24+510G>A:,RPL21P122:ENST00000579522:intron_variant:MODIFIER:exon1/3:n.186+510G>A:							0.0000	0.0000	0.0000														0	0					RPL21P122 (inh=n/a pLI=n/a)	0							
chr17	30302737	30302737	T	-	0.0256	416	0.0000	348	"not-cod-spli;freq-tum"	49	SUZ12	intron_variant	SUZ12:ENST00000322652:intron_variant:MODIFIER:exon7/15:c.823+15delT:,SUZ12:ENST00000580398:intron_variant:MODIFIER:exon6/14:c.754+15delT:			Polycomb group (PcG) protein. Component of the PRC2/EED- EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A			rs763857580	0.0000	0.04136	0.02682														0	0					SUZ12 (inh=n/a pLI=1.00)	0							
chr17	37571106	37571106	A	G	0.0649	79	0.0000	54	"not-cod-spli;off-target"	59	MED1	intron_variant	MED1:ENST00000300651:intron_variant:MODIFIER:exon16/16:c.1499+173T>C:,MED1:ENST00000394287:intron_variant:MODIFIER:exon16/17:c.1499+173T>C:,MED1:ENST00000577831:intron_variant:MODIFIER:exon15/15:c.*1072+173T>C:			Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors	"Control of Gene Expression by Vitamin D Receptor;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);Multi-step Regulation of Transcription by Pitx2;Role of PPAR-gamma Coactivators in Obesity and Thermogenesis"			0.0000	0.0000	0.0000														0	0					MED1 (inh=n/a pLI=1.00)	1	SomaticAndTreatment,						
chr17	37571110	37571110	A	T	0.0698	88	0.0000	59	"not-cod-spli;off-target"	66	MED1	intron_variant	MED1:ENST00000300651:intron_variant:MODIFIER:exon16/16:c.1499+169T>A:,MED1:ENST00000394287:intron_variant:MODIFIER:exon16/17:c.1499+169T>A:,MED1:ENST00000577831:intron_variant:MODIFIER:exon15/15:c.*1072+169T>A:			Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors	"Control of Gene Expression by Vitamin D Receptor;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);Multi-step Regulation of Transcription by Pitx2;Role of PPAR-gamma Coactivators in Obesity and Thermogenesis"			0.0000	0.0000	0.0000														0	0					MED1 (inh=n/a pLI=1.00)	1	SomaticAndTreatment,						
chr17	40856503	40856503	C	T	0.1204	109	0.0000	56	"not-cod-spli;off-target"	77	EZH1	intron_variant	EZH1:ENST00000428826:intron_variant:MODIFIER:exon18/20:c.2017+117G>A:,EZH1:ENST00000415827:intron_variant:MODIFIER:exon18/20:c.1990+117G>A:,EZH1:ENST00000435174:intron_variant:MODIFIER:exon16/18:c.1600+117G>A:,EZH1:ENST00000592743:intron_variant:MODIFIER:exon17/19:c.2017+117G>A:,EZH1:ENST00000588897:intron_variant:MODIFIER:exon16/18:c.*1524+117G>A:,EZH1:ENST00000585893:intron_variant:MODIFIER:exon17/19:c.1897+117G>A:,EZH1:ENST00000590078:intron_variant:MODIFIER:exon17/19:c.1807+117G>A:,EZH1:ENST00000586103:intron_variant:MODIFIER:exon18/18:n.2124+117G>A:,EZH1:ENST00000585912:intron_variant:MODIFIER:exon16/16:n.1897+117G>A:,EZH1:ENST00000585550:intron_variant:MODIFIER:exon10/10:n.1249+117G>A:,EZH1:ENST00000591330:intron_variant:MODIFIER:exon17/17:n.2025+117G>A:,EZH1:ENST00000590783:intron_variant:MODIFIER:exon6/6:n.565+117G>A:			Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH1-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation				0.0000	0.0000	0.0000														0	0					EZH1 (inh=n/a pLI=0.00)	0							
chr17	40856505	40856505	A	G	0.1545	124	0.0000	59	"not-cod-spli;off-target"	88	EZH1	intron_variant	EZH1:ENST00000428826:intron_variant:MODIFIER:exon18/20:c.2017+115T>C:,EZH1:ENST00000415827:intron_variant:MODIFIER:exon18/20:c.1990+115T>C:,EZH1:ENST00000435174:intron_variant:MODIFIER:exon16/18:c.1600+115T>C:,EZH1:ENST00000592743:intron_variant:MODIFIER:exon17/19:c.2017+115T>C:,EZH1:ENST00000588897:intron_variant:MODIFIER:exon16/18:c.*1524+115T>C:,EZH1:ENST00000585893:intron_variant:MODIFIER:exon17/19:c.1897+115T>C:,EZH1:ENST00000590078:intron_variant:MODIFIER:exon17/19:c.1807+115T>C:,EZH1:ENST00000586103:intron_variant:MODIFIER:exon18/18:n.2124+115T>C:,EZH1:ENST00000585912:intron_variant:MODIFIER:exon16/16:n.1897+115T>C:,EZH1:ENST00000585550:intron_variant:MODIFIER:exon10/10:n.1249+115T>C:,EZH1:ENST00000591330:intron_variant:MODIFIER:exon17/17:n.2025+115T>C:,EZH1:ENST00000590783:intron_variant:MODIFIER:exon6/6:n.565+115T>C:			Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH1-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation				0.0000	0.0000	0.0000														0	0					EZH1 (inh=n/a pLI=0.00)	1	SomaticAndTreatment,						
chr17	40856508	40856508	G	A	0.0922	144	0.0000	62	"not-cod-spli;off-target"	74	EZH1	intron_variant	EZH1:ENST00000428826:intron_variant:MODIFIER:exon18/20:c.2017+112C>T:,EZH1:ENST00000415827:intron_variant:MODIFIER:exon18/20:c.1990+112C>T:,EZH1:ENST00000435174:intron_variant:MODIFIER:exon16/18:c.1600+112C>T:,EZH1:ENST00000592743:intron_variant:MODIFIER:exon17/19:c.2017+112C>T:,EZH1:ENST00000588897:intron_variant:MODIFIER:exon16/18:c.*1524+112C>T:,EZH1:ENST00000585893:intron_variant:MODIFIER:exon17/19:c.1897+112C>T:,EZH1:ENST00000590078:intron_variant:MODIFIER:exon17/19:c.1807+112C>T:,EZH1:ENST00000586103:intron_variant:MODIFIER:exon18/18:n.2124+112C>T:,EZH1:ENST00000585912:intron_variant:MODIFIER:exon16/16:n.1897+112C>T:,EZH1:ENST00000585550:intron_variant:MODIFIER:exon10/10:n.1249+112C>T:,EZH1:ENST00000591330:intron_variant:MODIFIER:exon17/17:n.2025+112C>T:,EZH1:ENST00000590783:intron_variant:MODIFIER:exon6/6:n.565+112C>T:			Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH1-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation				0.0000	0.0000	0.0000														0	0					EZH1 (inh=n/a pLI=0.00)	1	SomaticAndTreatment,						
chr17	40856510	40856510	G	A	0.0342	149	0.0000	63	"not-cod-spli;freq-tum;off-target"	61	EZH1	intron_variant	EZH1:ENST00000428826:intron_variant:MODIFIER:exon18/20:c.2017+110C>T:,EZH1:ENST00000415827:intron_variant:MODIFIER:exon18/20:c.1990+110C>T:,EZH1:ENST00000435174:intron_variant:MODIFIER:exon16/18:c.1600+110C>T:,EZH1:ENST00000592743:intron_variant:MODIFIER:exon17/19:c.2017+110C>T:,EZH1:ENST00000588897:intron_variant:MODIFIER:exon16/18:c.*1524+110C>T:,EZH1:ENST00000585893:intron_variant:MODIFIER:exon17/19:c.1897+110C>T:,EZH1:ENST00000590078:intron_variant:MODIFIER:exon17/19:c.1807+110C>T:,EZH1:ENST00000586103:intron_variant:MODIFIER:exon18/18:n.2124+110C>T:,EZH1:ENST00000585912:intron_variant:MODIFIER:exon16/16:n.1897+110C>T:,EZH1:ENST00000585550:intron_variant:MODIFIER:exon10/10:n.1249+110C>T:,EZH1:ENST00000591330:intron_variant:MODIFIER:exon17/17:n.2025+110C>T:,EZH1:ENST00000590783:intron_variant:MODIFIER:exon6/6:n.565+110C>T:			Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH1-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation				0.0000	0.0000	0.0000														0	0					EZH1 (inh=n/a pLI=0.00)	0							
chr17	40881034	40881035	AA	-	0.0411	353	0.0000	255	"not-cod-spli;freq-tum;off-target"	59	EZH1	intron_variant	EZH1:ENST00000428826:intron_variant:MODIFIER:exon2/20:c.-11-65_-11-64delTT:,EZH1:ENST00000415827:intron_variant:MODIFIER:exon2/20:c.-11-65_-11-64delTT:,EZH1:ENST00000435174:intron_variant:MODIFIER:exon2/18:c.-187-65_-187-64delTT:,EZH1:ENST00000592743:intron_variant:MODIFIER:exon1/19:c.-11-65_-11-64delTT:,EZH1:ENST00000588897:intron_variant:MODIFIER:exon2/18:c.-11-65_-11-64delTT:,EZH1:ENST00000585893:intron_variant:MODIFIER:exon2/19:c.-11-65_-11-64delTT:,EZH1:ENST00000590078:intron_variant:MODIFIER:exon2/19:c.-93-1254_-93-1253delTT:,EZH1:ENST00000586103:intron_variant:MODIFIER:exon2/18:n.97-65_97-64delTT:,EZH1:ENST00000585912:intron_variant:MODIFIER:exon2/16:n.119-65_119-64delTT:,EZH1:ENST00000591330:intron_variant:MODIFIER:exon2/17:n.119-65_119-64delTT:,EZH1:ENST00000586382:intron_variant:MODIFIER:exon2/9:c.-11-65_-11-64delTT:,EZH1:ENST00000586867:intron_variant:MODIFIER:exon2/8:c.-11-65_-11-64delTT:,EZH1:ENST00000586089:intron_variant:MODIFIER:exon1/4:c.-11-65_-11-64delTT:,EZH1:ENST00000593214:intron_variant:MODIFIER:exon3/7:c.-11-65_-11-64delTT:,EZH1:ENST00000592492:intron_variant:MODIFIER:exon3/5:c.-11-65_-11-64delTT:,EZH1:ENST00000590082:intron_variant:MODIFIER:exon2/4:n.119-65_119-64delTT:			Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH1-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation				0.0000	0.0000	0.0000														0	0					EZH1 (inh=n/a pLI=0.00)	0							
chr18	12913818	12913818	T	A	0.3713	345	0.0000	259	"not-cod-spli;off-target"	417	PTPN2,RP11-773H22.2	intron_variant,non_coding_transcript_exon_variant	PTPN2:ENST00000592059:intron_variant:MODIFIER:exon1/4:c.-229+15680A>T:,RP11-773H22.2:ENST00000587313:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.976T>A:			Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3, STAT5A, STAT5B and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a multifaceted and important role in the development of the immune system. Functions in T-cell receptor signaling through dephosphorylation of FYN and LCK to control T-cells differentiation and activation. Dephosphorylates CSF1R, negatively regulating its downstream signaling and macrophage differentiation. Negatively regulates cytokine (IL2/interleukin-2 and interferon)-mediated signaling through dephosphorylation of the cytoplasmic kinases JAK1, JAK3 and their substrate STAT1, that propagate signaling downstream of the cytokine receptors. Also regulates the IL6/interleukin-6 and IL4/interleukin-4 cytokine signaling through dephosphorylation of STAT3 and STAT6 respectively. Beside the immune system, it is involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. Activated by the integrin ITGA1/ITGB1, it dephosphorylates EGFR and negatively regulates EGF signaling. Dephosphorylates PDGFRB and negatively regulates platelet-derived growth factor receptor-beta signaling pathway and therefore cell proliferation. Negatively regulates tumor necrosis factor-mediated signaling downstream via MAPK through SRC dephosphorylation. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of the hepatocyte growth factor receptor MET. Plays also an important role in glucose homeostasis. For instance, negatively regulates the insulin receptor signaling pathway through the dephosphorylation of INSR and control gluconeogenesis and liver glucose production through negative regulation of the IL6 signaling pathways. Finally, it negatively regulates prolactin-mediated signaling pathway through dephosphorylation of STAT5A and STAT5B. May also bind DNA			rs373489470	0.0000	0.0000	0.0000														0	0					PTPN2 (inh=n/a pLI=1.00), RP11-773H22.2 (inh=n/a pLI=n/a)	0							
chr18	59167749	59167749	G	A	0.3315	537	0.0000	487	not-cod-spli	629	CDH20	intron_variant	CDH20:ENST00000262717:intron_variant:MODIFIER:exon4/11:c.661+14G>A:,CDH20:ENST00000538374:intron_variant:MODIFIER:exon4/11:c.661+14G>A:,CDH20:ENST00000536675:intron_variant:MODIFIER:exon3/10:c.661+14G>A:			"Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types"				0.0000	0.0000	0.0000														0	0					CDH20 (inh=n/a pLI=0.98)	0							
chr19	2223323	2223323	C	T	0.3506	464	0.0000	441		553	DOT1L	missense_variant	DOT1L:ENST00000398665:missense_variant:MODERATE:exon25/28:c.3434C>T:p.Ser1145Phe,DOT1L:ENST00000457590:missense_variant:MODERATE:exon2/7:c.74C>T:p.Ser25Phe		Lysine degradation	Histone methyltransferase. Methylates 'Lys-79' of histone H3. Nucleosomes are preferred as substrate compared to free histones. Binds to DNA				0.0000	0.0000	0.0000					7.246000,7.246000	T,T	,D,D,D	,D,D	,T,T	28. Okt				0	0					DOT1L (inh=n/a pLI=1.00)	0		chr19_2223323_2223323_C_T	predicted passenger	.	ENST00000398665	DOT1L	Missense
chr19	7126639	7126639	G	A	0.4132	409	0.0000	355		600	INSR	missense_variant	INSR:ENST00000302850:missense_variant:MODERATE:exon16/22:c.2969C>T:p.Pro990Leu,INSR:ENST00000341500:missense_variant:MODERATE:exon15/21:c.2933C>T:p.Pro978Leu		"Adherens junction;Insulin signaling pathway;Type II diabetes mellitus;Dentatorubropallidoluysian atrophy (DRPLA)"	"Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src- homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti- apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K- AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin"	"Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK);Growth Hormone Signaling Pathway;Insulin Signaling Pathway"			0.0000	0.0000	0.00001		"147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];"			5.132.000	T	T,T	B,B	T,T	24.40				0	0					INSR (inh=AR+AD pLI=0.19)	0		chr19_7126639_7126639_G_A	predicted passenger	.	ENST00000302850	INSR	Missense
chr19	11217941	11217941	A	G	0.3465	101	0.0000	85	"not-cod-spli;off-target"	145	LDLR	intron_variant	LDLR:ENST00000557933:intron_variant:MODIFIER:exon5/17:c.818-127A>G:,LDLR:ENST00000558518:intron_variant:MODIFIER:exon5/17:c.818-127A>G:,LDLR:ENST00000455727:intron_variant:MODIFIER:exon3/15:c.314-127A>G:,LDLR:ENST00000535915:intron_variant:MODIFIER:exon4/16:c.695-127A>G:,LDLR:ENST00000545707:intron_variant:MODIFIER:exon4/15:c.437-127A>G:,LDLR:ENST00000558013:intron_variant:MODIFIER:exon5/17:c.818-127A>G:,LDLR:ENST00000252444:intron_variant:MODIFIER:exon5/17:c.1070-127A>G:,LDLR:ENST00000560467:intron_variant:MODIFIER:exon2/5:c.416-127A>G:,LDLR:ENST00000558528:intron_variant:MODIFIER:exon1/1:n.333-127A>G:			Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. In case of HIV-1 infection, functions as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells	"FXR and LXR Regulation of Cholesterol Metabolism;Low-density lipoprotein (LDL) pathway during atherogenesis;SREBP control of lipid synthesis"			0.0000	0.0000	0.0000		"606945 [LDLR (confirmed) Hypercholesterolemia,familial,143890|LDL cholesterol level QTL2,143890];"												0	0					LDLR (inh=AD pLI=0.00)	0							
chr19	15300025	15300025	G	A	0.3855	166	0.0000	159	"not-cod-spli;off-target"	270	NOTCH3	intron_variant	NOTCH3:ENST00000263388:intron_variant:MODIFIER:exon7/32:c.1193-40C>T:,NOTCH3:ENST00000601011:intron_variant:MODIFIER:exon7/22:c.1190-40C>T:		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs755562917	0.0000	0.00001	0.00001		"600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];"												0	0					NOTCH3 (inh=AD pLI=0.21)	0							
chr19	15383551	15383551	G	A	0.2653	98	0.0000	74	"not-cod-spli;off-target"	122	BRD4	intron_variant	BRD4:ENST00000263377:intron_variant:MODIFIER:exon2/19:c.285+75C>T:,BRD4:ENST00000371835:intron_variant:MODIFIER:exon2/11:c.285+75C>T:,BRD4:ENST00000360016:intron_variant:MODIFIER:exon2/11:c.285+75C>T:,BRD4:ENST00000594841:intron_variant:MODIFIER:exon2/8:c.285+75C>T:,BRD4:ENST00000597315:intron_variant:MODIFIER:exon2/5:c.285+75C>T:,BRD4:ENST00000601071:intron_variant:MODIFIER:exon1/3:n.167+75C>T:,BRD4:ENST00000601941:intron_variant:MODIFIER:exon3/3:c.285+75C>T:			"Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P- TEFb complex and recruiting it to promoters: BRD4 is required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P- TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II. Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II. According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo (PubMed:22509028). In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B. Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters"				0.0000	0.0000	0.0000														0	0					BRD4 (inh=n/a pLI=1.00)	0							
chr19	38934185	38934185	C	T	0.3759	283	0.0000	205	not-cod-spli	349	RYR1	intron_variant	RYR1:ENST00000359596:intron_variant:MODIFIER:exon3/105:c.271-13C>T:,RYR1:ENST00000355481:intron_variant:MODIFIER:exon3/104:c.271-13C>T:,RYR1:ENST00000360985:intron_variant:MODIFIER:exon3/104:c.271-13C>T:		"Calcium signaling pathway;Long-term depression"	Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis (By similarity)				0.0000	0.0000	0.0000		"180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];"												0	0					RYR1 (inh=AR+AD pLI=0.00)	0							
chr19	39018584	39018584	G	A	0.3261	47	0.0000	50	"not-cod-spli;off-target"	107	RYR1,AC067969.1	intron_variant	RYR1:ENST00000359596:intron_variant:MODIFIER:exon73/105:c.10824+160G>A:,AC067969.1:ENST00000597015:intron_variant:MODIFIER:exon1/2:n.236-169C>T:,RYR1:ENST00000355481:intron_variant:MODIFIER:exon72/104:c.10809+160G>A:,RYR1:ENST00000360985:intron_variant:MODIFIER:exon73/104:c.10824+160G>A:,RYR1:ENST00000594335:intron_variant:MODIFIER:exon32/48:c.*1552+160G>A:,RYR1:ENST00000599547:intron_variant:MODIFIER:exon12/18:c.1629+160G>A:		"Calcium signaling pathway;Long-term depression"	Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis (By similarity)				0.0000	0.0000	0.0000		"180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];"												0	0					RYR1 (inh=AR+AD pLI=0.00), AC067969.1 (inh=n/a pLI=n/a)	0							
chr19	40763080	40763080	T	G	0.2000	88	0.0469	64	"not-cod-spli;freq-nor;off-target"	63	AKT2	intron_variant	AKT2:ENST00000392038:intron_variant:MODIFIER:exon2/13:c.47-119A>C:,AKT2:ENST00000391844:intron_variant:MODIFIER:exon1/12:c.-130-119A>C:,AKT2:ENST00000424901:intron_variant:MODIFIER:exon1/12:c.47-119A>C:,AKT2:ENST00000584288:intron_variant:MODIFIER:exon2/13:c.-130-119A>C:,AKT2:ENST00000311278:intron_variant:MODIFIER:exon1/11:c.47-119A>C:,AKT2:ENST00000579047:intron_variant:MODIFIER:exon1/11:c.-140-119A>C:,AKT2:ENST00000492463:intron_variant:MODIFIER:exon1/6:c.-130-119A>C:,AKT2:ENST00000537834:intron_variant:MODIFIER:exon2/6:n.355-119A>C:,AKT2:ENST00000441941:intron_variant:MODIFIER:exon2/5:c.47-119A>C:,AKT2:ENST00000486368:intron_variant:MODIFIER:exon2/5:c.47-119A>C:,AKT2:ENST00000596634:intron_variant:MODIFIER:exon2/5:c.47-119A>C:,AKT2:ENST00000452077:intron_variant:MODIFIER:exon2/4:c.47-119A>C:,AKT2:ENST00000392037:intron_variant:MODIFIER:exon1/3:c.47-119A>C:,AKT2:ENST00000416362:intron_variant:MODIFIER:exon4/6:c.47-119A>C:,AKT2:ENST00000578123:intron_variant:MODIFIER:exon2/4:c.47-119A>C:,AKT2:ENST00000423127:intron_variant:MODIFIER:exon4/6:c.47-119A>C:,AKT2:ENST00000358335:intron_variant:MODIFIER:exon2/4:c.47-119A>C:,AKT2:ENST00000456441:intron_variant:MODIFIER:exon3/5:c.47-119A>C:,AKT2:ENST00000583859:intron_variant:MODIFIER:exon2/4:c.47-119A>C:,AKT2:ENST00000580747:intron_variant:MODIFIER:exon2/4:c.47-119A>C:,AKT2:ENST00000416994:intron_variant:MODIFIER:exon2/3:c.47-119A>C:,AKT2:ENST00000427375:intron_variant:MODIFIER:exon3/4:c.47-119A>C:		"MAPK signaling pathway;ErbB signaling pathway;mTOR signaling pathway;Apoptosis;VEGF signaling pathway;Focal adhesion;Tight junction;Toll-like receptor signaling pathway;Jak-STAT signaling pathway;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Insulin signaling pathway;Adipocytokine signaling pathway;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer"	AKT2 is one of 3 closely related serine/threonine- protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)- response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development				0.0000	0.0000	0.0000		"164731 [AKT2 (provisional) Diabetes mellitus,type II,125853|Hypoinsulinemic hypoglycemia with hemihypertrophy,240900];"												0	0					AKT2 (inh=AR+AD pLI=1.00)	2	TEST_SomaticAndTreatment,						
chr19	45287354	45287354	C	T	0.5200	25	0.0000	31	"not-cod-spli;off-target"	75	CBLC	sequence_feature,intron_variant	CBLC:ENST00000270279:sequence_feature:LOW::c.780-167C>T:,CBLC:ENST00000270279:intron_variant:MODIFIER:exon4/10:c.780-167C>T:,CBLC:ENST00000341505:intron_variant:MODIFIER:exon4/9:c.779+1606C>T:		"ErbB signaling pathway;Ubiquitin mediated proteolysis;Jak-STAT signaling pathway;T cell receptor signaling pathway;Insulin signaling pathway;Chronic myeloid leukemia"	Regulator of EGFR mediated signal transduction				0.0000	0.0000	0.0000														0	0					CBLC (inh=n/a pLI=0.00)	0							
chr19	45873730	45873730	G	A	0.4107	57	0.0000	49	off-target	124	ERCC2	splice_region_variant,5_prime_UTR_premature_start_codon_gain_variant,5_prime_UTR_variant,intron_variant	ERCC2:ENST00000586131:splice_region_variant:LOW:exon1/10:c.-69C>T:,ERCC2:ENST00000391941:5_prime_UTR_premature_start_codon_gain_variant:LOW:exon1/21:c.-307C>T:,ERCC2:ENST00000586131:5_prime_UTR_premature_start_codon_gain_variant:LOW:exon1/10:c.-69C>T:,ERCC2:ENST00000586856:5_prime_UTR_premature_start_codon_gain_variant:LOW:exon1/4:c.-307C>T:,ERCC2:ENST00000391941:5_prime_UTR_variant:MODIFIER:exon1/21:c.-307C>T:,ERCC2:ENST00000586131:5_prime_UTR_variant:MODIFIER:exon1/10:c.-69C>T:,ERCC2:ENST00000586856:5_prime_UTR_variant:MODIFIER:exon1/4:c.-307C>T:,ERCC2:ENST00000391945:intron_variant:MODIFIER:exon1/22:c.5+64C>T:,ERCC2:ENST00000391944:intron_variant:MODIFIER:exon1/20:c.5+64C>T:,ERCC2:ENST00000391940:intron_variant:MODIFIER:exon1/12:c.-68+64C>T:,ERCC2:ENST00000221481:intron_variant:MODIFIER:exon1/7:c.5+64C>T:,ERCC2:ENST00000591309:intron_variant:MODIFIER:exon1/6:c.5+64C>T:,ERCC2:ENST00000586737:intron_variant:MODIFIER:exon1/4:n.20+64C>T:,ERCC2:ENST00000586441:intron_variant:MODIFIER:exon1/5:n.20+64C>T:		Nucleotide excision repair	ATP-dependent 5'-3' DNA helicase, component of the core- TFIIH basal transcription factor. Involved in nucleotide excision repair (NER) of DNA by opening DNA around the damage, and in RNA transcription by RNA polymerase II by anchoring the CDK-activating kinase (CAK) complex, composed of CDK7, cyclin H and MAT1, to the core-TFIIH complex. Involved in the regulation of vitamin-D receptor activity. As part of the mitotic spindle-associated MMXD complex it plays a role in chromosome segregation. Might have a role in aging process and could play a causative role in the generation of skin cancers				0.0000	0.0000	0.0000		"126340 [ERCC2 (confirmed) Xeroderma pigmentosum,group D,278730|Trichothiodystrophy 1,photosensitive,601675|Cerebrooculofacioskeletal syndrome 2,610756];"												0	1					ERCC2 (inh=AR pLI=0.00)	0							
chr19	45916687	45916687	C	A	0.1042	48	0.0000	23	"not-cod-spli;off-target"	58	ERCC1	intron_variant	ERCC1:ENST00000300853:intron_variant:MODIFIER:exon9/9:c.843+248G>T:,ERCC1:ENST00000423698:intron_variant:MODIFIER:exon8/8:c.627+248G>T:,ERCC1:ENST00000588738:intron_variant:MODIFIER:exon3/3:n.406+248G>T:,ERCC1:ENST00000340192:intron_variant:MODIFIER:exon8/8:c.771+248G>T:,ERCC1:ENST00000590701:intron_variant:MODIFIER:exon3/3:c.233+248G>T:,ERCC1:ENST00000591636:intron_variant:MODIFIER:exon5/5:c.602+3392G>T:,ERCC1:ENST00000589165:intron_variant:MODIFIER:exon9/9:c.843+248G>T:		Nucleotide excision repair	Structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair				0.0000	0.0000	0.0000		"126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];"												0	0					ERCC1 (inh=AR pLI=0.00)	0							
chr20	9543582	9543582	C	A	0.3833	622	0.0000	523		794	PAK7	missense_variant	PAK7:ENST00000353224:missense_variant:MODERATE:exon6/10:c.1572G>T:p.Glu524Asp,PAK7:ENST00000378423:missense_variant:MODERATE:exon7/11:c.1572G>T:p.Glu524Asp,PAK7:ENST00000378429:missense_variant:MODERATE:exon7/11:c.1572G>T:p.Glu524Asp	Serine/threonine-protein_kinase-like_domain__1_,Serine/threonine-protein_kinase__catalytic__domain__1_,Protein_kinase-like_domain__1_,Protein_kinase__catalytic_domain__1_	"ErbB signaling pathway;Axon guidance;Focal adhesion;T cell receptor signaling pathway;Regulation of actin cytoskeleton;Renal cell carcinoma"	Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, proliferation or cell survival. Activation by various effectors including growth factor receptors or active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates the proto-oncogene RAF1 and stimulates its kinase activity. Promotes cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Phosphorylates CTNND1, probably to regulate cytoskeletal organization and cell morphology. Keeps microtubules stable through MARK2 inhibition and destabilizes the F-actin network leading to the disappearance of stress fibers and focal adhesions	Agrin in Postsynaptic Differentiation			0.0000	0.0000	0.00000					1.365.000	T	D,D,D,D	D,D	T,T,T	29. Okt				0	0					PAK5 (inh=n/a pLI=1.00)	0		chr20_9543582_9543582_C_A	predicted passenger	.	ENST00000378429	PAK7	Missense
chr20	10621842	10621842	C	T	0.3839	883	0.0017	579	syn-var	933	JAG1	synonymous_variant	JAG1:ENST00000254958:synonymous_variant:LOW:exon24/26:c.2967G>A:p.Leu989Leu,JAG1:ENST00000423891:synonymous_variant:LOW:exon22/25:c.2490G>A:p.Leu830Leu		Notch signaling pathway	Ligand for multiple Notch receptors and involved in the mediation of Notch signaling. May be involved in cell-fate decisions during hematopoiesis. Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation (By similarity). Enhances fibroblast growth factor-induced angiogenesis (in vitro)	Phosphoinositides and their downstream targets			0.0000	0.0000	0.0000		"601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];"												0	0					JAG1 (inh=AD pLI=1.00)	0		chr20_10621842_10621842_C_T	not protein-affecting	.	ENST00000254958	JAG1	Synonymous
chr20	40744716	40744716	C	T	0.3368	193	0.0000	209		282	PTPRT	missense_variant,intron_variant	PTPRT:ENST00000373184:missense_variant:MODERATE:exon21/31:c.2975G>A:p.Gly992Glu,PTPRT:ENST00000373198:intron_variant:MODIFIER:exon22/31:c.3040-761G>A:,PTPRT:ENST00000356100:intron_variant:MODIFIER:exon21/30:c.3010-761G>A:,PTPRT:ENST00000373187:intron_variant:MODIFIER:exon21/30:c.2983-761G>A:,PTPRT:ENST00000373190:intron_variant:MODIFIER:exon21/30:c.2980-761G>A:,PTPRT:ENST00000373193:intron_variant:MODIFIER:exon21/30:c.2992-761G>A:,PTPRT:ENST00000373201:intron_variant:MODIFIER:exon20/29:c.2953-761G>A:			May be involved in both signal transduction and cellular adhesion in the CNS				0.0000	0.0000	0.0000					3.018.000	T	D		T	21. Okt				0	0					PTPRT (inh=n/a pLI=1.00)	0		chr20_40744716_40744716_C_T	not protein-affecting	ambiguous	ENST00000373187	PTPRT	IntronicSNV
chr20	41100966	41100966	G	A	0.3447	439	0.0000	434	syn-var	576	PTPRT	synonymous_variant	PTPRT:ENST00000373198:synonymous_variant:LOW:exon8/32:c.1390C>T:p.Leu464Leu,PTPRT:ENST00000356100:synonymous_variant:LOW:exon8/31:c.1390C>T:p.Leu464Leu,PTPRT:ENST00000373184:synonymous_variant:LOW:exon8/31:c.1390C>T:p.Leu464Leu,PTPRT:ENST00000373187:synonymous_variant:LOW:exon8/31:c.1390C>T:p.Leu464Leu,PTPRT:ENST00000373190:synonymous_variant:LOW:exon8/31:c.1390C>T:p.Leu464Leu,PTPRT:ENST00000373193:synonymous_variant:LOW:exon8/31:c.1390C>T:p.Leu464Leu,PTPRT:ENST00000373201:synonymous_variant:LOW:exon8/30:c.1390C>T:p.Leu464Leu			May be involved in both signal transduction and cellular adhesion in the CNS				0.0000	0.0000	0.0000														0	0					PTPRT (inh=n/a pLI=1.00)	0		chr20_41100966_41100966_G_A	not protein-affecting	ambiguous	ENST00000373187	PTPRT	Synonymous
chr20	57415619	57415619	C	T	0.4224	832	0.0000	547		986	GNAS,GNAS-AS1	missense_variant,intron_variant,non_coding_transcript_exon_variant	GNAS:ENST00000313949:missense_variant:MODERATE:exon1/13:c.458C>T:p.Ser153Phe,GNAS:ENST00000371098:missense_variant:MODERATE:exon1/4:c.458C>T:p.Ser153Phe,GNAS:ENST00000371075:missense_variant:MODERATE:exon1/13:c.458C>T:p.Ser153Phe,GNAS:ENST00000453292:missense_variant:MODERATE:exon1/3:c.221C>T:p.Ser74Phe,GNAS:ENST00000419558:missense_variant:MODERATE:exon1/5:c.59C>T:p.Ser20Phe,GNAS-AS1:ENST00000424094:intron_variant:MODIFIER:exon4/4:n.819+1373G>A:,GNAS-AS1:ENST00000598163:intron_variant:MODIFIER:exon2/3:n.388+8315G>A:,GNAS-AS1:ENST00000443966:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.281G>A:		"Calcium signaling pathway;Gap junction;Long-term depression;Taste transduction;GnRH signaling pathway;Melanogenesis;Vibrio cholerae infection"		"Activation of cAMP-dependent protein kinase, PKA;Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;Attenuation of GPCR Signaling;CCR3 signaling in Eosinophils;Corticosteroids and cardioprotection;Erk1/Erk2 Mapk Signaling pathway;How Progesterone Initiates Oocyte Membrane;Ion Channels and Their Functional Role in Vascular Endothelium;Phospholipase C-epsilon pathway;Regulation of Spermatogenesis by CREM;Signaling Pathway from G-Protein Families;b-arrestins in GPCR Desensitization;Transcription factor CREB and its extracellular signals"			0.0000	0.0000	0.0000		"610540 [GNAS-AS1 (provisional) Pseudohypoparathyroidism,type IB,603233]:139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];"			0.155000,0.155000	T,T	,D,D,D,D	,B		Dez 79				0	0					GNAS (inh=AD pLI=1.00), GNAS-AS1 (inh=AD pLI=n/a)	0							
chr20	57429531	57429531	C	T	0.3545	721	0.0000	387		617	GNAS	missense_variant,intron_variant,non_coding_transcript_exon_variant	GNAS:ENST00000371100:missense_variant:MODERATE:exon1/13:c.1211C>T:p.Ser404Phe,GNAS:ENST00000371099:missense_variant:MODERATE:exon1/2:c.1211C>T:p.Ser404Phe,GNAS:ENST00000371102:missense_variant:MODERATE:exon1/12:c.1211C>T:p.Ser404Phe,GNAS:ENST00000306120:missense_variant:MODERATE:exon1/1:c.1021C>T:p.Pro341Ser,GNAS:ENST00000313949:intron_variant:MODIFIER:exon1/12:c.*42+13590C>T:,GNAS:ENST00000371098:intron_variant:MODIFIER:exon1/3:c.*42+13590C>T:,GNAS:ENST00000371075:intron_variant:MODIFIER:exon1/12:c.*42+13590C>T:,GNAS:ENST00000453292:intron_variant:MODIFIER:exon1/2:c.*42+13590C>T:,GNAS:ENST00000419558:intron_variant:MODIFIER:exon1/4:c.*42+13590C>T:,GNAS:ENST00000491348:intron_variant:MODIFIER:exon1/2:n.533+12601C>T:,GNAS:ENST00000472183:intron_variant:MODIFIER:exon1/7:n.391+12601C>T:,GNAS:ENST00000462499:intron_variant:MODIFIER:exon1/3:n.258+12601C>T:,GNAS:ENST00000482112:intron_variant:MODIFIER:exon1/6:n.258+12601C>T:,GNAS:ENST00000490374:intron_variant:MODIFIER:exon1/6:n.254+12601C>T:,GNAS:ENST00000493744:intron_variant:MODIFIER:exon1/3:n.232+12601C>T:,GNAS:ENST00000467227:intron_variant:MODIFIER:exon2/7:n.122+10402C>T:,GNAS:ENST00000464624:non_coding_transcript_exon_variant:MODIFIER:exon1/14:n.1214C>T:,GNAS:ENST00000481768:non_coding_transcript_exon_variant:MODIFIER:exon1/6:n.308C>T:		"Calcium signaling pathway;Gap junction;Long-term depression;Taste transduction;GnRH signaling pathway;Melanogenesis;Vibrio cholerae infection"		"Activation of cAMP-dependent protein kinase, PKA;Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;Attenuation of GPCR Signaling;CCR3 signaling in Eosinophils;Corticosteroids and cardioprotection;Erk1/Erk2 Mapk Signaling pathway;How Progesterone Initiates Oocyte Membrane;Ion Channels and Their Functional Role in Vascular Endothelium;Phospholipase C-epsilon pathway;Regulation of Spermatogenesis by CREM;Signaling Pathway from G-Protein Families;b-arrestins in GPCR Desensitization;Transcription factor CREB and its extracellular signals"			0.0000	0.0000	0.0000		"139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];"			0.216000,0.216000	D,D	T,D,D,D	,B	,D,D	16.87				0	0					GNAS (inh=AD pLI=1.00)	0							
chr20	57429532	57429532	C	T	0.3570	718	0.0000	388		599	GNAS	missense_variant,synonymous_variant,intron_variant,non_coding_transcript_exon_variant	GNAS:ENST00000306120:missense_variant:MODERATE:exon1/1:c.1022C>T:p.Pro341Leu,GNAS:ENST00000371100:synonymous_variant:LOW:exon1/13:c.1212C>T:p.Ser404Ser,GNAS:ENST00000371099:synonymous_variant:LOW:exon1/2:c.1212C>T:p.Ser404Ser,GNAS:ENST00000371102:synonymous_variant:LOW:exon1/12:c.1212C>T:p.Ser404Ser,GNAS:ENST00000313949:intron_variant:MODIFIER:exon1/12:c.*42+13591C>T:,GNAS:ENST00000371098:intron_variant:MODIFIER:exon1/3:c.*42+13591C>T:,GNAS:ENST00000371075:intron_variant:MODIFIER:exon1/12:c.*42+13591C>T:,GNAS:ENST00000453292:intron_variant:MODIFIER:exon1/2:c.*42+13591C>T:,GNAS:ENST00000419558:intron_variant:MODIFIER:exon1/4:c.*42+13591C>T:,GNAS:ENST00000491348:intron_variant:MODIFIER:exon1/2:n.533+12602C>T:,GNAS:ENST00000472183:intron_variant:MODIFIER:exon1/7:n.391+12602C>T:,GNAS:ENST00000462499:intron_variant:MODIFIER:exon1/3:n.258+12602C>T:,GNAS:ENST00000482112:intron_variant:MODIFIER:exon1/6:n.258+12602C>T:,GNAS:ENST00000490374:intron_variant:MODIFIER:exon1/6:n.254+12602C>T:,GNAS:ENST00000493744:intron_variant:MODIFIER:exon1/3:n.232+12602C>T:,GNAS:ENST00000467227:intron_variant:MODIFIER:exon2/7:n.122+10403C>T:,GNAS:ENST00000464624:non_coding_transcript_exon_variant:MODIFIER:exon1/14:n.1215C>T:,GNAS:ENST00000481768:non_coding_transcript_exon_variant:MODIFIER:exon1/6:n.309C>T:		"Calcium signaling pathway;Gap junction;Long-term depression;Taste transduction;GnRH signaling pathway;Melanogenesis;Vibrio cholerae infection"		"Activation of cAMP-dependent protein kinase, PKA;Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;Attenuation of GPCR Signaling;CCR3 signaling in Eosinophils;Corticosteroids and cardioprotection;Erk1/Erk2 Mapk Signaling pathway;How Progesterone Initiates Oocyte Membrane;Ion Channels and Their Functional Role in Vascular Endothelium;Phospholipase C-epsilon pathway;Regulation of Spermatogenesis by CREM;Signaling Pathway from G-Protein Families;b-arrestins in GPCR Desensitization;Transcription factor CREB and its extracellular signals"		rs756634082	0.0000	0.00003	0.00001		"139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];"			-0.644000	T	D			14.77				0	0					GNAS (inh=AD pLI=1.00)	0							
chr20	57430556	57430556	G	A	0.3613	194	0.0070	142	"not-cod-spli;off-target"	208	GNAS	intron_variant	GNAS:ENST00000371100:intron_variant:MODIFIER:exon1/12:c.2068+168G>A:,GNAS:ENST00000313949:intron_variant:MODIFIER:exon1/12:c.*42+14615G>A:,GNAS:ENST00000371098:intron_variant:MODIFIER:exon1/3:c.*42+14615G>A:,GNAS:ENST00000371075:intron_variant:MODIFIER:exon1/12:c.*42+14615G>A:,GNAS:ENST00000453292:intron_variant:MODIFIER:exon1/2:c.*42+14615G>A:,GNAS:ENST00000419558:intron_variant:MODIFIER:exon1/4:c.*42+14615G>A:,GNAS:ENST00000491348:intron_variant:MODIFIER:exon1/2:n.533+13626G>A:,GNAS:ENST00000472183:intron_variant:MODIFIER:exon1/7:n.391+13626G>A:,GNAS:ENST00000462499:intron_variant:MODIFIER:exon1/3:n.258+13626G>A:,GNAS:ENST00000482112:intron_variant:MODIFIER:exon1/6:n.258+13626G>A:,GNAS:ENST00000490374:intron_variant:MODIFIER:exon1/6:n.254+13626G>A:,GNAS:ENST00000493744:intron_variant:MODIFIER:exon1/3:n.232+13626G>A:,GNAS:ENST00000467227:intron_variant:MODIFIER:exon2/7:n.122+11427G>A:,GNAS:ENST00000371099:intron_variant:MODIFIER:exon1/1:c.2069-53G>A:,GNAS:ENST00000371102:intron_variant:MODIFIER:exon1/11:c.2068+168G>A:,GNAS:ENST00000464624:intron_variant:MODIFIER:exon1/13:n.2071+168G>A:,GNAS:ENST00000481768:intron_variant:MODIFIER:exon1/5:n.1166-53G>A:,GNAS:ENST00000450130:intron_variant:MODIFIER:exon1/5:c.226+168G>A:,GNAS:ENST00000349036:intron_variant:MODIFIER:exon1/5:c.187+168G>A:,GNAS:ENST00000423897:intron_variant:MODIFIER:exon1/3:c.154+168G>A:		"Calcium signaling pathway;Gap junction;Long-term depression;Taste transduction;GnRH signaling pathway;Melanogenesis;Vibrio cholerae infection"		"Activation of cAMP-dependent protein kinase, PKA;Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;Attenuation of GPCR Signaling;CCR3 signaling in Eosinophils;Corticosteroids and cardioprotection;Erk1/Erk2 Mapk Signaling pathway;How Progesterone Initiates Oocyte Membrane;Ion Channels and Their Functional Role in Vascular Endothelium;Phospholipase C-epsilon pathway;Regulation of Spermatogenesis by CREM;Signaling Pathway from G-Protein Families;b-arrestins in GPCR Desensitization;Transcription factor CREB and its extracellular signals"			0.0000	0.0000	0.0000		"139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];"												0	0					GNAS (inh=AD pLI=1.00)	0							
chr20	61512146	61512146	C	T	0.3350	810	0.0000	355		557	DIDO1	missense_variant	DIDO1:ENST00000266070:missense_variant:MODERATE:exon16/16:c.5162G>A:p.Gly1721Glu,DIDO1:ENST00000395343:missense_variant:MODERATE:exon16/16:c.5162G>A:p.Gly1721Glu			Putative transcription factor, weakly pro-apoptotic when overexpressed (By similarity). Tumor suppressor				0.0000	0.0000	0.0000					0.739000	T	D,D	B	T,T	20.80				0	0					DIDO1 (inh=n/a pLI=1.00)	0		chr20_61512146_61512146_C_T	predicted passenger	LoF	ENST00000266070	DIDO1	Missense
chr21	11047743	11047743	A	G	0.0893	280	0.0000	275	"not-cod-spli;off-target"	119	BAGE2	intron_variant	BAGE2:ENST00000496773:intron_variant:MODIFIER:exon2/14:n.336-148T>C:,BAGE2:ENST00000470054:intron_variant:MODIFIER:exon4/9:n.660-148T>C:			Unknown. Candidate gene encoding tumor antigens				0.0000	0.0000	0.0000														0	0					BAGE2 (inh=n/a pLI=n/a)	0							
chr22	22535221	22535221	G	A	0.3525	278	0.0000	310	"not-cod-spli;off-target"	416	IGLVIV-59-IGLVV-58	intergenic_region	IGLVIV-59-IGLVV-58:ENSG00000254308-ENSG00000253637:intergenic_region:MODIFIER::n.22535221G>A:							0.0000	0.0000	0.0000		"151410 [BCR (confirmed) Leukemia,chronic myeloid,somatic,608232|Leukemia,acute lymphocytic,somatic,613065];"												0	0					IGLVIV-59-IGLVV-58 (inh=n/a pLI=n/a)	0							
chr22	23551998	23551998	T	G	0.0504	139	0.0000	81	not-cod-spli	68	BCR	intron_variant	BCR:ENST00000305877:intron_variant:MODIFIER:exon1/22:c.1279+27572T>G:,BCR:ENST00000479188:intron_variant:MODIFIER:exon1/4:n.129+29979T>G:,BCR:ENST00000398512:intron_variant:MODIFIER:exon1/1:c.1279+27572T>G:,BCR:ENST00000359540:intron_variant:MODIFIER:exon1/21:c.1279+27572T>G:,BCR:ENST00000463770:intron_variant:MODIFIER:exon1/1:n.133+11426T>G:,BCR:ENST00000487679:intron_variant:MODIFIER:exon2/2:n.196+10459T>G:		Chronic myeloid leukemia	GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity	"Inhibition of Cellular Proliferation by Gleevec;Integrin Signaling Pathway"			0.0000	0.0000	0.0000		"151410 [BCR (confirmed) Leukemia,chronic myeloid,somatic,608232|Leukemia,acute lymphocytic,somatic,613065];"												0	0					BCR (inh=n/a pLI=1.00)	0							
chr22	29099638	29099638	G	A	0.3276	58	0.0000	56	"not-cod-spli;off-target"	116	CHEK2	intron_variant	CHEK2:ENST00000382580:intron_variant:MODIFIER:exon8/15:c.976-84C>T:,CHEK2:ENST00000434810:intron_variant:MODIFIER:exon2/9:c.76-84C>T:,CHEK2:ENST00000456369:intron_variant:MODIFIER:exon2/5:c.100-84C>T:,CHEK2:ENST00000348295:intron_variant:MODIFIER:exon7/13:c.847-84C>T:,CHEK2:ENST00000382565:intron_variant:MODIFIER:exon2/4:c.320-14384C>T:,CHEK2:ENST00000382566:intron_variant:MODIFIER:exon7/13:c.847-3713C>T:,CHEK2:ENST00000382578:intron_variant:MODIFIER:exon5/12:c.574-84C>T:,CHEK2:ENST00000416671:intron_variant:MODIFIER:exon8/15:c.*337-84C>T:,CHEK2:ENST00000544772:intron_variant:MODIFIER:exon8/15:c.184-84C>T:,CHEK2:ENST00000404276:intron_variant:MODIFIER:exon6/13:c.847-84C>T:,CHEK2:ENST00000328354:intron_variant:MODIFIER:exon7/14:c.847-84C>T:,CHEK2:ENST00000405598:intron_variant:MODIFIER:exon8/15:c.847-84C>T:,CHEK2:ENST00000417588:intron_variant:MODIFIER:exon5/12:c.*144-84C>T:,CHEK2:ENST00000433728:intron_variant:MODIFIER:exon6/12:c.847-3713C>T:,CHEK2:ENST00000448511:intron_variant:MODIFIER:exon6/13:c.*239-84C>T:,CHEK2:ENST00000402731:intron_variant:MODIFIER:exon6/12:c.847-84C>T:,CHEK2:ENST00000403642:intron_variant:MODIFIER:exon4/11:c.574-84C>T:,CHEK2:ENST00000447421:intron_variant:MODIFIER:exon5/7:c.646-84C>T:,CHEK2:ENST00000433028:intron_variant:MODIFIER:exon7/9:c.*572-84C>T:,CHEK2:ENST00000464581:intron_variant:MODIFIER:exon3/5:n.199-84C>T:,CHEK2:ENST00000491919:intron_variant:MODIFIER:exon2/4:n.404-84C>T:,CHEK2:ENST00000425190:intron_variant:MODIFIER:exon6/8:c.184-84C>T:,CHEK2:ENST00000439346:intron_variant:MODIFIER:exon4/5:c.*144-84C>T:		"Cell cycle;p53 signaling pathway"	Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X- R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells	"ATM Signaling Pathway;Cell Cycle: G2/M Checkpoint;Regulation of cell cycle progression by Plk3;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility"			0.0000	0.0000	0.0000		"604373 [CHEK2 (provisional) Li-Fraumeni syndrome,609265|Osteosarcoma,somatic,259500|Breast cancer,susceptibility to,114480|Prostate cancer,familial,susceptibility to,176807|Breast and colorectal cancer,susceptibility to];"												0	0					CHEK2 (inh=AD pLI=0.00)	0							
chr22	29683386	29683386	G	A	0.0358	282	0.0000	111	"not-cod-spli;freq-tum"	75	EWSR1	sequence_feature,intron_variant	EWSR1:ENST00000414183:sequence_feature:LOW::c.811+263G>A:,EWSR1:ENST00000397938:sequence_feature:LOW::c.793+263G>A:,EWSR1:ENST00000406548:sequence_feature:LOW::c.793+263G>A:,EWSR1:ENST00000333395:sequence_feature:LOW::c.793+263G>A:,EWSR1:ENST00000332035:sequence_feature:LOW::c.625+263G>A:,EWSR1:ENST00000414183:intron_variant:MODIFIER:exon8/17:c.811+263G>A:,EWSR1:ENST00000332050:intron_variant:MODIFIER:exon7/14:c.793+263G>A:,EWSR1:ENST00000397938:intron_variant:MODIFIER:exon7/16:c.793+263G>A:,EWSR1:ENST00000406548:intron_variant:MODIFIER:exon7/16:c.793+263G>A:,EWSR1:ENST00000437155:intron_variant:MODIFIER:exon7/7:c.796+263G>A:,EWSR1:ENST00000331029:intron_variant:MODIFIER:exon7/14:c.793+263G>A:,EWSR1:ENST00000483415:intron_variant:MODIFIER:exon7/7:n.817+263G>A:,EWSR1:ENST00000333395:intron_variant:MODIFIER:exon7/8:c.793+263G>A:,EWSR1:ENST00000455726:intron_variant:MODIFIER:exon6/6:c.625+263G>A:,EWSR1:ENST00000332035:intron_variant:MODIFIER:exon6/15:c.625+263G>A:,EWSR1:ENST00000479135:intron_variant:MODIFIER:exon3/11:n.2968+263G>A:			Might normally function as a transcriptionnal repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes				0.0000	0.0000	0.0000		"133450 [EWSR1 (confirmed) Ewing sarcoma,612219|Neuroepithelioma,612219];"												0	0					EWSR1 (inh=n/a pLI=1.00)	0							
chr22	35727284	35727284	T	A	0.1642	84	0.0000	40		70	TOM1	splice_region_variant&intron_variant,intron_variant	TOM1:ENST00000404284:splice_region_variant&intron_variant:LOW:exon9/16:c.*796-5T>A:,TOM1:ENST00000382034:splice_region_variant&intron_variant:LOW:exon9/16:c.699-5T>A:,TOM1:ENST00000411850:intron_variant:MODIFIER:exon8/14:c.899+811T>A:,TOM1:ENST00000447733:intron_variant:MODIFIER:exon8/14:c.800+811T>A:,TOM1:ENST00000456128:intron_variant:MODIFIER:exon8/9:c.881+811T>A:,TOM1:ENST00000449058:intron_variant:MODIFIER:exon8/14:c.899+811T>A:,TOM1:ENST00000425375:intron_variant:MODIFIER:exon7/13:c.764+811T>A:,TOM1:ENST00000424387:intron_variant:MODIFIER:exon7/13:c.*736+811T>A:,TOM1:ENST00000436462:intron_variant:MODIFIER:exon7/13:c.785+811T>A:,TOM1:ENST00000491987:intron_variant:MODIFIER:exon3/6:n.298+811T>A:			May be involved in intracellular trafficking. Probable association with membranes				0.0000	0.0000	0.0000														0	0					TOM1 (inh=n/a pLI=0.00)	1	SomaticAndTreatment,						
chrX	31496188	31496188	C	T	0.2228	203	0.0000	203	"not-cod-spli;off-target"	201	DMD	intron_variant	DMD:ENST00000357033:intron_variant:MODIFIER:exon59/78:c.8937+35G>A:,DMD:ENST00000358062:intron_variant:MODIFIER:exon12/29:c.2025+35G>A:,DMD:ENST00000343523:intron_variant:MODIFIER:exon16/30:c.1557+35G>A:,DMD:ENST00000359836:intron_variant:MODIFIER:exon16/33:c.1557+35G>A:,DMD:ENST00000378707:intron_variant:MODIFIER:exon16/35:c.1557+35G>A:,DMD:ENST00000541735:intron_variant:MODIFIER:exon16/31:c.1557+35G>A:,DMD:ENST00000378677:intron_variant:MODIFIER:exon59/78:c.8925+35G>A:,DMD:ENST00000474231:intron_variant:MODIFIER:exon16/34:c.1557+35G>A:			Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin- associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission	Agrin in Postsynaptic Differentiation			0.0000	0.0000	0.0000		"300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];"												0	0					DMD (inh=XLR pLI=1.00)	0							
chrX	32398619	32398619	G	A	0.3456	869	0.0000	560		809	DMD	splice_region_variant&intron_variant,intron_variant	DMD:ENST00000357033:splice_region_variant&intron_variant:LOW:exon34/78:c.4845+8C>T:,DMD:ENST00000378677:splice_region_variant&intron_variant:LOW:exon34/78:c.4833+8C>T:,DMD:ENST00000488902:intron_variant:MODIFIER:exon2/4:n.336-163439C>T:,DMD:ENST00000420596:intron_variant:MODIFIER:exon2/3:c.94-15303C>T:,DMD:ENST00000448370:intron_variant:MODIFIER:exon2/2:c.94-15792C>T:			Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin- associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission	Agrin in Postsynaptic Differentiation			0.0000	0.0000	0.0000		"300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];"	"RCV000283500.1 [uncertain significance]; "											0	0					DMD (inh=XLR pLI=1.00)	0							
chrX	32583963	32583963	G	A	0.3370	550	0.0000	466	syn-var	629	DMD	synonymous_variant,intron_variant	DMD:ENST00000357033:synonymous_variant:LOW:exon16/79:c.1848C>T:p.Ser616Ser,DMD:ENST00000378677:synonymous_variant:LOW:exon16/79:c.1836C>T:p.Ser612Ser,DMD:ENST00000288447:synonymous_variant:LOW:exon16/18:c.1824C>T:p.Ser608Ser,DMD:ENST00000488902:intron_variant:MODIFIER:exon2/4:n.336-348783C>T:,DMD:ENST00000420596:intron_variant:MODIFIER:exon2/3:c.94-200647C>T:,DMD:ENST00000448370:intron_variant:MODIFIER:exon2/2:c.94-201136C>T:			Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin- associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission	Agrin in Postsynaptic Differentiation		rs376024929	0.0000	0.00001	0.00001		"300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];"												0	0					DMD (inh=XLR pLI=1.00)	0		chrX_32583963_32583963_G_A	not protein-affecting	.	ENST00000357033	DMD	Synonymous
chrX	41198203	41198203	C	T	0.3846	13	0.0000	25	"not-cod-spli;depth-tum;off-target"	60	DDX3X	intron_variant	DDX3X:ENST00000399959:intron_variant:MODIFIER:exon2/16:c.104-86C>T:,DDX3X:ENST00000478993:intron_variant:MODIFIER:exon2/18:n.959-86C>T:,DDX3X:ENST00000457138:intron_variant:MODIFIER:exon2/15:c.103+1485C>T:,DDX3X:ENST00000441189:intron_variant:MODIFIER:exon2/5:c.104-86C>T:,DDX3X:ENST00000542215:intron_variant:MODIFIER:exon2/12:c.236-86C>T:			"Multifunctional ATP-dependent RNA helicase. The ATPase activity can be stimulated by various ribo- and deoxynucleic acids indicative for a relaxed substrate specificity. In vitro can unwind partially double stranded DNA with a preference for 5'- single stranded DNA overhangs. Is involved in several steps of gene expression, such as transcription, mRNA maturation, mRNA export and translation. However, the exact mechanisms are not known and some functions may be specific for a subset of mRNAs. Involved in transcriptional regulation. Can enhance transcription from the CDKN1A/WAF1 promoter in a SP1-dependent manner. Found associated with the E-cadherin promoter and can down-regulate transcription from the promoter. Involved in regulation of translation initiation. Proposed to be involved in positive regulation of translation such as of cyclin E1/CCNE1 mRNA and specifically of mRNAs containing complex secondary structures in their 5'UTRs; these functions seem to require RNA helicase activity. Specifically promotes translation of a subset of viral and cellular mRNAs carrying a 5'proximal stem-loop structure in their 5'UTRs and cooperates with the eIF4F complex. Proposed to act prior to 43S ribosomal scanning and to locally destabilize these RNA structures to allow recognition of the mRNA cap or loading onto the 40S subunit. After association with 40S ribosomal subunits seems to be involved in the functional assembly of 80S ribosomes; the function seems to cover translation of mRNAs with structured and non-structured 5'UTRs and is independent of RNA helicase activity. Also proposed to inhibit cap-dependent translation by competetive interaction with EIF4E which can block the EIF4E:EIF4G complex formation. Proposed to be involved in stress response and stress granule assembly; the function is independent of RNA helicase activity and seems to involve association with EIF4E. May be involved in nuclear export of specific mRNAs but not in bulk mRNA export via interactions with XPO1 and NXF1. Also associates with polyadenylated mRNAs independently of NXF1. Associates with spliced mRNAs in an exon junction complex (EJC)-dependent manner and seems not to be directly involved in splicing. May be involved in nuclear mRNA export by association with DDX5 and regulating its nuclear location. Involved in innate immune signaling promoting the production of type I interferon (IFN-alpha and IFN-beta); proposed to act as viral RNA sensor, signaling intermediate and transcriptional coactivator. Involved in TBK1 and IKBKE-dependent IRF3 activation leading to IFN-beta induction. Also found associated with IFN-beta promoters; the function is independent of IRF3. Can bind to viral RNAs and via association with MAVS/IPS1 and DDX58/RIG-I is thought to induce signaling in early stages of infection. Involved in regulation of apoptosis. May be required for activation of the intrinsic but inhibit activation of the extrinsic apoptotic pathway. Acts as an antiapoptotic protein through association with GSK3A/B and BIRC2 in an apoptosis antagonizing signaling complex; activation of death receptors promotes caspase-dependent cleavage of BIRC2 and DDX3X and relieves the inhibition. May be involved in mitotic chromosome segregation. Appears to be a prime target for viral manipulations. Hepatitis B virus (HBV) polymerase and possibly vaccinia virus (VACV) protein K7 inhibit IFN-beta induction probably by dissociating DDX3X from TBK1 or IKBKE. Is involved in hepatitis C virus (HCV) replication; the function may involve the association with HCV core protein. HCV core protein inhibits the IPS1- dependent function in viral RNA sensing and may switch the function from a INF-beta inducing to a HCV replication mode. Involved in HIV-1 replication. Acts as a cofactor for XPO1- mediated nuclear export of incompletely spliced HIV-1 Rev RNAs"				0.0000	0.0000	0.0000		"300160 [DDX3X (provisional) Mental retardation,X-linked 102,300958];"												0	0					DDX3X (inh=XLD pLI=1.00)	0							
chrX	53222094	53222094	G	A	0.3178	131	0.0000	83	"not-cod-spli;off-target"	152	KDM5C	3_prime_UTR_variant,intron_variant	KDM5C:ENST00000375401:3_prime_UTR_variant:MODIFIER:exon26/26:c.*55C>T:,KDM5C:ENST00000404049:3_prime_UTR_variant:MODIFIER:exon26/26:c.*55C>T:,KDM5C:ENST00000452825:intron_variant:MODIFIER:exon23/23:c.4047-75C>T:			Histone demethylase that specifically demethylates 'Lys- 4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements				0.0000	0.0000	0.0000		"314690 [KDM5C (confirmed) Mental retardation,X-linked,syndromic,Claes-Jensen type,300534];"												0	0					KDM5C (inh=XLR pLI=1.00)	0							
chrX	65176544	65176544	G	A	0.3684	326	0.0000	278	"not-cod-spli;off-target"	392	RP6-159A1.2	non_coding_transcript_exon_variant	RP6-159A1.2:ENST00000456392:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.495C>T:							0.0000	0.0000	0.0000														0	0					RP6-159A1.2 (inh=n/a pLI=n/a)	0							
chrX	70338535	70338535	C	T	0.2759	59	0.0000	56	"not-cod-spli;off-target"	104	MED12	5_prime_UTR_variant	MED12:ENST00000333646:5_prime_UTR_variant:MODIFIER:exon1/45:c.-70C>T:			Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. This subunit may specifically regulate transcription of targets of the Wnt signaling pathway and SHH signaling pathway				0.0000	0.0000	0.0000		"300188 [MED12 (confirmed) Opitz-Kaveggia syndrome,305450|Lujan-Fryns syndrome,309520|Ohdo syndrome,X-linked,300895];"												0	0					MED12 (inh=XLR pLI=1.00)	0							
chrX	70466166	70466166	G	A	0.3293	251	0.0000	183	"not-cod-spli;off-target"	278	ZMYM3	intron_variant	ZMYM3:ENST00000373988:intron_variant:MODIFIER:exon15/24:c.2578+37C>T:,ZMYM3:ENST00000314425:intron_variant:MODIFIER:exon15/24:c.2572+37C>T:,ZMYM3:ENST00000353904:intron_variant:MODIFIER:exon15/24:c.2572+37C>T:,ZMYM3:ENST00000373998:intron_variant:MODIFIER:exon15/24:c.2536+37C>T:,ZMYM3:ENST00000489332:intron_variant:MODIFIER:exon14/23:n.2913+37C>T:,ZMYM3:ENST00000373984:intron_variant:MODIFIER:exon15/23:c.2578+37C>T:			Plays a role in the regulation of cell morphology and cytoskeletal organization				0.0000	0.0000	0.0000														0	0					ZMYM3 (inh=n/a pLI=1.00)	0							
chrX	72744727	72744727	G	A	0.3189	185	0.0000	166	"not-cod-spli;off-target"	240	MAP2K4P1	non_coding_transcript_exon_variant	MAP2K4P1:ENST00000602584:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.1923C>T:							0.0000	0.0000	0.0000														0	0					MAP2K4P1 (inh=n/a pLI=n/a)	0							
chrX	97645381	97645381	C	T	0.3259	135	0.0000	104	"not-cod-spli;off-target"	178	EEF1A1P15	non_coding_transcript_exon_variant	EEF1A1P15:ENST00000395772:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.872C>T:							0.0000	0.0000	0.0000														0	0					EEF1A1P15 (inh=n/a pLI=n/a)	0							
chrX	118971584	118971584	A	T	0.2632	77	0.0000	89	"not-cod-spli;off-target"	105	UPF3B	intron_variant	UPF3B:ENST00000276201:intron_variant:MODIFIER:exon10/10:c.1302+136T>A:,UPF3B:ENST00000345865:intron_variant:MODIFIER:exon9/9:c.1263+136T>A:			"Involved in nonsense-mediated decay (NMD) of mRNAs containing premature stop codons by associating with the nuclear exon junction complex (EJC) and serving as link between the EJC core and NMD machinery. Recruits UPF2 at the cytoplasmic side of the nuclear envelope and the subsequent formation of an UPF1-UPF2- UPF3 surveillance complex (including UPF1 bound to release factors at the stalled ribosome) is believed to activate NMD. In cooperation with UPF2 stimulates both ATPase and RNA helicase activities of UPF1. Binds spliced mRNA upstream of exon-exon junctions. In vitro, stimulates translation; the function is indepenedent of association with UPF2 and components of the EJC core"				0.0000	0.0000	0.0000		"300298 [UPF3B (provisional) Mental retardation,X-linked,syndromic 14,300676];"												0	0					UPF3B (inh=XLR pLI=0.93)	0							
chrX	119694319	119694319	C	T	0.3442	674	0.0000	425		626	CUL4B	missense_variant,non_coding_transcript_exon_variant	CUL4B:ENST00000404115:missense_variant:MODERATE:exon3/22:c.229G>A:p.Asp77Asn,CUL4B:ENST00000371322:missense_variant:MODERATE:exon1/20:c.175G>A:p.Asp59Asn,CUL4B:ENST00000336592:missense_variant:MODERATE:exon2/21:c.190G>A:p.Asp64Asn,CUL4B:ENST00000467641:non_coding_transcript_exon_variant:MODIFIER:exon2/3:n.332G>A:		"Nucleotide excision repair;Ubiquitin mediated proteolysis"	Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition subunit. CUL4B may act within the complex as a scaffold protein, contributing to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. Plays a role as part of the E3 ubiquitin-protein ligase complex in polyubiquitination of CDT1, histone H2A, histone H3 and histone H4 in response to radiation- induced DNA damage. Targeted to UV damaged chromatin by DDB2 and may be important for DNA repair and DNA replication. Required for ubiquitination of cyclin E, and consequently, normal G1 cell cycle progression. Regulates the mammalian target-of-rapamycin (mTOR) pathway involved in control of cell growth, size and metabolism. Specific CUL4B regulation of the mTORC1-mediated pathway is dependent upon 26S proteasome function and requires interaction between CUL4B and MLST8				0.0000	0.0000	0.0000		"300304 [CUL4B (confirmed) Mental retardation,X-linked,syndromic 15 (Cabezas type),300354];"			7.487.000	T	T,T,T	B,B	T,T,T	24.20				0	0					CUL4B (inh=XLR pLI=1.00)	0		chrX_119694319_119694319_C_T	predicted passenger	.	ENST00000404115	CUL4B	Missense
chrX	135961587	135961587	G	T	0.0277	492	0.0000	257	freq-tum	106	RBMX	missense_variant,5_prime_UTR_variant,intron_variant,non_coding_transcript_exon_variant	RBMX:ENST00000419968:missense_variant:MODERATE:exon1/8:c.3C>A:p.Asn1Lys,RBMX:ENST00000320676:5_prime_UTR_variant:MODIFIER:exon2/9:c.-1C>A:,RBMX:ENST00000431446:5_prime_UTR_variant:MODIFIER:exon2/8:c.-1C>A:,RBMX:ENST00000568578:5_prime_UTR_variant:MODIFIER:exon2/8:c.-1C>A:,RBMX:ENST00000464781:5_prime_UTR_variant:MODIFIER:exon2/8:c.-1C>A:,RBMX:ENST00000570135:5_prime_UTR_variant:MODIFIER:exon2/8:c.-234C>A:,RBMX:ENST00000562646:5_prime_UTR_variant:MODIFIER:exon2/8:c.-1C>A:,RBMX:ENST00000563370:5_prime_UTR_variant:MODIFIER:exon2/4:c.-1C>A:,RBMX:ENST00000565438:intron_variant:MODIFIER:exon1/6:c.-169+1169C>A:,RBMX:ENST00000567262:non_coding_transcript_exon_variant:MODIFIER:exon2/5:n.155C>A:,RBMX:ENST00000565907:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.152C>A:			"RNA-binding protein that plays several role in the regulation of pre- and post-transcriptional processes. Implicated in tissue-specific regulation of gene transcription and alternative splicing of several pre-mRNAs. Binds to and stimulates transcription from the tumor suppressor TXNIP gene promoter; may thus be involved in tumor suppression. When associated with SAFB, binds to and stimulates transcription from the SREBF1 promoter. Associates with nascent mRNAs transcribed by RNA polymerase II. Component of the supraspliceosome complex that regulates pre-mRNA alternative splice site selection. Can either activate or suppress exon inclusion; acts additively with TRA2B to promote exon 7 inclusion of the survival motor neuron SMN2. Represses the splicing of MAPT/Tau exon 10. Binds preferentially to single- stranded 5'-CC[A/C]-rich RNA sequence motifs localized in a single-stranded conformation; probably binds RNA as a homodimer. Binds non-specifically to pre-mRNAs. Plays also a role in the cytoplasmic TNFR1 trafficking pathways; promotes both the IL-1- beta-mediated inducible proteolytic cleavage of TNFR1 ectodomains and the release of TNFR1 exosome-like vesicles to the extracellular compartment"			rs2011584	0.677351	0.57329	0.52528		"300199 [RBMX (confirmed) Mental retardation,X-linked,syndromic 11,Shashi type,300238];"												896	714					RBMX (inh=XLR pLI=0.95)	1	SomaticAndTreatment,						
chrMT	3197	3197	T	C	0.9492	59	0.1250	8	"not-cod-spli;depth-nor;off-target"	104	MT-RNR2	non_coding_transcript_exon_variant	MT-RNR2:ENST00000387347:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1527T>C:			Plays a role as a neuroprotective factor. Protects against death induced by multiple different familial Alzheimer disease genes and beta amyloid proteins in Alzheimer disease. Suppresses apoptosis by binding to BAX and preventing the translocation of BAX from the cytosol to mitochondria. Binds to IGFBP3 and specifically blocks IGFBP3-induced cell death Induces chemotaxis of mononuclear phagocytes via FPR2. Reduces the aggregation and fibrillary formation by suppressing the effect of APP on mononuclear phagocytes and acts by competitively inhibiting the access of FPRL1 to APP			rs2854131	0.0000	0.0000	0.0000														98	7					MT-RNR2 (inh=n/a pLI=n/a)	2	SomaticAndTreatment,						
